Macrocyclic heterocycles and uses thereof
By inhibiting GEFs such as SOS proteins through a new compound, interfering with Ras signaling, the limitations of existing Ras mutant treatment methods have been solved, and effective treatment of cancer, especially the inhibition of K-Ras mutants has been achieved.
Patent Information
- Application Number
- CN202380028108.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-02-24
- Filing Date
- 2023-04-19
- Publication Date
- 2024-12-06
AI Technical Summary
The existing treatment methods for Ras mutant are limited, especially the application of G12C mutants is limited. Due to the high affinity for Ras protein and the lack of obvious targeting regions, it leads to problems with therapeutic resistance and durability, and GEFs such as SOS proteins. The suppression technology has not been effectively resolved.
A compound is provided that interferes with the Ras signaling pathway by specifically inhibiting GEFs such as SOS proteins for the treatment of a variety of diseases, including cancer, by interacting with SOS1 proteins to reduce Ras signaling output.
This compound can effectively inhibit Ras signaling, potentially improving the therapeutic effect on a variety of Ras mutants, including K-Ras mutants, reduce cell growth and proliferation, and enhance the potential for cancer treatment.
Smart Images

Figure BDA0005045254570000021 
Figure BDA0005045254570000072 
Figure BDA0005045254570000141
Abstract
Description
[0001] Cross-references
[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 332,794, filed April 20, 2022; U.S. Provisional Application No. 63 / 404,482, filed September 7, 2022; and U.S. Provisional Application No. 63 / 486,922, filed February 24, 2023, each of which is incorporated herein by reference in its entirety.
[0003] Sequence Listing
[0004] This application contains a sequence listing submitted electronically in XML format and hereby incorporated by reference in its entirety. The XML copy was created on April 18, 2023, is named 56690_748_601_SL.xml, and is 7,953 bytes in size. Background Art
[0005] Cancer (e.g., tumors, neoplasms, metastases) is the second leading cause of death worldwide, accounting for an estimated 10 million deaths annually. Many types of cancer are marked by mutations in one or more proteins involved in various signaling pathways, leading to the uncontrolled growth of cancer cells. In some cases, approximately 25% to 30% of tumors are known to contain rat sarcoma (Ras) mutations.
[0006] After activation by guanine nucleotide exchange factors (GEFs), Ras in the GTP-bound state interacts with many effectors. The return to the inactive state is driven by GTPase-activating proteins (GAPs), which downregulate active Ras by accelerating the weak intrinsic GTPase activity. However, in oncogenic Ras mutants, GAP activity is impaired or greatly reduced, resulting in persistent activation, which drives oncogenic Ras signaling through, for example, the RAS-RAF-MEK-ERK and RAS-PI3K-PDK1-AKT pathways, both of which are essential for cell survival and proliferation.
[0007] The most studied GEF for Ras is the Son of Sevenless (SOS) protein, of which two human isoforms are known, SOS1 and SOS2. SOS1 is the human homolog of the originally identified Drosophila protein Son of Sevenless. SOS1 has two binding sites for Ras proteins; a catalytic site that binds GDP-bound Ras proteins to promote guanine nucleotide exchange and an allosteric site that binds GTP-bound Ras to further promote Ras protein activation. Son of Sevenless 2 (SOS2) is a homolog of SOS1 in mammalian cells. Double SOS1 and SOS2 knockout leads to rapid lethality in adult mice (Baltanas et al., Mol. Cell. Biol., 2013, 33(22):4562-78).
[0008] Ras proteins have long been considered "undruggable," in part due to their high affinity for their substrate guanosine-5'-triphosphate (GTP) and / or their smooth surface without any obvious targetable regions. The specific G12C Ras gene mutation has been identified as a druggable target, and a number of G12C-specific inhibitors have been developed against this target. However, the application of such therapies remains limited because the G12C mutation in Ras exhibits a much lower prevalence compared to other known Ras mutations, including G12D and G12V. Drug resistance and lack of persistence further limit such therapies. Summary of the Invention
[0009] In view of the foregoing, there remains a significant need for new therapeutic and diagnostic designs that can specifically inhibit Ras pathway signaling, for example by inhibiting GEFs such as SOS proteins. Such compositions and methods may be particularly useful for treating a variety of diseases, including but not limited to cancer and neoplasia. The present disclosure addresses these needs and provides the additional advantage of being applicable to the diagnosis, prognosis, and treatment of a variety of diseases.
[0010] In certain aspects, the present disclosure provides a compound of formula (I):
[0011]
[0012] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0013] Selected from C 5-7 Carbocyclic and 5- to 7-membered heterocyclic rings, each of which is optionally substituted by one or more R 11 replace;
[0014] Not present or selected from C3-8 Carbocyclic and 3 to 8 membered heterocyclic rings, each of which is optionally substituted by one or more R 11a replace;
[0015] L 1 Selected from bond, C 1-6 Alkylene and C 1-6 alkylene halide;
[0016] L 2 Selected from C 5-25 Alkylene, C 5-25 Alkenylene, C 5-25 Alkyne, 5- to 25-membered heteroalkylene, and 5- to 25-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b Substituted, where L 2 Covalently bound to W 3 、W 4 、W 5 、W 6 or W 7 One of; or L 2 Yes-L 3 -DL 4 -, where L 4 Covalently bound to W 3 、W 4 、W 5 、W 6 or W 7 one of;
[0017] L 3 Selected from C 1-10 Alkylene, C 1-10 Alkenylene, C 1-10 Alkyne, 2- to 10-membered heteroalkylene, and 2- to 10-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b replace;
[0018] D does not exist or is selected from C 3-12 Carbocyclic and 3 to 12 membered heterocyclic rings, each of which is optionally substituted by one or more R 11d replace;
[0019] L 4 Selected from C 1-10 Alkylene, C 1-10 Alkenylene, C 1-10 Alkyne, 2- to 10-membered heteroalkylene, and 2- to 10-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b replace;
[0020] W 2 Selected from N(R 2b )、N、C(R2 )、C(R 2 )(R 2a ) and C(O);
[0021] W 3 Selected from N(R 3b )、N、C(R 3 )、C(R 3 )(R 3a ) and C(O);
[0022] W 4 Selected from N(R 4b )、N、C(R 4 )、C(R 4 )(R 4a ) and C(O);
[0023] W 5 Selected from N(R 5b )、N、C(R 5 )、C(R 5 )(R 5a ) and C(O);
[0024] W 6 Selected from N(R 6b )、N、C(R 6 )、C(R 6 )(R 6a ) and C(O);
[0025] W 7 Selected from N(R 7b )、N、C(R 7 )、C(R 7 )(R 7a ) and C(O);
[0026] W 8 Selected from N(R 8b )、N、C(R 8 )、C(R 8 )(R 8a ) and C(O);
[0027] W 9 Selected from N, C(R 9 ) and C;
[0028] W 10 Selected from N, C(R 10 ) and C;
[0029] R 1 is optionally replaced by one or more R 11c Substituted C 1-3 alkyl;
[0030] R 2 、R 2a 、R 3a 、R 4a 、R 5a 、R 6a 、R 7a 、R 8 and R 8a are independently selected from hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0031] R 3 、R 4 、R 5 、R 6 and R 7 Each independently selected from L 2 bonds, hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0032] R 2b and R 8b Each independently selected from hydrogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 ),-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0033] R 3b 、R 4b 、R 5b 、R 6b and R 7b Each independently selected from L 2 bonds, hydrogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 ),-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0034] R 9 and R 10 are each independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocyclic ring), 3- to 10-membered heterocyclic ring, and -CH2-(3- to 10-membered heterocyclic ring), wherein each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocyclic ring), 3 to 10 membered heterocyclic ring and -CH2-(3 to 10 membered heterocyclic ring) are independently optionally replaced by one, two or three R 20 replace;
[0035] R 11 、R 11a and R11d Each occurrence is independently selected from halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 、-CH2S(O)2N(R 12 )(R 13 )、-CH2N(R 12 )S(O)2(R 13 ) and -P(O)(R 17 )(R 17a ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0036] R 11b is independently selected at each occurrence from halogen, oxo, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 、-CH2S(O)2N(R 12 )(R 13 )、-CH2N(R 12 )S(O)2(R 13 ) and -P(O)(R 17 )(R 17a ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0037] R 11c is independently selected at each occurrence from halogen, -OR 12 and -N(R 12 )(R 13 );
[0038] R 12 independently selected at each occurrence from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0039] R 13 independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 haloalkyl; or R 12 and R 13 Together with the nitrogen atom to which they are attached, they form a 20 substituted 3- to 10-membered heterocycle;
[0040] R 14 independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 alkyl halide;
[0041] R 15 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0042] R 17 and R 17a Each occurrence is independently selected from C 1-6 Alkyl and C 3-6 Cycloalkyl, wherein C1-6 Alkyl and C 3-6 The cycloalkyl group is optionally substituted by one, two or three R 20 Replacement; or R 17 and R 17a Together with the phosphorus atom to which they are attached, they form a 3- to 10-membered heterocyclic ring;
[0043] R 20 is independently selected at each occurrence from halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3- to 10-membered heterocycle, -CH2-(3- to 10-membered heterocycle), -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 )、-OCH2C(O)OR 22 and -OC(O)R 25 , where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3 to 10 membered heterocycle and -CH2-(3 to 10 membered heterocycle) are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 ) and -OC(O)R 25 ;
[0044] R 21 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0045] R 22 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0046] R 23independently selected at each occurrence from H and C 1-6 alkyl;
[0047] R 24 independently selected at each occurrence from H and C 1-6 alkyl;
[0048] R 25 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings; and represents a single or double bond such that all valences are satisfied.
[0049] In certain aspects, the present disclosure provides a compound of formula (I):
[0050]
[0051] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0052] Selected from C 5-7 Carbocyclic and 5- to 7-membered heterocyclic rings, each of which is optionally substituted by one or more R 11 replace;
[0053] Not present or selected from C 3-8 Carbocyclic and 3 to 8 membered heterocyclic rings, each of which is optionally substituted by one or more R 11a replace;
[0054] L 1 Selected from bond, C 1-6 Alkylene and C 1-6 alkylene halide;
[0055] L 2 Selected from C 5-25 Alkylene, C 5-25 Alkenylene, C 5-25 Alkyne, 5- to 25-membered heteroalkylene, and 5- to 25-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b Substituted, where L 2 Covalently bound to W3 、W 4 、W 5 、W 6 or W 7 one of;
[0056] W 2 Selected from N(R 2b )、N、C(R 2 )、C(R 2 )(R 2a ) and C(O);
[0057] W 3 Selected from N(R 3b )、N、C(R 3 )、C(R 3 )(R 3a ) and C(O);
[0058] W 4 Selected from N(R 4b )、N、C(R 4 )、C(R 4 )(R 4a ) and C(O);
[0059] W 5 Selected from N(R 5b )、N、C(R 5 )、C(R 5 )(R 5a ) and C(O);
[0060] W 6 Selected from N(R 6b )、N、C(R 6 )、C(R 6 )(R 6a ) and C(O);
[0061] W 7 Selected from N(R 7b )、N、C(R 7 )、C(R 7 )(R 7a ) and C(O);
[0062] W 8 Selected from N(R 8b )、N、C(R 8 )、C(R 8 )(R 8a ) and C(O);
[0063] W 9 Selected from N, C(R 9 ) and C;
[0064] W10 Selected from N, C(R 10 ) and C;
[0065] R 1 is optionally replaced by one or more R 11c Substituted C 1-3 alkyl;
[0066] R 2 、R 2a 、R 3a 、R 4a 、R 5a 、R 6a 、R 7a 、R 8 and R 8a are independently selected from hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0067] R 3 、R 4 、R 5 、R 6 and R 7 Each independently selected from L 2 bonds, hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14)C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0068] R 2b and R 8b Each independently selected from hydrogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 ),-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0069] R 3b 、R 4b、R 5b 、R 6b and R 7b Each independently selected from L 2 bonds, hydrogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 ),-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0070] R 9 and R 10 are each independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocyclic ring), 3- to 10-membered heterocyclic ring, and -CH2-(3- to 10-membered heterocyclic ring), wherein each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C3-10 Carbocyclic ring, -CH2-(C 3-10 carbocyclic ring), 3 to 10 membered heterocyclic ring and -CH2-(3 to 10 membered heterocyclic ring) are independently optionally replaced by one, two or three R 20 Replacement; R 11 and R 11a Each occurrence is independently selected from halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 、-CH2S(O)2N(R 12 )(R 13 )、-CH2N(R 12 )S(O)2(R 13 ) and -P(O)(R 17 )(R 17a ), where C1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0071] R 11b is independently selected at each occurrence from halogen, oxo, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 、-CH2S(O)2N(R 12 )(R 13 )、-CH2N(R 12 )S(O)2(R 13 ) and -P(O)(R 17 )(R17a ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0072] R 11c is independently selected at each occurrence from halogen, -OR 12 and -N(R 12 )(R 13 );
[0073] R 12 independently selected at each occurrence from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0074] R 13 independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 haloalkyl; or R 12 and R 13 Together with the nitrogen atom to which they are attached, they form a 20 substituted 3- to 10-membered heterocycle;
[0075] R 14 independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 alkyl halide;
[0076] R 15 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0077] R17 and R 17a Each occurrence is independently selected from C 1-6 Alkyl and C 3-6 Cycloalkyl, wherein C 1-6 Alkyl and C 3-6 The cycloalkyl group is optionally substituted by one, two or three R 20 Replacement; or R 17 and R 17a Together with the phosphorus atom to which they are attached, they form a 3- to 10-membered heterocyclic ring;
[0078] R 20 is independently selected at each occurrence from halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3- to 10-membered heterocycle, -CH2-(3- to 10-membered heterocycle), -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 )、-OCH2C(O)OR 22 and -OC(O)R 25 , where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10carbocycle), 3 to 10 membered heterocycle and -CH2-(3 to 10 membered heterocycle) are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 ) and -OC(O)R 25 ;
[0079] R 21 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0080] R 22 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0081] R 23 independently selected at each occurrence from H and C 1-6 alkyl;
[0082] R 24 independently selected at each occurrence from H and C 1-6 alkyl;
[0083] R 25 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings; and represents a single or double bond such that all valences are satisfied.
[0084] The compound of formula (I) may be a compound of formula (IA):
[0085] or a pharmaceutically acceptable salt or solvate thereof.
[0086] The compound of formula (I) may be a compound of formula (IB):
[0087] or a pharmaceutically acceptable salt or solvate thereof. The compound of formula (I) may be a compound of formula (IC):
[0088] or a pharmaceutically acceptable salt or solvate thereof.
[0089] The compound of formula (I) may be a compound of formula (ID):
[0090] or a pharmaceutically acceptable salt or solvate thereof.
[0091] The compound of formula (I) may be a compound of formula (IE):
[0092] or a pharmaceutically acceptable salt or solvate thereof.
[0093] For compounds of formula (I), (IA), (IB), (IC), (ID) or (IE),
[0094] L 2 Can be selected from C 5-25 Alkylene, C 5-25 Alkenylene, C 5-25 Alkyne, 5- to 25-membered heteroalkylene, and 5- to 25-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b Substituted, where L 2 Covalently bound to W 3 、W 4 、W 5 、W 6 or W 7 one of them.
[0095] In some embodiments, for compounds of Formula (I), (IA), (IB), (IC), (ID), or (IE):
[0096] Selected from C 5-7 Cycloalkyl, 5- to 7-membered heterocycloalkyl, 5- to 7-membered heteroaryl and phenyl, each of which is optionally substituted by one or more R 11 replace;
[0097] L 1 Selected from bond, C 1-2 Alkylene and C 1-2 a haloalkylene group; and
[0098] R 1 is optionally replaced by one or more R 11c Substituted C 1-2 alkyl.
[0099] In some embodiments, for compounds of Formula (I), (IA), (IB), (IC), (ID), or (IE):
[0100] R 7 Selected from L 2 bonds, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace; and
[0101] R 7b Selected from L 2 The bond, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 ),-C(O)R 15 、-S(O)R 15、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace.
[0102] For compounds of Formula (I), (IA), (IB), (IC), (ID), or (IE), W 2 Can be N. In some embodiments, W 3 Selected from N(R 3b )、N、C(R 3 ) and C(O), such as W 3 Selected from C(R 3 ) and C(O). In some embodiments, W 4 Selected from N(R 4b )、N、C(R 4 ) and C(O), such as W 4 Selected from N(R 4b ) and N. In some embodiments, W 5 Selected from N(R 5b )、N、C(R 5 ) and C(O), such as W 5 Selected from N(R 5b ), N and C (R 5 ). In some embodiments, W 5 Selected from N(R 5b ) and C(R 5 ). In some embodiments, W 6 Selected from C(R 6) and C(O). In some embodiments, W 7 It is C(R 7 ). In some embodiments, W 8 It is C(R 8 ), such as CH. In some embodiments, W 9 is C. In some embodiments, W 10 is C. In some embodiments, W 2 It is N; W 3 It is N(R 3b );W 4 is C(O); and W 9 and W 10 Each is C. In some embodiments, W 2 It is N; W 3 is C(O); W 4 It is N(R 4b ); and W 9 and W 10 Each is C. In some embodiments, W 2 It is N; W 3 It is C(R 3 );W 4 is N; and W 9 and W 10 Each is C. In some embodiments, W 5 It is C(R 5 );W 6 It is C(R 6 );W 7 It is C(R 7 );W 8 It is C(R 8 ); and W 9 and W 10 Each is C. In some embodiments, W 5 It is N(R 5b );W 6 is C(O); W 7 It is C(R 7 );W 8 It is C(R 8 ); and W 9 and W 10 Each is C. In some embodiments, W 5 It is N; W 6 It is C(R 6 );W 7 It is C(R 7 );W 8 It is C(R 8 ); and W 9 and W 10 Each is C. In some embodiments, W2 It is N; W 3 Selected from N(R 3b )、N、C(R 3 ) and C(O); W 4 Selected from N(R 4b )、N、C(R 4 ) and C(O); W 5 Selected from N(R 5b ), N and C (R 5 );W 6 Selected from C(R 6 ) and C(O); W 7 It is C(R 7 );W 8 It is C(R 8 ); and W 9 and W 10 Each is C. In some embodiments, W 2 It is N; W 3 Selected from C(R 3 ) and C(O); W 4 Selected from N(R 4b ) and N; W 5 Selected from N(R 5b ) and C(R 5 );W 6 Selected from C(R 6 ) and C(O); W 7 It is C(R 7 );W 8 is CH; and W 9 and W 10 Each is C.
[0103] The compound of formula (IB) may be a compound of formula (I-B1) or (I-B2):
[0104]
[0105] or a pharmaceutically acceptable salt or solvate thereof.
[0106] The compound of formula (IC) may be a compound of formula (I-C1), (I-C2) or (I-C3):
[0107] or a pharmaceutically acceptable salt or solvate thereof.
[0108] The compound of formula (ID) may be a compound of formula (I-D1) or (I-D2):
[0109] or a pharmaceutically acceptable salt or solvate thereof.
[0110] The compound of formula (IE) may be a compound of formula (I-E1): or a pharmaceutically acceptable salt or solvate thereof.
[0111] For compounds of Formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), R 1 Can be unsubstituted C 1-2 In some embodiments, R 3 Selected from hydrogen, halogen, -CN, -OR 12 and optionally one, two or three R 20 Substituted C 1-6 In some embodiments, R 3 is optionally replaced by one, two or three R 20 Substituted C 1-6 In some embodiments, R 3 is hydrogen or -CH3. In some embodiments, R 3b is -CH3. In some embodiments, R 5 Selected from hydrogen, -OR 12 and optionally one, two or three R 20 Substituted C 1-6 In some embodiments, R 5 In some embodiments, R 5b selected from hydrogen and optionally substituted by one, two or three R 20 Substituted C 1-6 In some embodiments, R 5b is -CH3. In some embodiments, R 6 Selected from hydrogen, -OR 12 and optionally one, two or three R 20 Substituted C 1-6 alkyl, and wherein R 12 Selected from C 1-6 In some embodiments, R 6 is selected from hydrogen and -OCH3.
[0112] For compounds of Formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), R7 Can be selected from C 1-6 Alkyl, C 3-10 Carbocyclic ring, 3- to 10-membered heterocyclic ring, -N(R 12 )(R 13 ),-C(O)R 15 、-C(O)N(R 12 )(R 13 )、-S(O)2R 15 、-SO2N(R 12 )(R 13 ), where C 1-6 Alkyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 In some embodiments, R 7 Selected from C 1-6 Alkyl, C 3-10 Cycloalkyl, 3- to 10-membered heterocycloalkyl and -N(R 12 )(R 13 ), where C 1-6 Alkyl, C 3-10 Cycloalkyl and 3 to 10 membered heterocycloalkyl are optionally substituted by one, two or three R 20 In some embodiments, R 7 is optionally replaced by one, two or three R 20 In some embodiments, R 7 is optionally replaced by one, two or three R 20 Substituted C 3-10 In some embodiments, R 7 is optionally replaced by an R 20 Substituted C 3-4 In some embodiments, R 20 In some embodiments, R 7 yes In some embodiments, R 7 is optionally replaced by one, two or three R 20 Substituted C 1-6 In some embodiments, R 7 Yes-N(R 12 )(R 13 ). In some embodiments, R 7 Selected from
[0113] In some embodiments, R 7 Selected from
[0114] For compounds of Formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), R 8 may be selected from hydrogen, halogen and optionally substituted by one, two or three R 20 Substituted C 1-6 In some embodiments, R 8 It's hydrogen.
[0115] For compounds of Formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), may be selected from phenyl and 5 to 7 membered heteroaryl, each of which is optionally substituted by one or more R 11 In some embodiments, is selected from phenyl, pyridyl and thienyl, each of which is optionally substituted by one or more R 11 In some embodiments, Selected from In some embodiments, R 11 When present, at each occurrence, is independently selected from fluoro and -CH3.
[0116] For compounds of Formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), L 1 Can be selected from bonds and C 1-3 In some embodiments, L 1 It is C 1-3 In some embodiments, L 1 Selected from -CF2-, -CF2CH2- and -CF2CH2CH2-.
[0117] For compounds of Formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), is selected from the group consisting of absent, phenyl and 4 to 8 membered heterocyclic rings, wherein the phenyl and 4 to 8 membered heterocyclic rings are optionally replaced by one or more R11a In some embodiments, is selected from the group consisting of absent, phenyl, azetidine, pyrrolidine and piperidine, wherein phenyl, azetidine, pyrrolidine and piperidine are optionally replaced by one or more R 11a In some embodiments, is selected from azetidine, pyrrolidine and piperidine, each of which is optionally substituted with one or more -CH3.
[0118] For compounds of Formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), L 2 Together with the atoms to which it is attached, it can form a 16- to 36-membered macrocyclic ring. 2 Together with the atoms to which it is attached, it forms a 16- to 24-membered macrocyclic ring. 2 Selected from C 6-15 Alkylene, C 6-15 Alkenylene, C 6-15 Alkyne, 6 to 15 membered heteroalkylene and 6 to 15 membered heteroalkenylene, each of which is optionally substituted by one or more R 11b In some embodiments, L 2 Selected from C 5-10 Alkylene, C 5-10 alkenylene, 5- to 10-membered heteroalkylene, and 5- to 10-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b Substitution. Alkenylene and heteroalkenylene may contain one carbon-carbon double bond. Heteroalkylene and heteroalkenylene may contain at least one oxygen or nitrogen atom. In some embodiments, R 11b Selected from halogen, oxo, C 1-6 Alkyl, C 1-6 Halogenated alkyl, (C 1-6 In some embodiments, R 11b Selected from -F, =O, -CH3, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2OH and -OH.
[0119] In some embodiments, for compounds of Formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), R 5 is hydrogen; R 5b is -CH3; R6 is selected from hydrogen and -OCH3; R 7 Selected from C 1-6 Alkyl, C 3-10 Carbocyclic ring, 3- to 10-membered heterocyclic ring, -N(R 12 )(R 13 ),-C(O)R 15 、-C(O)N(R 12 )(R 13 )、-S(O)2R 15 and -SO2N(R 12 )(R 13 ), where C 1-6 Alkyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 Replace; and R 8 In some embodiments, R 3 is hydrogen or -CH3; R 3b is -CH3; R 6 is selected from hydrogen and -OCH3; R 7 Selected from C 1-6 Alkyl, C 3-10 Carbocyclic ring, 3- to 10-membered heterocyclic ring, -N(R 12 )(R 13 ),-C(O)R 15 、-C(O)N(R 12 )(R 13 )、-S(O)2R 15 and -SO2N(R 12 )(R 13 ), where C 1-6 Alkyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 Replace; and R 8 In some embodiments, R 7 Selected from
[0120] In some embodiments, R 1 is -CH3; is selected from phenyl and 5- to 7-membered heteroaryl, each of which is optionally substituted by one or more R 11 Replace; L 1 Selected from bonds and C 1-3 alkylene halide; is selected from the group consisting of absent, phenyl and 4 to 8 membered heterocyclic rings, wherein the phenyl and 4 to 8 membered heterocyclic rings are optionally replaced by one or more R 11a Replace; and L 2 Selected from C5-10 Alkylene, C 5-10 alkenylene, 5- to 10-membered heteroalkylene, and 5- to 10-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b In some embodiments, R 11 When present, it is fluorine; R 11a When present, it is -CH3; and R 11b When present, is selected from halogen, oxo, C 1-6 Alkyl, C 1-6 Halogenated alkyl, (C 1-6 alkyl)-OH and -OH.
[0121] The compound of formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE) or (I-E1) may be a compound having the following structure:
[0122] or a pharmaceutically acceptable salt or solvate thereof.
[0123] In some embodiments, the present disclosure provides a compound of formula (I-C1), or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0124]
[0125] is selected from azetidine, pyrrolidine and piperidine, each of which is optionally substituted with one or more -CH3;
[0126] L 1 It is C 1-3 alkylene halide;
[0127] L 2 is optionally replaced by one or more R 11b Substituted C 5-10 alkenylene;
[0128] R 1 is -CH3;
[0129] R 3 is -CH3;
[0130] R 7 Selected from R 8 It is hydrogen;
[0131] R 11 is selected from fluorine and -CH3; and
[0132] R11b Selected from halogen, oxo, C 1-6 Alkyl, C 1-6 Halogenated alkyl, (C 1-6 alkyl)-OH and -OH.
[0133] In some embodiments, the present disclosure provides a compound of formula (I-C1), or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0134] Selected from
[0135] is selected from azetidine, pyrrolidine and piperidine, each of which is optionally substituted with one or more -CH3;
[0136] L 1 It is C 1-3 alkylene halide;
[0137] L 2 Selected from optionally one or more R 11b substituted 5- to 10-membered heteroalkylene;
[0138] R 1 is -CH3;
[0139] R 3 is hydrogen or -CH3;
[0140] R 7 Selected from R 8 It is hydrogen;
[0141] R 11 is selected from fluorine and -CH3; and
[0142] R 11b Selected from halogen, oxo, C 1-6 Alkyl, C 1-6 Halogenated alkyl, (C 1-6 alkyl)-OH and -OH.
[0143] In certain aspects, the present disclosure provides a compound of formula (III):
[0144]
[0145] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0146] Selected from optionally one or more R 11a substituted 3- to 8-membered heterocycles;
[0147] L 1Selected from bond, C 1-6 Alkylene and C 1-6 alkylene halide;
[0148] L 2 Selected from C 5-25 Alkylene, C 5-25 Alkenylene, C 5-25 Alkyne, 5- to 25-membered heteroalkylene, and 5- to 25-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b Substituted, where L 2 Covalently bound to W 3 、W 4 、W 5 、W 6 or W 7 One of; or L 2 Yes-L 3 -DL 4 -, where L 4 Covalently bound to W 3 、W 4 、W 5 、W 6 or W 7 one of;
[0149] L 3 Selected from C 1-10 Alkylene, C 1-10 Alkenylene, C 1-10 Alkyne, 2- to 10-membered heteroalkylene, and 2- to 10-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b replace;
[0150] D does not exist or is selected from C 3-12 Carbocyclic and 3 to 12 membered heterocyclic rings, each of which is optionally substituted by one or more R 11d replace;
[0151] L 4 Selected from C 1-10 Alkylene, C 1-10 Alkenylene, C 1-10 Alkyne, 2- to 10-membered heteroalkylene, and 2- to 10-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b replace;
[0152] W 3 Selected from N(R 3b ) and N, and W 4 Selected from C(R 4 ) and C(O); or W 3 Selected from C(R 3 ) and C(O), and W 4 Selected from N(R4b ) and N;
[0153] W 5 Selected from N(R 5b ), N and C (R 5 );
[0154] W 6 Selected from N, C(R 6 ) and C(O);
[0155] W 7 Selected from N, C(R 7 ) and C(O);
[0156] R 50 is hydrogen or a halogen;
[0157] R 3 、R 4 、R 5 、R 6 and R 7 Each independently selected from L 2 bonds, hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13)、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0158] R 3b 、R 4b and R 5b Each independently selected from L 2 bonds, hydrogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 ),-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0159] R 11a and R 11d Each occurrence is independently selected from halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 、-CH2S(O)2N(R 12 )(R 13 )、-CH2N(R 12 )S(O)2(R 13 ) and -P(O)(R 17 )(R17a ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0160] R 11b is independently selected at each occurrence from halogen, oxo, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 、-CH2S(O)2N(R 12 )(R 13 )、-CH2N(R 12 )S(O)2(R 13) and -P(O)(R 17 )(R 17a ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0161] R 12 independently selected at each occurrence from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0162] R 13 independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 haloalkyl; or R 12 and R 13 Together with the nitrogen atom to which they are attached, they form a 20 substituted 3- to 10-membered heterocycle;
[0163] R 14 independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 alkyl halide;
[0164] R 15 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0165] R 17 and R 17a Each occurrence is independently selected from C 1-6 Alkyl and C 3-6 Cycloalkyl, wherein C1-6 Alkyl and C 3-6 The cycloalkyl group is optionally substituted by one, two or three R 20 Replacement; or R 17 and R 17a Together with the phosphorus atom to which they are attached, they form a 3- to 10-membered heterocyclic ring;
[0166] R 20 is independently selected at each occurrence from halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3- to 10-membered heterocycle, -CH2-(3- to 10-membered heterocycle), -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 )、-OCH2C(O)OR 22 and -OC(O)R 25 , where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3 to 10 membered heterocycle and -CH2-(3 to 10 membered heterocycle) are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 ) and -OC(O)R 25 ;
[0167] R 21 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0168] R 22 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0169] R 23independently selected at each occurrence from H and C 1-6 alkyl;
[0170] R 24 independently selected at each occurrence from H and C 1-6 alkyl;
[0171] R 25 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings; and represents a single or double bond such that all valences are satisfied.
[0172] In certain aspects, the present disclosure provides a compound of formula (III):
[0173]
[0174] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0175] Selected from optionally one or more R 11a substituted 3- to 8-membered heterocycles;
[0176] L 1 Selected from bond, C 1-6 Alkylene and C 1-6 alkylene halide;
[0177] L 2 Selected from C 5-25 Alkylene, C 5-25 Alkenylene, C 5-25 Alkyne, 5- to 25-membered heteroalkylene, and 5- to 25-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b Substituted, where L 2 Covalently bound to W 3 、W 4 、W 5 、W 6 or W 7 one of;
[0178] W 3 Selected from N(R3b ) and N, and W 4 Selected from C(R 4 ) and C(O); or W 3 Selected from C(R 3 ) and C(O), and W 4 Selected from N(R 4b ) and N;
[0179] W 5 Selected from N(R 5b ), N and C (R 5 );
[0180] W 6 Selected from N, C(R 6 ) and C(O);
[0181] W 7 Selected from N, C(R 7 ) and C(O);
[0182] R 50 is hydrogen or a halogen;
[0183] R 3 、R 4 、R 5 、R 6 and R 7 Each independently selected from L 2 bonds, hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0184] R 3b 、R 4b and R 5b Each independently selected from L 2 bonds, hydrogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 ),-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14)C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0185] R 11a is independently selected at each occurrence from halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 、-CH2S(O)2N(R12 )(R 13 )、-CH2N(R 12 )S(O)2(R 13 ) and -P(O)(R 17 )(R 17a ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0186] R 11b is independently selected at each occurrence from halogen, oxo, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R15 、-CH2S(O)2N(R 12 )(R 13 )、-CH2N(R 12 )S(O)2(R 13 ) and -P(O)(R 17 )(R 17a ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 Replacement; R 12 independently selected at each occurrence from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 Replacement; R 13 independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 haloalkyl; or R 12 and R 13 Together with the nitrogen atom to which they are attached, they form a 20 substituted 3- to 10-membered heterocycle;
[0187] R 14 independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 alkyl halide;
[0188] R 15 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0189] R 17 and R 17aEach occurrence is independently selected from C 1-6 Alkyl and C 3-6 Cycloalkyl, wherein C 1-6 Alkyl and C 3-6 The cycloalkyl group is optionally substituted by one, two or three R 20 Replacement; or R 17 and R 17a Together with the phosphorus atom to which they are attached, they form a 3- to 10-membered heterocyclic ring;
[0190] R 20 is independently selected at each occurrence from halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3- to 10-membered heterocycle, -CH2-(3- to 10-membered heterocycle), -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 )、-OCH2C(O)OR 22 and -OC(O)R 25 , where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10carbocycle), 3 to 10 membered heterocycle and -CH2-(3 to 10 membered heterocycle) are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 ) and -OC(O)R 25 ;
[0191] R 21 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0192] R 22 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0193] R 23 independently selected at each occurrence from H and C 1-6 alkyl;
[0194] R 24 independently selected at each occurrence from H and C 1-6 alkyl;
[0195] R 25 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings; and represents a single or double bond such that all valences are satisfied.
[0196] In certain aspects, the present disclosure provides a compound as described herein or a pharmaceutically acceptable salt or solvate thereof. In certain aspects, the present disclosure provides a pharmaceutical composition comprising a compound as described herein or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.
[0197] In certain aspects, the present disclosure provides a method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound as described herein or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the cancer is a solid tumor or a hematological cancer. In some embodiments, an additional agent or therapy is administered to the subject.
[0198] In certain aspects, the present disclosure provides a method for reducing Ras signaling output, comprising contacting an SOS1 protein with an effective amount of a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, thereby reducing Ras signaling output. In some embodiments, the compound disrupts the interaction between the Ras protein and SOS1. In some embodiments, the Ras protein is wild-type K-Ras or a mutant K-Ras.
[0199] In certain aspects, the present disclosure provides a method of inhibiting cell growth, comprising administering an effective amount of a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, to a cell expressing SOS1, thereby inhibiting the growth of the cell.
[0200] In certain aspects, the present disclosure provides a method of reducing the Ras signaling output of a cell, comprising contacting the cell with an effective amount of a compound as described herein, or a pharmaceutically acceptable salt or solvate thereof, and an additional agent, wherein the additional agent is a chemotherapeutic agent, a radiopharmaceutical agent, an immunomodulatory agent, or an inhibitor of one or more targets selected from the group consisting of: MEK, epidermal growth factor receptor (EGFR), FGFR1, FGFR2, FGFR3, FGFR4, mitotic kinase, topoisomerase, ALK, c-MET, ErbB2, AXL, , NTRK1, RET, A-Raf, B-Raf, C-Raf, ERK, MDM2, mTOR, BET, IGF1 / 2, IGF1-R, CDK9, SHC, GAB, GRB, PI3-kinase, MAPK, SHIP1, SHIP2, SHP1, SHP2, SRC, JAK, PARP, BTK, FLT3, HDAC, VEGFR, PDGFR, LCK, Bcr-Abl, AKT, wild-type KRas, KRas mutants (e.g., KrasG12C, KRas G12D, KRas G12S, KRas G12V, KRas G13D, KRas G13C, or KRas G13V), ROS1, CDK4 / 6, and mutants of one or more targets thereof. In some embodiments, the additional agent is an inhibitor of one or more targets selected from MEK, epidermal growth factor receptor (EGFR), A-Raf, B-Raf, C-Raf, SHP2, wild-type KRas, KRas mutants, and CDK4 / 6. In some embodiments, the additional agent is a chemotherapeutic agent, a radiopharmaceutical, or an immunomodulatory agent.
[0201] In certain aspects, the present disclosure provides an SOS1 protein bound by a compound described herein or a pharmaceutically acceptable salt or solvate thereof, wherein the interaction of the SOS1 protein with the Ras protein is reduced compared to the SOS1 protein not bound to the compound.
[0202] In certain aspects, the present disclosure provides a method having the formula AL AB -B, wherein: A is a monovalent form of a compound described herein;
[0203] L AB is a covalent linker bonded to A and B; and
[0204] B is the monovalent form of the degradation enhancer.
[0205] In some embodiments, the degradation enhancer is capable of binding to a protein selected from the group consisting of: E3A, mdm2, APC, EDD1, SOCS / BC-box / eloBC / CUL5 / RING, LNXp80, CBX4, CBLL1, HACE1, HECTD1, HECTD2, HECTD3, HECTD4, HECW1, HECW2, HERC1, HERC2, HERC3, HERC4, HER5, HERC6, HUWE1, ITCH, NEDD4, NEDD4L, PPIL2, PRPF19, PIAS1, PIAS2, PIAS3, PIAS4, RANBP2, RNF4, RBX1, SMURF1, SMURF2, S TUB1, TOPORS, TRIP12, UBE3A, UBE3B, UBE3C, UBE3D, UBE4A, UBE4B, UBOX5, UBR5, VHL (von-Hippel-Lindau ubiquitin ligase), WWP1, WWP2, Parkin, MKRN1, CMA (chaperone-mediated autophagy), SCFb-TRCP (slip-retaining protein-F box (β-TRCP) ubiquitin complex), b-TRCP (b-transducing repeat-containing protein), cIAP1 (inhibitor of apoptosis protein 1), APC / C (anaphase-promoting complex / cyclin), CRBN (cereblon), CUL4-RBX1-DDB1-CRBN (CRL4 CRBN) ubiquitin ligases, XIAP, IAP, KEAP1, DCAF15, RNF114, DCAF16, AhR, SOCS2, KLHL12, UBR2, SPOP, KLHL3, KLHL20, KLHDC2, SPSB1, SPSB2, SPSB4, SOCS6, FBXO4, FBXO31, BTRC, FBW7, CDC20, PML, TRIM21, TRIM24, TRIM33, GID4, avadomide, iberdomide, and CC-885. In some embodiments, the degradation enhancer is capable of binding to a protein selected from the group consisting of: UBE2A, UBE2B, UBE2C, UBE2D1, UBE2D2, UBE2D3, UBE2DR, UBE2E1, UBE2E2, UBE2E3, UBE2F, UBE2G1, UBE2G2, UBE2H, UBE2I, UBE2J1, UBE2J2, UBE2K, UBE2L3, UBE2L6, UBE2L1, UBE2L2, UBE2L4, UBE2M, UBE2N, UBE2O, UBE2Q1, UBE2Q2, UBE2R1, UBE2R2, UBE2S, UBE2T, UBE2U, UBE2V1, UBE2V2, UBE2W, UBE2Z, ATG3, BIRC6, and UFC1.
[0206] In some embodiments, L AB Yes-L AB1 -L AB2 -L AB3 -L AB4 -L AB5 -;
[0207] L AB1 , L AB2 , L AB3 , L AB4 and L AB5 are independently selected from a bond, -O-, -N(R 100 )-、-C(O)-、-N(R 100 )C(O)-、-C(O)N(R 100 )-, -S-, -S(O)2-, -S(O)-, -S(O)2N(R 100 )-、-S(O)N(R 100 )-、-N(R 100 )S(O)-、-N(R 100 )S(O)2-、C 1-6 Alkylene, -(OC 1-6 alkyl) z -、-(C 1-6Alkyl-O) z -、C 2-6 Alkenylene, C 2-6 Alkynylidene, C 1-6 Halogenated alkylene, C 3-12 Carbocyclylene and 3 to 10 membered heterocyclylene, wherein C 1-6 Alkylene, C 2-6 Alkenylene, C 2-6 Alkynylidene, C 1-6 Halogenated alkylene, C 3-12 Carbocyclylene and 3 to 10 membered heterocyclylene are optionally substituted by one, two or three R 20 Replace; and wherein – (OC 1-6 alkyl) z -and–(C 1-6 Alkyl-O) z - Each C 1-6 The alkyl group is optionally substituted by one, two or three R 20 replace;
[0208] z is independently an integer from 0 to 10;
[0209] Each R 100 are independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocyclic ring), 3 to 10 membered heterocyclic ring and -CH2-(3 to 10 membered heterocyclic ring), wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3 to 10 membered heterocycle and -CH2-(3 to 10 membered heterocycle) are optionally substituted by one, two or three R 20 replace;
[0210] R 20 is independently selected at each occurrence from halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3- to 10-membered heterocycle, -CH2-(3- to 10-membered heterocycle), -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22)(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 )、-OCH2C(O)OR 22 and -OC(O)R 25 , where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3 to 10 membered heterocycle and -CH2-(3 to 10 membered heterocycle) are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 ) and -OC(O)R 25 ;
[0211] R 21 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0212] R 22 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0213] R 23 independently selected at each occurrence from H and C 1-6 alkyl;
[0214] R 24 independently selected at each occurrence from H and C 1-6 alkyl; and
[0215] R 25 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 3-10 carbocyclic rings and 3- to 10-membered heterocyclic rings.
[0216] In some embodiments, L AB is -(O-C2 alkyl) z -, and z is an integer from 1 to 10. In some embodiments, L AB is -(C2 alkyl-O-) z -, and z is an integer from 1 to 10. In some embodiments, L AB Yes - (CH2) zz1 L AB2 (CH2O) zz2 -, where L AB2 Selected from a bond, a 5- to 6-membered heterocyclylene, a phenylene group, a -C 2-4 alkylene, -SO2- and -NH-; and zz1 and zz2 are independently an integer from 0 to 10. In some embodiments, L AB Yes - (CH2) zz1 (CH2O) zz2 -, wherein zz1 and zz2 are each independently an integer from 0 to 10. In some embodiments, L AB In some embodiments, B is a monovalent form of a compound selected from:
[0217]
[0218]
[0219] Incorporation by reference
[0220] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. DETAILED DESCRIPTION
[0221] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this disclosure belongs. If there are multiple definitions of terms herein, those in this section shall prevail. All patents, patent applications, publications, and disclosed nucleotide and amino acid sequences (e.g., sequences available in GenBank or other databases) mentioned herein are incorporated herein by reference. Chemical structures are herein referred to as in The terms "a," "an," and "the" are used in conjunction with the IUPAC conventions implemented in the INCLUD software (Perkin Elmer, Inc., Cambridge, MA). Section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. As used in the specification and claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
[0222] The term "C x-y ” or “C x -C y " when used in conjunction with a chemical moiety such as alkyl, alkenyl, or alkynyl is intended to include groups containing x to y carbons in the chain. For example, the term "C x-y "Alkyl" refers to a substituted or unsubstituted saturated hydrocarbon group, including straight chain alkyl and branched chain alkyl groups containing x to y carbons in the chain.
[0223] "Alkyl" refers to a substituted or unsubstituted saturated hydrocarbon group, including straight-chain and branched alkyl groups. Alkyl groups may contain 1 to 12 carbon atoms (e.g., C 1-12 Alkyl), such as 1 to 8 carbon atoms (C 1-8 alkyl) or 1 to 6 carbon atoms (C 1-6 Alkyl). Exemplary alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, and decyl. The alkyl group is attached to the rest of the molecule by a single bond. Unless otherwise specifically stated in the specification, the alkyl group is optionally substituted with one or more substituents, such as those described herein.
[0224] "Haloalkyl" refers to an alkyl group substituted with one or more halogens. Exemplary haloalkyl groups include trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, and 1,2-dibromoethyl.
[0225] "Alkenyl" refers to a substituted or unsubstituted hydrocarbon group containing at least one double bond, including straight-chain and branched alkenyl groups. Alkenyl groups can contain 2 to 12 carbon atoms (e.g., C 2-12 alkenyl), such as 2 to 8 carbon atoms (C 2-8 alkenyl) or 2 to 6 carbon atoms (C 2-6 Exemplary alkenyl groups include ethenyl (i.e., vinyl), prop-1-enyl, but-1-enyl, pent-1-enyl, pent-1,4-dienyl, and the like. Unless otherwise specifically stated in the specification, an alkenyl group is optionally substituted with one or more substituents, such as those described herein.
[0226] "Alkynyl" refers to a substituted or unsubstituted hydrocarbon group containing at least one triple bond, including straight-chain and branched alkynyl groups. Alkynyl groups can contain 2 to 12 carbon atoms (e.g., C 2-12 Alkynyl), such as 2 to 8 carbon atoms (C 2-8 Alkynyl) or 2 to 6 carbon atoms (C 2-6 Alkynyl). Exemplary alkynyl groups include ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like. Unless stated otherwise specifically in the specification, an alkynyl group is optionally substituted with one or more substituents, such as those described herein.
[0227] "Alkylene" or "alkylene chain" refers to a substituted or unsubstituted divalent saturated hydrocarbon radical, including straight-chain alkylene and branched-chain alkylene, containing 1 to 12 carbon atoms (e.g., C 1-12 Alkylene), such as 1 to 8 carbon atoms (C 1-8 Alkylene) or 1 to 6 carbon atoms (C 1-6 Alkylene). Exemplary alkylene groups include methylene, ethylene, propylene, and n-butylene. Similarly, "alkenylene" and "alkynylene" refer to alkylene groups as defined above, each containing one or more carbon-carbon double bonds or carbon-carbon triple bonds. The point of attachment of the alkylene, alkenylene, or alkynylene chain to the rest of the molecule can be through one carbon or any two carbons in the chain. Unless specifically stated otherwise in the specification, an alkylene, alkenylene, or alkynylene group is optionally substituted with one or more substituents, such as those described herein.
[0228] "Heteroalkyl", "heteroalkenyl" and "heteroalkynyl" refer to substituted or unsubstituted alkyl, alkenyl and alkynyl groups, respectively, in which one or more (e.g., 1, 2, or 3) carbon atoms are replaced by heteroatoms (e.g., O, N, P, Si, S, or combinations thereof). Any nitrogen, phosphorus, and sulfur heteroatoms present in the chain may optionally be oxidized, and any nitrogen heteroatom may optionally be quaternized. If given, the numerical range refers to the total chain length. For example, a 3- to 8-membered heteroalkyl group has a chain length of 3 to 8 atoms. Connection to the rest of the molecule may be through a heteroatom or carbon in the heteroalkyl, heteroalkenyl, or heteroalkynyl chain. Unless specifically stated otherwise in the specification, a heteroalkyl, heteroalkenyl, or heteroalkynyl group is optionally substituted by one or more substituents, such as those described herein.
[0229] "Heteroalkylene," "heteroalkenylene," and "heteroalkynylene" refer to substituted or unsubstituted alkylene, alkenylene, and alkynylene, respectively, wherein one or more (e.g., 1, 2, or 3) carbon atoms are replaced by heteroatoms (e.g., O, N, P, Si, S, or combinations thereof). Any nitrogen, phosphorus, and sulfur heteroatoms present in the chain may optionally be oxidized, and any nitrogen heteroatom may optionally be quaternized. If given, the numerical range refers to the total chain length. For example, a 3- to 8-membered heteroalkylene has a chain length of 3 to 8 atoms. The point of attachment of the heteroalkylene, heteroalkenylene, or heteroalkynylene chain to the rest of the molecule may be through one heteroatom or one carbon, or any two heteroatoms, any two carbons, or any one heteroatom and any one carbon in the heteroalkylene, heteroalkenylene, or heteroalkynylene chain. Unless specifically stated otherwise in the specification, the heteroalkylene, heteroalkenylene, or heteroalkynylene is optionally substituted with one or more substituents, such as those described herein.
[0230] "Carbocycle" refers to a saturated, unsaturated, or aromatic ring in which each atom of the ring is a carbon atom. 3-10 Single ring, C 6-12 Double ring, C 6-12 Spirocyclic and C 6-12 Each ring of the bicyclic carbocyclic ring can be selected from saturated rings, unsaturated rings and aromatic rings. In some embodiments, the carbocyclic ring is C 6-12 Aryl, such as C 6-10 In some embodiments, the carbocyclic ring is C 6-12 In some embodiments, the carbocyclic ring is C 6-12 Cycloalkenyl. In an exemplary embodiment, an aromatic ring (e.g., phenyl) can be fused to a saturated ring or an unsaturated ring (e.g., cyclohexane, cyclopentane, or cyclohexene). As long as valence permits, any combination of saturated bicyclic, unsaturated bicyclic, and aromatic bicyclic is included in the definition of carbocycle. Exemplary carbocycles include cyclopentyl, cyclohexyl, cyclohexenyl, adamantyl, phenyl, indanyl, and naphthyl. Unless specifically stated otherwise in the specification, carbocycle is optionally substituted with one or more substituents (e.g., those substituents described herein).
[0231] "Heterocycle" refers to a saturated ring, unsaturated ring or aromatic ring containing one or more heteroatoms, such as 1,2 or 3 heteroatoms selected from O, S and N. Heterocycle includes 3 to 10 monocycles, 6 to 12 bicycles, 6 to 12 spirocycles and 6 to 12 bridged rings. Each ring of the bicyclic heterocycle can be selected from saturated rings, unsaturated rings and aromatic rings. If valence allows, the heterocycle can be connected to the rest of the molecule by any atom of the heterocycle (such as a carbon atom or nitrogen atom of the heterocycle). In some embodiments, the heterocycle is a 5 to 10 heteroaryl, such as a 5 or 6 heteroaryl. In some embodiments, the heterocycle is a 3 to 12 heterocycloalkyl. In an exemplary embodiment, the heterocycle (such as pyridyl) can be fused with a saturated ring or an unsaturated ring (such as cyclohexane, cyclopentane or cyclohexene). Exemplary heterocycles include pyrrolidinyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, piperidinyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, thienyl, oxazolyl, thiazolyl, morpholinyl, indazolyl, indolyl and quinolinyl. Unless otherwise specifically stated in the specification, the heterocycle is optionally substituted with one or more substituents, such as those described herein.
[0232] "Heteroaryl" refers to a 5- to 12-membered aromatic ring containing at least one heteroatom, such as 1, 2, or 3 heteroatoms selected from O, S, and N. As used herein, heteroaryl rings can be selected from monocyclic or bicyclic rings, including fused ring systems, spirocyclic ring systems, and bridged ring systems, wherein at least one of the rings in the ring system is aromatic. The heteroatoms in the heteroaryl group can be optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. If valence permits, the heteroaryl group can be attached to the rest of the molecule through any atom of the heteroaryl group, such as a carbon or nitrogen atom of the heteroaryl group. Examples of heteroaryl groups include, but are not limited to, azepine, benzimidazolyl, benzisothiazolyl, benzisoxazolyl, benzofuranyl, benzothiazolyl, benzothienyl, benzoxazolyl, furanyl, imidazolyl, indazolyl, indolyl, isoquinolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, purinyl, pyrazinyl, pyrazolidinyl, pyrazolyl, pyridazinyl, pyridazolyl, pyridinyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, tetrahydroquinolyl, thiadiazolyl, thiazolyl, and thienyl. Unless specifically stated otherwise in the specification, heteroaryl groups are optionally substituted with one or more substituents, such as those described herein.
[0233] Unless otherwise stated, hydrogen atoms are implicit in the structures depicted herein to the extent necessary to satisfy valence requirements.
[0234] Squiggly lines drawn across keys or dotted key The terms "bond breaking" and "bond joining" are used interchangeably herein to indicate where a bond breaks or joins. For example, in the structure In the case of R 7Yes 1-cyclopropyl-1-carbonitrile in the 7 can be described as
[0235] The term "substituted" refers to a portion of a substituent having a hydrogen replacement on one or more carbons or heteroatoms of a structure. It should be understood that "substituted" or "substituted by ... " include implicit restrictive conditions, i.e., such substitutions conform to the valence allowed for the substituted atom and substituent, and the substitution results in a stable compound, for example, one that does not spontaneously undergo transformations such as by rearrangement, cyclization, elimination, etc. As used herein, the term "substituted" is intended to include all substituents allowed of an organic compound. In a broad sense, the substituents allowed include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of an organic compound. For suitable organic compounds, the substituents allowed may be one or more and may be the same or different. For purposes of this disclosure, heteroatoms such as nitrogen may have any substituent allowed of an organic compound as described herein that satisfies the valence of a heteroatom.
[0236] The compounds disclosed herein, such as compounds of formula (I), are optionally substituted with one or more, such as 1, 2 or 3, substituents selected from:
[0237] Halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3- to 10-membered heterocycle, -CH2-(3- to 10-membered heterocycle), -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 )、-OCH2C(O)OR 22 and -OC(O)R 25 , where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3 to 10 membered heterocycle and -CH2-(3 to 10 membered heterocycle) are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 ) and -OC(O)R 25 ;
[0238] R 21 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0239] R 22 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0240] R 23 independently selected at each occurrence from H and C 1-6 alkyl;
[0241] R 24 independently selected at each occurrence from H and C 1-6 alkyl; and
[0242] R 25 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 3-10 carbocyclic rings and 3- to 10-membered heterocyclic rings.
[0243] In some embodiments, the compounds disclosed herein, such as compounds of formula (I), are optionally substituted with one or more, such as 1, 2, or 3, substituents selected from:
[0244] Halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3- to 10-membered heterocycle, -CH2-(3- to 10-membered heterocycle), -OR 21 、-SR 21 、-N(R 22 )(R23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 )、-OCH2C(O)OR 22 and -OC(O)R 25 , where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3 to 10 membered heterocycle and -CH2-(3 to 10 membered heterocycle) are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 、-SR 21 and -N(R 22 )(R 23 );
[0245] R 21 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0246] R22 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0247] R 23 independently selected at each occurrence from H and C 1-6 alkyl;
[0248] R 24 independently selected at each occurrence from H and C 1-6 alkyl; and
[0249] R 25 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 3-10 carbocyclic rings and 3- to 10-membered heterocyclic rings.
[0250] In some embodiments, the compounds disclosed herein, such as compounds of formula (I), are optionally substituted with one or more, such as 1, 2, or 3, substituents selected from the group consisting of halogen, oxo, =NH, -CN, -NO2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3- to 10-membered heterocycle, -CH2-(3- to 10-membered heterocycle), -OH, -OCH3, -OCH2CH3, -NH2, -NHCH3, and -NHCH2CH3, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10-C(CH3)3, -OH, -OCH3, -OCH2CH3, -NH2, -NHCH3 and -NHCH2CH3.
[0251] Those skilled in the art will appreciate that substituents themselves may be substituted, if appropriate. Unless specifically stated as "unsubstituted," references to chemical moieties herein are to be understood to include substituted variants. For example, reference to a "heteroaryl" group or moiety implicitly includes both substituted and unsubstituted variants.
[0252] Where divalent substituents are designated herein by their conventional chemical formula written from left to right, they are intended to encompass the isomers resulting from writing the structure from right to left, e.g., -CH2O- is also intended to encompass -OCH2-.
[0253] "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not. For example, an "optionally substituted" group can be unsubstituted or substituted.
[0254] The compounds of the present disclosure also include crystalline and amorphous forms of these compounds, pharmaceutically acceptable salts, and active metabolites having the same type of activity, including, for example, polymorphs, pseudopolymorphs, solvates, hydrates, unsolvated polymorphs (including anhydrates), conformational polymorphs, amorphous forms of the compounds, and mixtures thereof.
[0255] The compounds described herein may exhibit their natural isotopic abundance, or one or more of the atoms may be artificially enriched with a particular isotope having the same atomic number but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. All isotopic variations of the disclosed compounds, whether radioactive or not, are encompassed within the scope of the present disclosure. For example, hydrogen has three naturally occurring isotopes, represented as 1 H (hydrogen), 2 H (deuterium) and 3 H (tritium). Protium is the most abundant hydrogen isotope in nature. Deuterium enrichment can provide certain therapeutic advantages, such as increasing half-life and / or exposure in vivo, or can provide compounds useful for studying drug elimination and metabolic pathways in vivo. Examples of isotopes that can be incorporated into the compounds of the present disclosure include, but are not limited to 2 H. 3 H. 13 C.14 C. 15 N. 18 O. 17 O. 35 S. 36 Cl and 18 F. Of particular interest are compounds of formula (I) enriched with tritium or carbon-14, which can be used, for example, in tissue distribution studies; compounds of the present disclosure enriched with deuterium (particularly at metabolic sites), which result, for example, in compounds with greater metabolic stability; and compounds enriched with positron-emitting isotopes such as 11 C. 18 F. 15 O and 13 Compounds of formula (I) having N, which can be used, for example, in positron emission tomography (PET) studies. Isotopically enriched compounds can be prepared by conventional techniques known to those skilled in the art.
[0256] As used herein, the phrases "formula," "having the formula," or "having the structure" are not intended to be limiting and are used in the same manner as the term "comprising" is generally used. For example, if a structure is described, it is understood that all stereoisomers and tautomeric forms are encompassed unless otherwise indicated.
[0257] Some compounds described herein contain one or more asymmetric centers and therefore can produce enantiomers, diastereomers and other stereoisomeric forms, whose asymmetric centers can be defined as (R)- or (S)- according to absolute stereochemistry. In some embodiments, in order to optimize the therapeutic activity of the compounds of the present disclosure, for example, to treat fibrosis, it may be necessary for the carbon atoms to have a specific configuration (e.g., (R, R), (S, S), (S, R) or (R, S)) or to be enriched in stereoisomeric forms with such configurations. The compounds of the present disclosure can be provided as racemic mixtures. Therefore, unless otherwise stated, the present disclosure relates to racemic mixtures, pure stereoisomers (e.g., enantiomers and diastereomers), mixtures enriched in stereoisomers, etc. When describing a chemical structure without any stereochemistry herein, it is understood that all possible stereoisomers are encompassed by such structures. Similarly, when specific stereoisomers are shown or named herein, those skilled in the art will understand that, unless otherwise indicated, minor amounts of other stereoisomers may be present in the compositions of the present disclosure, provided that the presence of such other isomers does not abrogate the utility of the composition as a whole. Individual stereoisomers can be obtained by a number of methods known in the art, including preparation using chiral synthons or chiral reagents, resolution using chiral chromatography utilizing a suitable chiral stationary phase or support, or by chemically converting them to diastereomers, separating the diastereomers by conventional means such as chromatography or recrystallization, and then regenerating the original stereoisomers.
[0258] Additionally, where applicable, all cis-trans or E / Z isomers (geometric isomers), tautomeric forms, and topoisomeric forms of the compounds described herein are included within the scope of the present disclosure unless otherwise indicated.
[0259] The term "pharmaceutically acceptable" refers to a material that is biologically or otherwise unacceptable when used in the subject composition and method. For example, the term "pharmaceutically acceptable carrier" refers to a material such as an adjuvant, excipient, glidant, sweetener, diluent, preservative, dye, colorant, flavor enhancer, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier, which can be incorporated into the composition and applied to the patient without causing unacceptable biological effects or interacting with other components of the composition in an unacceptable manner. This type of pharmaceutically acceptable material typically meets the required standards of toxicology and production testing, and includes those materials that are determined as suitable inactive ingredients by the U.S. Food and Drug Administration.
[0260] The terms "salt" and "pharmaceutically acceptable salt" refer to salts prepared from bases or acids. Pharmaceutically acceptable salts are suitable for administration to patients such as mammals (e.g., salts with acceptable mammalian safety for a given dosage regimen). Salts can be formed from inorganic bases, organic bases, inorganic acids, and organic acids. In addition, when a compound contains both a basic moiety (such as an amine, pyridine, or imidazole) and an acidic moiety (such as a carboxylic acid or tetrazole), zwitterions can be formed and are included in the term "salt" as used herein. Preferred pharmaceutically acceptable salts of the compounds described herein are pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
[0261] "Pharmaceutically acceptable acid addition salts" refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid, hydrofluoric acid, phosphorous acid, and the like. Also included are salts formed with organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, and the like, and include, for example, acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Thus, exemplary salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, octanoate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, malate, tartrate, methanesulfonate, etc. Salts of amino acids such as arginate, gluconate, and galacturonate are also contemplated (see, e.g., Berge SM et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 66: 1-19 (1997)). In some embodiments, acid addition salts of basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt according to methods and techniques familiar to skilled artisans.
[0262] "Pharmaceutically acceptable base addition salts" refer to salts that retain the biological effectiveness and properties of the free acids and are not biologically or otherwise undesirable. These salts are prepared by adding inorganic or organic bases to the free acids. In some embodiments, pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali metals and alkaline earth metals, or organic amines. Salts derived from inorganic bases include, but are not limited to, sodium salts, potassium salts, lithium salts, ammonium salts, calcium salts, magnesium salts, iron salts, zinc salts, copper salts, manganese salts, aluminum salts, and the like. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, N,N-dibenzylethylenediamine, chloroprocaine, hydrabamine, choline, betaine, ethylenediamine, ethylenediphenylamine, N-methylglucamine, glucamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, and the like. See Berge et al. (supra).
[0263] The term "effective amount" or "therapeutically effective amount" refers to an amount of a pharmaceutical agent sufficient to achieve a beneficial or desired result. The therapeutically effective amount can vary depending on one or more of the following: the subject and disease condition being treated, the subject's weight and age, the severity of the disease condition, the mode of administration, etc., which can be readily determined by one of ordinary skill in the art. An effective amount of the active agent can be administered in a single dose or in multiple doses. A component can be described herein as having at least an effective amount or at least an effective amount, such as an amount related to a particular goal or purpose, such as any goal or purpose described herein. The term "effective amount" also applies to a dose that will provide a detectable image by an appropriate imaging method. The specific dose can vary depending on one or more of the following: the particular agent selected, the dosing regimen to be followed, whether it is administered in combination with other compounds, the time of administration, the tissue to be imaged, and the physical delivery system in which it is carried.
[0264] As used herein, "treatment" refers to methods used to obtain beneficial or desired results for a disease, disorder, or medical condition (such as cancer) in a subject, including but not limited to the following: (a) preventing the occurrence of the disease or medical condition, e.g., preventing the recurrence of the disease or medical condition, or prophylactically treating a subject susceptible to the disease or medical condition; (b) ameliorating the disease or medical condition, e.g., eliminating or causing regression of the disease or medical condition in a subject; (c) inhibiting the disease or medical condition, e.g., slowing or arresting the development of the disease or medical condition in a subject; or (d) alleviating the symptoms of the disease or medical condition in a subject. For example, "treating cancer" would include preventing the occurrence of cancer, ameliorating cancer, inhibiting cancer, and alleviating the symptoms of cancer. In addition, a therapeutic benefit is achieved by eradicating or ameliorating one or more of the physiological symptoms associated with the underlying disorder, such that an improvement is observed in the subject, notwithstanding that the subject may still be suffering from the underlying disorder.
[0265] As used herein, the term "therapeutic effect" encompasses therapeutic benefits and / or prophylactic benefits as described above. A prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, stopping, or reversing the progression of a disease or condition, or any combination thereof.
[0266] The terms "antagonist" and "inhibitor" are used interchangeably and refer to compounds that have the ability to inhibit a biological function (e.g., activity, expression, binding, protein-protein interaction) of a target protein (e.g., SOS1). Thus, the terms "antagonist" and "inhibitor" are defined in the context of the biological effects of the target protein. Although preferred antagonists herein specifically interact with (e.g., bind to) the target, compounds that inhibit the biological activity of the target protein by interacting with other members of the signal transduction pathway of which the target protein is a member are also specifically included in the definition.
[0267] The term "selective inhibition" or "selectively inhibit" refers to the ability of a biologically active agent to preferentially reduce target signaling activity over off-target signaling activity via direct or indirect interaction with the target.
[0268] The terms "subject" and "patient" refer to animals, such as mammals, for example, humans. The methods described herein can be used for both human therapy and veterinary applications. In some embodiments, the subject is a mammal, such as a human. "Mammal" includes humans and livestock animals, such as laboratory animals and domestic pets (e.g., cats, dogs, pigs, cows, sheep, goats, horses, rabbits), as well as non-livestock animals, such as wild animals, etc.
[0269] The terms "therapeutic agent," "therapeutic-capable agent," or "treatment agent" are used interchangeably and refer to a molecule or compound that confers some beneficial effect upon administration to a subject. Beneficial effects include enabling a diagnostic determination; ameliorating a disease, symptom, disorder, or pathological condition; reducing or preventing the onset of a disease, symptom, disorder, or condition; and generally combating a disease, symptom, disorder, or pathological condition.
[0270] The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may contain modified amino acids, and may be interrupted by non-amino acids. The term also encompasses amino acid polymers that have been modified (e.g., by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation to a labeling component). As used herein, the term "amino acid" refers to natural and / or non-natural or synthetic amino acids, including glycine and the D optical isomer or the L optical isomer, as well as amino acid analogs and peptide mimetics.
[0271] The terms "polynucleotide," "nucleotide," "nucleotide sequence," "nucleic acid," and "oligonucleotide" are used interchangeably. They refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or their analogs. A polynucleotide can have any three-dimensional structure and can perform any function, known or unknown. The following are non-limiting examples of polynucleotides: coding or non-coding regions of a gene or gene fragment, loci defined by linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, short interfering RNA (siRNA), short hairpin RNA (shRNA), microRNA (miRNA), ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. Polynucleotides can comprise one or more modified nucleotides, such as methylated nucleotides and nucleotide analogs, such as peptide nucleic acids (PNA), morpholino oligonucleotides and locked nucleic acids (LNA), glycerol nucleic acids (GNA), threose nucleic acids (TNA), 2'-fluoro nucleic acids, 2'-OMe nucleic acids and thiophosphate DNA. If present, the modification of the nucleotide structure can be given before or after the assembly of the polymer. The sequence of nucleotides can be interrupted by non-nucleotide components. Polynucleotides can be further modified after polymerization, such as by being put together with a labeling component or other put together targets.
[0272] As used herein, "expression" refers to the process by which a polynucleotide is transcribed from a DNA template (e.g., into mRNA or other RNA transcripts) and / or the process by which the transcribed mRNA is subsequently translated into a peptide, polypeptide, or protein. Transcripts and encoded polypeptides may be collectively referred to as "gene products." If the polynucleotide is derived from genomic DNA, expression may include splicing of mRNA in eukaryotic cells.
[0273] An "antigen" is a part or molecule that contains an epitope and therefore specifically binds to an antibody. An "antigen binding unit" can be a whole or fragment (or multiple fragments) of a full-length antibody, a structural variant thereof, a functional variant thereof, or a combination thereof. A full-length antibody can be, for example, a monoclonal antibody, a recombinant antibody, a chimeric antibody, a deimmunized antibody, a humanized antibody, and a human antibody. Examples of fragments of a full-length antibody can include, but are not limited to, a variable heavy chain (VH), a variable light chain (VL), a heavy chain found in camelids such as camels, llamas, and alpacas (VHH or VL), and a variable light chain (VL). H H), heavy chains found in sharks (V-NAR domains), single-domain antibodies (sdAbs, or "nanoantibodies") containing a single antigen-binding domain, Fv, Fd, Fab, Fab', F(ab')2, and "rIgG" (or half antibodies). Examples of modified fragments of antibodies may include, but are not limited to, scFv, di-scFv or bi(s)-scFv, scFv-Fc, scFv-zipper, scFab, Fab2, Fab3, diabody, single-chain diabody, tandem diabody (Tandab), tandem di-scFv, tandem tri-scFv, minibody (e.g., (VH-VL-CH3)2, (scFv-CH3)2, ((scFv)2-CH3+CH3), ((scFv)2-CH3) or (scFv-CH3-scFv)2, and multibody (e.g., triabody or tetrabody).
[0274] The term "antibody" encompasses any antigen binding unit, including but not limited to monoclonal antibodies, human antibodies, humanized antibodies, camelized antibodies, chimeric antibodies, and any other epitope-binding fragments.
[0275] "Prodrug" is meant to represent a compound that can be converted under physiological conditions or by solvolysis to a biologically active compound as described herein (e.g., a compound of Formula (I)). Thus, the term "prodrug" refers to a precursor of a pharmaceutically acceptable biologically active compound. In some aspects, a prodrug may be inactive when administered to a subject, but is converted to an active compound in vivo, for example, by hydrolysis. Prodrug compounds often provide advantages in solubility, tissue compatibility, or delayed release in mammalian organisms (see, e.g., Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam); Higuchi, T. et al., "Pro-drugs as Novel Delivery Systems," (1987) ACS Symposium Series, Vol. 14; and Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press (each of which is incorporated herein by reference in its entirety). The term "prodrug" is also meant to include any covalently bonded carriers that release the active compound in vivo when such prodrug is administered to a mammalian subject. As described herein, prodrugs of an active compound are generally prepared by modifying functional groups present in the active compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent active compound. Prodrugs include compounds in which a hydroxyl, amino, or sulfhydryl group is bonded to any group that, when the prodrug of the active compound is administered to a mammalian subject, cleaves to form a free hydroxyl, free amino, or free sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate, and benzoate derivatives of hydroxy functional groups, or acetamide, formamide, and benzamide derivatives of amine functional groups in the active compound, and the like.
[0276] The term "in vivo" refers to an event that occurs in the body of a subject. The term "ex vivo" refers to an event that first occurs outside of the body of a subject for subsequent application to the body of the subject in vivo. For example, an ex vivo preparation may involve preparing cells outside of the body of a subject for the purpose of introducing the prepared cells into the body of the same or a different subject. The term "in vitro" refers to an event that occurs outside of the body of a subject. For example, an in vitro assay encompasses any assay that is performed outside of the body of a subject. In vitro assays encompass cell-based assays in which live or dead cells are employed. In vitro assays also encompass cell-free assays in which intact cells are not employed.
[0277] The present disclosure also means to cover the metabolites in vivo of the disclosed compounds. Such products can be produced by oxidation, reduction, hydrolysis, amidation, esterification, etc. of the compound administered, for example, mainly due to enzymatic processes. Therefore, the present disclosure includes compounds produced by a process comprising administering the compound disclosed herein to a mammal for a period of time sufficient to produce its metabolites. Such products are typically administered to animals (such as rats, mice, guinea pigs, monkeys, or humans) using a radiolabeled compound of the present disclosure in a detectable dose, allowing enough time for metabolism, and isolating its conversion products from urine, blood, or other biological samples for identification.
[0278] The term "Ras" or "RAS" refers to proteins in the rat sarcoma (Ras) superfamily of small GTPases, such as proteins in the Ras subfamily. The Ras superfamily includes, but is not limited to, the Ras subfamily, the Rho subfamily, the Rab subfamily, the Rap subfamily, the Arf subfamily, the Ran subfamily, the Rheb subfamily, the RGK subfamily, the Rit subfamily, the Miro subfamily, and the unclassified subfamily. In some embodiments, the Ras protein is selected from KRAS (K-Ras or K-ras or Kras), HRAS (or H-Ras), NRAS (or N-Ras), MRAS (or M-Ras), ERAS (or E-Ras), RRAS2 (or R-Ras2), RALA (or RalA), RALB (or RalB), RIT1, and any combination thereof, such as selected from KRAS, HRAS, NRAS, RALA, RALB, and any combination thereof.
[0279] The terms "mutant Ras" and "Ras mutant" as used interchangeably herein refer to Ras proteins having one or more amino acid mutations relative to a common reference sequence, such as a wild-type (WT) sequence. In some embodiments, the mutant Ras is selected from mutant KRAS, mutant HRAS, mutant NRAS, mutant MRAS, mutant ERAS, mutant RRAS2, mutant RALA, mutant RALB, mutant RIT1, and any combination thereof, such as selected from mutant KRAS, mutant HRAS, mutant NRAS, mutant RALA, mutant RALB, and any combination thereof. In some embodiments, the mutation may be an introduced mutation, a naturally occurring mutation, or a non-naturally occurring mutation. In some embodiments, the mutation may be a substitution (e.g., a substituted amino acid), an insertion (e.g., an addition of one or more amino acids), or a deletion (e.g., a removal of one or more amino acids). In some embodiments, two or more mutations may be continuous, non-continuous, or a combination thereof. In some embodiments, the mutation may be present at any position of Ras. In some embodiments, the mutation may be present at position 12, 13, 62, 92, 95, or any combination thereof relative to Ras of SEQ ID No. 1 when optimally aligned. In some embodiments, the mutant Ras may comprise about or at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, or more than 50 mutations. In some embodiments, the mutant Ras may comprise at most about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 mutations. In some embodiments, the mutant Ras is about or at most about 500, 400, 300, 250, 240, 233, 230, 220, 219, 210, 208, 206, 204, 200, 195, 190, 189, 188, 187, 186, 185, 180, 175, 174, 173, 172, 171, 170, 169, 168, 167, 166, 165, 160, 155, 150, 125, 100, 90, 80, 70, 60, 50, or less than 50 amino acids in length. In some embodiments, the mutated amino acid is a proteinogenic amino acid, a natural amino acid, a standard amino acid, a non-standard amino acid, an atypical amino acid, an essential amino acid, a non-essential amino acid, or an unnatural amino acid.In some embodiments, the mutated amino acid has a positively charged side chain, a negatively charged side chain, a polar uncharged side chain, a non-polar side chain, a hydrophobic side chain, a hydrophilic side chain, an aliphatic side chain, an aromatic side chain, a cyclic side chain, an acyclic side chain, a basic side chain, or an acidic side chain. In some embodiments, the mutation comprises a reactive portion. In some embodiments, the substituted amino acid comprises a reactive portion. In some embodiments, the mutant Ras can be further modified, for example, by conjugation with a detectable label. In some embodiments, the mutant Ras is a full-length or truncated polypeptide. For example, the mutant Ras can be a truncated polypeptide comprising residues 1-169 or residues 11-183 (e.g., residues 11-183 of mutant RALA or mutant RALB).
[0280] Compound
[0281] The compounds of Formula (I) disclosed herein (including compounds of Formulas (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), (I-E1), (II-B), (II-C), and (III)) or pharmaceutically acceptable salts or solvates thereof are SOS modulators and have broad applications in therapeutics, diagnostics, and other biomedical research.
[0282] In certain aspects, the present disclosure provides a compound of formula (I):
[0283]
[0284] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0285] Selected from C 5-7 Carbocyclic and 5- to 7-membered heterocyclic rings, each of which is optionally substituted by one or more R 11 replace;
[0286] Not present or selected from C 3-8 Carbocyclic and 3 to 8 membered heterocyclic rings, each of which is optionally substituted by one or more R 11a replace;
[0287] L 1 Selected from bond, C 1-6 Alkylene and C 1-6 alkylene halide;
[0288] L 2 Selected from C 5-25 Alkylene, C 5-25 Alkenylene, C 5-25Alkyne, 5- to 25-membered heteroalkylene, and 5- to 25-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b Substituted, where L 2 Covalently bound to W 3 、W 4 、W 5 、W 6 or W 7 One of; or L 2 Yes-L 3 -DL 4 -, where L 4 Covalently bound to W 3 、W 4 、W 5 、W 6 or W 7 one of;
[0289] L 3 Selected from C 1-10 Alkylene, C 1-10 Alkenylene, C 1-10 Alkyne, 2- to 10-membered heteroalkylene, and 2- to 10-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b replace;
[0290] D does not exist or is selected from C 3-12 Carbocyclic and 3 to 12 membered heterocyclic rings, each of which is optionally substituted by one or more R 11d replace;
[0291] L 4 Selected from C 1-10 Alkylene, C 1-10 Alkenylene, C 1-10 Alkyne, 2- to 10-membered heteroalkylene, and 2- to 10-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b replace;
[0292] W 2 Selected from N(R 2b )、N、C(R 2 )、C(R 2 )(R 2a ) and C(O);
[0293] W 3 Selected from N(R 3b )、N、C(R 3 )、C(R 3 )(R 3a ) and C(O);
[0294] W 4 Selected from N(R 4b)、N、C(R 4 )、C(R 4 )(R 4a ) and C(O);
[0295] W 5 Selected from N(R 5b )、N、C(R 5 )、C(R 5 )(R 5a ) and C(O);
[0296] W 6 Selected from N(R 6b )、N、C(R 6 )、C(R 6 )(R 6a ) and C(O);
[0297] W 7 Selected from N(R 7b )、N、C(R 7 )、C(R 7 )(R 7a ) and C(O);
[0298] W 8 Selected from N(R 8b )、N、C(R 8 )、C(R 8 )(R 8a ) and C(O);
[0299] W 9 Selected from N, C(R 9 ) and C;
[0300] W 10 Selected from N, C(R 10 ) and C;
[0301] R 1 is optionally replaced by one or more R 11c Substituted C 1-3 alkyl;
[0302] R 2 、R 2a 、R 3a 、R 4a 、R 5a 、R 6a 、R 7a 、R 8 and R 8a are independently selected from hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0303] R 3 、R 4 、R 5 、R 6 and R 7 Each independently selected from L 2 bonds, hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0304] R 2b and R 8b Each independently selected from hydrogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR12 、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 ),-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0305] R 3b 、R 4b 、R 5b 、R 6b and R 7b Each independently selected from L 2 bonds, hydrogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 ),-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R12 )(R 13 )、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0306] R 9 and R 10 are each independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocyclic ring), 3- to 10-membered heterocyclic ring, and -CH2-(3- to 10-membered heterocyclic ring), wherein each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocyclic ring), 3 to 10 membered heterocyclic ring and -CH2-(3 to 10 membered heterocyclic ring) are independently optionally replaced by one, two or three R 20 replace;
[0307] R 11 、R 11a and R 11d Each occurrence is independently selected from halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12)(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 、-CH2S(O)2N(R 12 )(R 13 )、-CH2N(R 12 )S(O)2(R 13 ) and -P(O)(R 17 )(R 17a ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0308] R 11b is independently selected at each occurrence from halogen, oxo, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 、-CH2S(O)2N(R 12 )(R 13 )、-CH2N(R 12 )S(O)2(R 13 ) and -P(O)(R 17 )(R 17a ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 Replacement; R 11c is independently selected at each occurrence from halogen, -OR 12 and -N(R 12 )(R 13 );
[0309] R 12 independently selected at each occurrence from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 Replacement; R 13 independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 haloalkyl; or R 12 and R 13 Together with the nitrogen atom to which they are attached, they form a 20 substituted 3- to 10-membered heterocycle;
[0310] R 14 independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 alkyl halide;
[0311] R 15 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0312] R 17 and R 17a Each occurrence is independently selected from C 1-6 Alkyl and C 3-6 Cycloalkyl, wherein C 1-6 Alkyl and C 3-6 The cycloalkyl group is optionally substituted by one, two or three R 20 Replacement; or R 17 and R 17a Together with the phosphorus atom to which they are attached, they form a 3- to 10-membered heterocyclic ring;
[0313] R 20 is independently selected at each occurrence from halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3- to 10-membered heterocycle, -CH2-(3- to 10-membered heterocycle), -OR21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 )、-OCH2C(O)OR 22 and -OC(O)R 25 , where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3 to 10 membered heterocycle and -CH2-(3 to 10 membered heterocycle) are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23)、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 ) and -OC(O)R 25 ;
[0314] R 21 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0315] R 22 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0316] R 23 independently selected at each occurrence from H and C 1-6 alkyl;
[0317] R 24 independently selected at each occurrence from H and C 1-6 alkyl;
[0318] R 25 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, C1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings; and represents a single or double bond such that all valences are satisfied.
[0319] In certain aspects, the present disclosure provides a compound of formula (I):
[0320]
[0321] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0322] Selected from C 5-7 Carbocyclic and 5- to 7-membered heterocyclic rings, each of which is optionally substituted by one or more R 11 replace;
[0323] Not present or selected from C 3-8 Carbocyclic and 3 to 8 membered heterocyclic rings, each of which is optionally substituted by one or more R 11a replace;
[0324] L 1 Selected from bond, C 1-6 Alkylene and C 1-6 alkylene halide;
[0325] L 2 Selected from C 5-25 Alkylene, C 5-25 Alkenylene, C 5-25 Alkyne, 5- to 25-membered heteroalkylene, and 5- to 25-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b Substituted, where L 2 Covalently bound to W 3 、W 4 、W 5 、W 6 or W 7 one of;
[0326] W 2 Selected from N(R 2b )、N、C(R 2 )、C(R 2 )(R 2a ) and C(O);
[0327] W 3 Selected from N(R 3b )、N、C(R 3 )、C(R 3 )(R3a ) and C(O);
[0328] W 4 Selected from N(R 4b )、N、C(R 4 )、C(R 4 )(R 4a ) and C(O);
[0329] W 5 Selected from N(R 5b )、N、C(R 5 )、C(R 5 )(R 5a ) and C(O);
[0330] W 6 Selected from N(R 6b )、N、C(R 6 )、C(R 6 )(R 6a ) and C(O);
[0331] W 7 Selected from N(R 7b )、N、C(R 7 )、C(R 7 )(R 7a ) and C(O);
[0332] W 8 Selected from N(R 8b )、N、C(R 8 )、C(R 8 )(R 8a ) and C(O);
[0333] W 9 Selected from N, C(R 9 ) and C;
[0334] W 10 Selected from N, C(R 10 ) and C;
[0335] R 1 is optionally replaced by one or more R 11c Substituted C 1-3 alkyl;
[0336] R 2 、R 2a 、R 3a 、R 4a 、R 5a 、R 6a 、R 7a 、R 8 and R 8aare independently selected from hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0337] R 3 、R 4 、R 5 、R 6 and R 7Each independently selected from L 2 bonds, hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0338] R 2b and R 8b Each independently selected from hydrogen, -CN, C 1-6Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 ),-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0339] R 3b 、R 4b 、R 5b 、R 6b and R 7b Each independently selected from L 2 bonds, hydrogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 ),-C(O)R 15 、-S(O)R15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0340] R 9 and R 10 are each independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocyclic ring), 3- to 10-membered heterocyclic ring, and -CH2-(3- to 10-membered heterocyclic ring), wherein each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocyclic ring), 3 to 10 membered heterocyclic ring and -CH2-(3 to 10 membered heterocyclic ring) are independently optionally replaced by one, two or three R 20 Replacement; R 11 and R 11a Each occurrence is independently selected from halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13)、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 、-CH2S(O)2N(R 12 )(R 13 )、-CH2N(R 12 )S(O)2(R 13 ) and -P(O)(R 17 )(R 17a ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 Replacement; R 11b is independently selected at each occurrence from halogen, oxo, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13)、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 、-CH2S(O)2N(R 12 )(R 13 )、-CH2N(R 12 )S(O)2(R 13 ) and -P(O)(R 17 )(R 17a ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 Replacement; R 11c is independently selected at each occurrence from halogen, -OR 12 and -N(R 12 )(R 13 );
[0341] R 12 independently selected at each occurrence from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 Replacement; R 13 independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 haloalkyl; or R 12 and R 13 Together with the nitrogen atom to which they are attached, they form a 20 substituted 3- to 10-membered heterocycle;
[0342] R 14 independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 alkyl halide;
[0343] R 15 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0344] R 17 and R 17a Each occurrence is independently selected from C 1-6 Alkyl and C 3-6 Cycloalkyl, wherein C 1-6 Alkyl and C 3-6 The cycloalkyl group is optionally substituted by one, two or three R 20 Replacement; or R 17 and R 17a Together with the phosphorus atom to which they are attached, they form a 3- to 10-membered heterocyclic ring;
[0345] R 20 is independently selected at each occurrence from halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10carbocycle), 3- to 10-membered heterocycle, -CH2-(3- to 10-membered heterocycle), -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 )、-OCH2C(O)OR 22 and -OC(O)R 25 , where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3 to 10 membered heterocycle and -CH2-(3 to 10 membered heterocycle) are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 ) and -OC(O)R 25 ;
[0346] R 21 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0347] R 22 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0348] R 23 independently selected at each occurrence from H and C 1-6 alkyl;
[0349] R 24 independently selected at each occurrence from H and C 1-6 alkyl;
[0350] R 25 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-10The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings; and represents a single or double bond such that all valences are satisfied.
[0351] In some embodiments, the compound of formula (I) is a compound of formula (IA):
[0352]
[0353] or a pharmaceutically acceptable salt or solvate thereof.
[0354] In some embodiments, the compound of Formula (IA) is a compound selected from:
[0355]
[0356]
[0357] In some embodiments, the compound of formula (I) is a compound of formula (IB), such as a compound of formula (I-B1) or (I-B2):
[0358]
[0359] or a pharmaceutically acceptable salt or solvate thereof.
[0360] In some embodiments, the compound of Formula (IB) is a compound selected from:
[0361]
[0362]
[0363] In some embodiments, the compound of formula (I) is a compound of formula (IC), such as a compound of formula (I-C1), (I-C2), or (I-C3):
[0364]
[0365] or a pharmaceutically acceptable salt or solvate thereof.
[0366] In some embodiments, the compound of formula (IC) is a compound selected from:
[0367]
[0368]
[0369] In some embodiments, the compound of formula (I) is a compound of formula (ID), such as a compound of formula (I-D1) or (I-D2):
[0370]
[0371] or a pharmaceutically acceptable salt or solvate thereof.
[0372] In some embodiments, the compound of formula (ID) is a compound selected from:
[0373]
[0374]
[0375] In some embodiments, the compound of formula (I) is a compound of formula (IE), such as a compound of formula (I-E1):
[0376]
[0377] or a pharmaceutically acceptable salt or solvate thereof.
[0378] In some embodiments, the compound of Formula (IE) is a compound selected from:
[0379]
[0380]
[0381] In some embodiments, for compounds of Formula (I), (IA), (IB), (IC), (ID), or (IE), W 2 Is N. In some embodiments, W 3 Selected from N(R 3b )、N、C(R 3 ) and C(O), such as NCH3, N, CH, CCH3 and C(O). In some embodiments, W 3 Selected from C(R 3 ) and C(O), such as CH, CCH3 and C(O). In some embodiments, W 3 Is CH. In some embodiments, W 3 is CCH3. In some embodiments, W 4 Selected from N(R 4b )、N、C(R 4 ) and C(O), such as N(R 4b )、N、C(R 4 ) and C(O), where R4b and R 4 Each is independently related to L 2 In some embodiments, W 4 Selected from N(R 4b ) and N, such as N(R 4b ), where R 4b Yes and L 2 In some embodiments, W 4 Is N. In some embodiments, W 5 Selected from N(R 5b )、N、C(R 5 ) and C(O), such as N(R 5b )、NCH3、N、CH、C(R 5 ) and C(O), where R 5b and R 5 Each is independently related to L 2 In some embodiments, W 5 Selected from N(R 5b ), N and C (R 5 ), such as N(R 5b ), NCH3, N, CH and C(R 5 ), where R 5b and R 5 Each is independently related to L 2 In some embodiments, W 5 Selected from N(R 5b ) and C(R 5 ), such as N(R 5b ), NCH3 and CH, where R 5b Yes and L 2 In some embodiments, W 5 It is N(R 5b ). In some embodiments, W 6 Selected from C(R 6 ) and C(O), such as COCH3, CH, C(R 6 ) and C(O), where R 6 Yes and L 2 In some embodiments, W 6 Is C(O). In some embodiments, W 7 It is C(R 7 ), such as W 7 It is C(R 7 ) where R 7 Yes and L 2 In some embodiments, W 7 It is C(R 7 ), where R 7 Not hydrogen, such as R7 Selected from C 3-10 Cycloalkyl, 3- to 10-membered heterocycloalkyl, and -OR 12 , where C 3-10 Cycloalkyl and 3 to 10 membered heterocycloalkyl are optionally substituted by one, two or three R 20 In some embodiments, W 8 It is C(R 8 ), such as W 8 Is CH. In some embodiments, W 9 is C. In some embodiments, W 10 It’s C.
[0382] In some embodiments, for compounds of Formula (I), (IA), (IC), (ID), or (IE), W 2 It is N; W 3 It is N(R 3b );W 4 is C(O); and W 9 and W 10 Each is C, such as W 2 It is N; W 3 is NCH3;W 4 is C(O); and W 9 and W 10 Each is C. In some embodiments, for compounds of Formula (I), (IB), (IC), (ID), or (IE), W 2 It is N; W 3 is C(O); W 4 It is N(R 4b ); and W 9 and W 10 Each is C, such as W 2 It is N; W 3 is C(O); W 4 It is N(R 4b ), where R 4b Yes and L 2 and W 9 and W 10 Each is C. In some embodiments, for compounds of Formula (I), (IA), (IC), (ID), or (IE), W 2 It is N; W 3 It is C(R 3 );W 4 is N; and W 9 and W 10 Each is C, such as W 2 It is N; W 3 is CH or CCH3; W 4 is N; and W9 and W 10 Each is C. In some embodiments, for compounds of Formula (I), (IA), (IB), (IC), (ID), or (IE), W 5 It is C(R 5 );W 6 It is C(R 6 );W 7 It is C(R 7 );W 8 It is C(R 8 ); and W 9 and W 10 Each is C, such as W 5 is CH or C(R 5 ), where R 5 Yes and L 2 Key; W 6 is CH or C(R 6 ), where R 6 Yes and L 2 Key; W 7 It is C(R 7 );W 8 is CH; and W 9 and W 10 Each is C. In some embodiments, for compounds of Formula (I), (IA), (IB), (IC) or (IE), W 5 It is N(R 5b );W 6 is C(O); W 7 It is C(R 7 );W 8 It is C(R 8 ); and W 9 and W 10 Each is C, such as W 5 Is NCH3 or N(R 5b ), where R 5b Yes and L 2 Key; W 6 is C(O); W 7 It is C(R 7 );W 8 is CH; and W 9 and W 10 Each is C. In some embodiments, for compounds of Formula (I), (IA), (IB), (ID), or (IE), W 5 It is N; W 6 It is C(R 6 );W 7 It is C(R 7 );W 8It is C(R 8 ); and W 9 and W 10 Each is C, such as W 5 It is N; W 6 is COCH3, CH or C(R 6 ), where R 6 Yes and L 2 Key; W 7 It is C(R 7 );W 8 is CH; and W 9 and W 10 Each is C. In some embodiments, for compounds of Formula (I), (IA), (IB), (IC), (ID), or (IE), W 2 It is N; W 3 Selected from N(R 3b )、N、C(R 3 ) and C(O); W 4 Selected from N(R 4b )、N、C(R 4 ) and C(O); W 5 Selected from N(R 5b ), N and C (R 5 );W 6 Selected from C(R 6 ) and C(O); W 7 It is C(R 7 );W 8 It is C(R 8 ); and W 9 and W 10 Each is C, such as W 2 It is N; W 3 is selected from NCH3, N, CH, CCH3 and C(O); W 4 Selected from N(R 4b )、N、C(R 4 ) and C(O), where R 4b and R 4 Each is independently related to L 2 Key; W 5 Selected from N(R 5b ), NCH3, N, CH and C(R 5 ), where R 5b and R 5 Each is independently related to L 2 Key; W 6 Selected from COCH3, CH, C(R 6 ) and C(O), where R 6 Yes and L 2 Key; W 7It is C(R 7 );W 8 is CH; and W 9 and W 10 Each is C. In some embodiments, for compounds of Formula (I), (IA), (IB), (IC), (ID), or (IE), W 2 It is N; W 3 Selected from C(R 3 ) and C(O); W 4 Selected from N(R 4b ) and N; W 5 Selected from N(R 5b ) and C(R 5 );W 6 Selected from C(R 6 ) and C(O); W 7 It is C(R 7 );W 8 is CH; and W 9 and W 10 Each is C, such as W 2 It is N; W 3 is selected from CH, CCH3 and C(O); W 4 Selected from N(R 4b ) and N, where R 4b Yes and L 2 Key; W 5 Selected from N(R 5b ), NCH3, CH and C(R 5 ), where R 5b and R 5 Each is independently related to L 2 Key; W 6 Selected from COCH3, CH, C(R 6 ) and C(O), where R 6 Yes and L 2 Key; W 7 It is C(R 7 );W 8 is CH; and W 9 and W 10 Each is C.
[0383] In some embodiments, for compounds of formula (I), Selected from
[0384] In some embodiments, Selected from
[0385]
[0386] In some embodiments, Selected from
[0387] In some embodiments, Selected from In some embodiments,
[0388] yes like In some embodiments, yes like In some embodiments, yes In some embodiments,
[0389] yes like In some embodiments, Selected from In some embodiments, yes In some embodiments, yes In some embodiments, yes
[0390] In some embodiments, for compounds of Formula (I), (IA), (IB), (IC), (ID), or (IE), R 2 、R 2a 、R 3a 、R 4a 、R 5a 、R 6a 、R 7a 、R 8 and R 8a are independently selected from hydrogen, halogen, -CN, C 1-3 Alkyl, C 1-3 In some embodiments, R 2 、R 2a 、R 3a 、R 4a 、R 5a 、R 6a 、R 7a 、R 8and R 8a Each is independently selected from hydrogen and -CH3, such as hydrogen.
[0391] In some embodiments, for compounds of Formula (I), (IA), (IB), (IC), (ID), or (IE), R 3 、R 4 、R 5 and R 6 Each independently selected from L 2 bonds, hydrogen, halogen, -CN, C 1-6 Alkyl, C 3-6 Carbocycle, 3- to 6-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 and -S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3 to 6 membered heterocyclic ring are independently optionally substituted by one, two or three R 20 Replace; and R 7 Selected from L 2 Key, C 1-6 Alkyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-N(R 12 )(R 13 ),-C(O)R 15 、-C(O)N(R 12 )(R 13 )、-S(O)2R 15 and -SO2N(R 12 )(R 13 ), where C 1-6 Alkyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 In some embodiments, R 3 、R 4 、R 5 and R 6Each independently selected from L 2 bonds, hydrogen, halogen, -CN, C 1-3 Alkyl, C 1-3 Haloalkyl, -OH, -OCH3, -NH2, -NHCH3, -N(CH3)2; and R 7 Selected from L 2 Key, C 1-6 Alkyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-N(R 12 )(R 13 ),-C(O)R 15 、-C(O)N(R 12 )(R 13 )、-S(O)2R 15 and -SO2N(R 12 )(R 13 ), where C 1-6 Alkyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 In some embodiments, R 3 、R 4 、R 5 and R 6 Each independently selected from L 2 bonds, hydrogen, -CH3 and -OCH3; and R 7 Selected from L 2 Key, C 1-6 Alkyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-N(R 12 )(R 13 ),-C(O)R 15 、-C(O)N(R 12 )(R 13 )、-S(O)2R 15 and -SO2N(R 12 )(R 13 ), where C 1-6 Alkyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace.
[0392] In some embodiments, for compounds of Formula (I), (IA), (IB), (IC), (ID), or (IE), R 2b and R 8b are each independently selected from hydrogen and C 1-3 Alkyl, such as hydrogen and -CH3. In some embodiments, R3b 、R 4b 、R 5b 、R 6b and R 7b Each independently selected from L 2 bonds, hydrogen and C 1-3 Alkyl, such as L 2 In some embodiments, R 3b 、R 4b 、R 5b 、R 6b and R 7b Each independently selected from L 2 In some embodiments, R 3b 、R 4b 、R 5b 、R 6b and R 7b Each independently selected from L 2 In some embodiments, R 9 and R 10 Each is hydrogen.
[0393] For compounds of formula (I) (wherein L 2 Yes-L 3 -DL 4 -), it should be understood that for R 3 、R 4 、R 5 、R 6 、R 7 、R 3b 、R 4b 、R 5b 、R 6b or R 7b One of them, choose "with L 2 The key" is inherently included with -L 3 -DL 4 -keys, especially with L 4 For the avoidance of doubt, including "with L 2 The key of "R 3 、R 4 、R 5 、R 6 、R 7 、R 3b 、R 4b 、R 5b 、R 6b and / or R 7b Any enumeration may also be deemed to include "with L 4 key".
[0394] In some embodiments, for compounds of Formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), R 1 Selected from C 1-3 Alkyl and C 1-3 In some embodiments, R 1 Selected from C 1-3 Alkyl, such as -CH3 and -CH2CH3. In some embodiments, R 1 is -CH3. In some embodiments, R 1 is (R)-CH3. In some embodiments, R 1 It is (S)-CH3.
[0395] In some embodiments, for compounds of Formula (I), (IB), (IC), (I-C1), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), R 3 Selected from hydrogen, halogen, -CN, C 1-6 Alkyl, C 3-6 Carbocycle, 3- to 6-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 and -S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3 to 6 membered heterocyclic ring are independently optionally substituted by one, two or three R 20 In some embodiments, R 3 Selected from hydrogen, halogen, -CN, C 1-3 Alkyl, C 1-3In some embodiments, R 3 Selected from hydrogen, halogen, -CN, -OR 12 and optionally one, two or three R 20 Substituted C 1-6 alkyl.
[0396] In some embodiments, R 3 is optionally replaced by one, two or three R 20 Substituted C 1-6 In some embodiments, R 3 is hydrogen or -CH3. In some embodiments, R 3 In some embodiments, R 3 It is -CH3.
[0397] In some embodiments, for compounds of Formula (I), (IB), (IC), (I-C2), (ID), or (IE), R 3b Selected from hydrogen and C 1-3 Alkyl, such as hydrogen and -CH3. In some embodiments, R 3b is -CH3. In some embodiments, R 3b It's hydrogen.
[0398] In some embodiments, for compounds of Formula (I), (IA), (IB), (I-B2), (ID), (I-D2), (IE), or (I-E1), R 5 Selected from hydrogen, halogen, -CN, C 1-6 Alkyl, C 3-6 Carbocycle, 3- to 6-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 and -S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3 to 6 membered heterocyclic ring are independently optionally substituted by one, two or three R20 In some embodiments, R 5 Selected from hydrogen, halogen, -CN, C 1-3 Alkyl, C 1-3 In some embodiments, R 5 Selected from hydrogen, -OR 12 and optionally one, two or three R 20 Substituted C 1-6 In some embodiments, R 5 is hydrogen or -CH3. In some embodiments, R 5 In some embodiments, R 5 It is -CH3.
[0399] In some embodiments, for compounds of Formula (I), (IA), (IB), (I-B1), (ID), or (IE), R 5b Selected from hydrogen and C 1-3 Alkyl, such as hydrogen and -CH3. In some embodiments, R 5b selected from hydrogen and optionally substituted by one, two or three R 20 Substituted C 1-6 In some embodiments, R 5b is -CH3. In some embodiments, R 5b In some embodiments, R 5b Yes and L 2 key.
[0400] In some embodiments, for compounds of Formula (I), (IA), (IB), (I-B2), (IC), (I-C3), (IE), or (I-E1), R 6 Selected from hydrogen, halogen, -CN, C 1-6 Alkyl, C 3-6 Carbocycle, 3- to 6-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 and -S(O)2N(R12 )(R 13 ), where each C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3 to 6 membered heterocyclic ring are independently optionally substituted by one, two or three R 20 In some embodiments, R 6 Selected from hydrogen, halogen, -CN, C 1-3 Alkyl, C 1-3 In some embodiments, R 6 Selected from hydrogen, -OR 12 and optionally one, two or three R 20 Substituted C 1-6 alkyl, and wherein R 12 Selected from C 1-6 In some embodiments, R 6 In some embodiments, R 6 In some embodiments, R 6 It is -OCH3.
[0401] In some embodiments, for compounds of Formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), or (I-D2), R 7 Selected from C 1-6 Alkyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 ),-C(O)R 15 、-C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 In some embodiments, R 7 Selected from C 1-6 Alkyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-N(R 12 )(R 13 ),-C(O)R 15 、-C(O)N(R 12 )(R 13 )、-S(O)2R 15 and -SO2N(R 12 )(R 13 ), where C 1-6 Alkyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 In some embodiments, R 7 Selected from C 1-6 Alkyl, C 3-10 Cycloalkyl, 3- to 10-membered heterocycloalkyl and -N(R 12 )(R 13 ), where C 1-6 Alkyl, C 3-10 Cycloalkyl and 3 to 10 membered heterocycloalkyl are optionally substituted by one, two or three R 20 In some embodiments, R 7 is optionally replaced by one, two or three R 20 Substituted 3 to 10 membered heterocycloalkyl, such as R 7 is optionally replaced by one, two or three R 20 In some embodiments, R 7 is optionally replaced by one, two or three R 20 substituted 3- to 10-membered heterocycloalkyl, wherein the heterocycloalkyl contains at least one O, N, or S, such as one O atom, one or two N atoms, or one S atom. In some embodiments, R 7 is optionally replaced by one, two or three R 20 substituted 3 to 6 membered heterocycloalkyl, wherein the heterocycloalkyl comprises S(O)2. In some embodiments, R 7 is optionally replaced by one, two or three R 20 Substituted C 3-10 Cycloalkyl, such as R 7 is optionally replaced by one, two or three R 20 Substituted C 3-6 In some embodiments, R 7is optionally replaced by an R 20 Substituted C 3-4 Cycloalkyl, optionally wherein R 20 In some embodiments, R 7 is optionally replaced by one, two or three R 20 Substituted C 1-6 Alkyl groups, such as R 7 Is one or two R 20 Substituted C 1-6 In some embodiments, R 7 Yes-N(R 12 )(R 13 ). In some embodiments, R 7 Yes-OR 12 , such as -O(3 to 6 membered heterocycloalkyl). In some embodiments, R 7 is substituted with at least one -CN. 7 is unsubstituted. In some embodiments, R 7 Selected from C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted by one, two or three R 20 In some embodiments, R 7 Selected from C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted by one, two or three groups selected from oxo, -CN and C 1-6 In some embodiments, R 7 is replaced by one, two or three selected from oxo, -CN and C 1-3 In some embodiments, R 7 is replaced by one, two or three selected from oxo, -CN and C 1-3 Alkyl substituents substituted C 3-4 Cycloalkyl.
[0402] In some embodiments, for compounds of Formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), or (I-D2), R 7 Selected from C 1-6 Alkyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 ),-C(O)R 15 、-C(O)N(R 12)(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)(NR 12 )R 15 、-S(O)2N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 、-CH2S(O)(NR 12 )R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 In some embodiments, R 7 Selected from C 1-6 Alkyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-N(R 12 )(R 13 ),-C(O)R 15 、-C(O)N(R 12 )(R 13 )、-S(O)2R 15 、-S(O)(NR 12 )R 15 and -SO2N(R 12 )(R 13 ), where C 1-6 Alkyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 In some embodiments, R 7 is optionally replaced by one, two or three R 20 Substituted 3 to 6 membered heterocycloalkyl, wherein the heterocycloalkyl group comprises S(O)(NR 12 ).
[0403] In some embodiments, for compounds of Formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), or (I-D2), R 7 yes in:
[0404] n1 is an integer from 1 to 3;
[0405] n2 is an integer from 0 to 2;
[0406] n3 is an integer from 0 to 2;
[0407] n4 is 0 or 1; and
[0408] X is selected from -O-, -S(O2)-, -P(O)-, -CH2-, -CH(OH)-, -CH(OR 12 )-、-CH(R 20 )-、-C(R 20 )2-、-NR 12 -、-CH(N(R 12 )(R 13 ))-、-CH(C(O)N(R 12 )(R 13 ))- and -CH(S(O)2N(R 12 )(R 13 ))-,
[0409] where R 12 、R 13 and R 20 as defined elsewhere herein, and
[0410] Optionally, two of R 20 Group or R 20 and R 12 Combined with the atoms to which they are attached to form a ring.
[0411] For example, R 7 Can be selected from In some embodiments, X is selected from -O-, -S(O)2-, -S(O)(NR 12 )-, -P(O)-, -CH2-, -CH(OH)-, -CH(OR 12 )-、-CH(R 20 )-、-C(R 20 )2-、-NR 12 -、-CH(N(R 12 )(R 13 ))-、-CH(C(O)N(R 12 )(R 13 ))- and -CH(S(O)2N(R 12 )(R 13 ))-.
[0412] In some embodiments, for compounds of Formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), or (I-D2), R 7 Selected from
[0413] In some embodiments, R 7 Selected from
[0414] In some embodiments, R 7 Selected from
[0415] In some embodiments, R 7 Selected from
[0416] In some embodiments, R 7 Selected from
[0417]
[0418] In some embodiments, R 7 Selected from
[0419] In some embodiments, R 7 Selected from
[0420] In some embodiments, R 7 Selected from
[0421] In some embodiments, R 7 Selected from
[0422]
[0423] In some embodiments, R 7 Selected from
[0424] In some embodiments, R 7 Selected from
[0425] In some embodiments, R 7 Selected from
[0426] In some embodiments, R 7 Selected from
[0427] In some embodiments, R 7 Selected from
[0428] In some embodiments, R 7 Selected from
[0429] In some embodiments, R 7 yes In some embodiments, R 7 Selected from
[0430]
[0431] In some embodiments, R 7 Selected from
[0432]
[0433] In some embodiments, R 7 Selected from
[0434]
[0435] In some embodiments, R 7 Selected from In some embodiments, R 7 yes In some embodiments, R 7 yes In some embodiments, R 7 yes In some embodiments, R 7 yes In some embodiments, R 7 yes In some embodiments, R 7 yes In some embodiments, R 7 yes In some embodiments, R 7 yes In some embodiments, R 7 yes In some embodiments, R 7 yes
[0436] In some embodiments, for compounds of Formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), R 8 is selected from hydrogen, halogen and optionally substituted by one, two or three R 20 Substituted C 1-6 In some embodiments, R 8 It's hydrogen.
[0437] In some embodiments, for a compound of Formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), Selected from C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, such as C 5-7 Carbocyclic and 5- to 7-membered heterocyclic rings, each of which is optionally substituted by one or more R 11 In some embodiments, Selected from C 5-7 Cycloalkyl, 5- to 7-membered heterocycloalkyl, 5- to 7-membered heteroaryl and phenyl, each of which is optionally substituted by one or more R 11In some embodiments, is selected from phenyl, pyridyl and thienyl, each of which is optionally substituted by one or more R 11 In some embodiments, Selected from like In some embodiments, R 11 When present, each occurrence is independently selected from fluoro and -CH3. In some embodiments, Selected from like In some embodiments, yes In some embodiments, yes In some embodiments, yes
[0438] In some embodiments, for compounds of Formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), L 1 Selected from C 1-6 Alkylene and C 1-6 Halogenated alkylene, such as C 1-3 Alkylene and C 1-3 In some embodiments, L 1 Selected from bonds and C 1-3 In some embodiments, L 1 It is C 1-3 In some embodiments, L 1 It is C 1-2 In some embodiments, L 1 In some embodiments, L 1 In some embodiments, L 1 is -CF2CH2CH2-. In some embodiments, L 1 In some embodiments, L 1 Selected from bond, -O-, -NR 12 -、-S-、C 1-6 Alkylene, C 1-6 Haloalkylene and 2 to 6 membered heteroalkylene, wherein C 1-6 Alkylene, C 1-6The haloalkylene and 2 to 6 membered heteroalkylene groups are optionally substituted with one or more R 11b In some embodiments, L 1 Selected from -O-, -NR 12 -, -S- and 2 to 6 membered heteroalkylene, wherein the 2 to 6 membered heteroalkylene is optionally replaced by one or more R 11b In some embodiments, L 1 is optionally replaced by one or more R 11b (such as one, two or three R 11b ) substituted C 1-6 In some embodiments, L 1 Selected from bond, -O-, -NR 12 -、-S-、C 1-3 Alkylene, C 1-3 Haloalkylene and 2 to 3 membered heteroalkylene, wherein C 1-3 Alkylene, C 1-3 The haloalkylene and 2 to 3 membered heteroalkylene groups are optionally substituted with one or more R 11b In some embodiments, L 1 Selected from -O-, -NR 12 -, -S- and 2 to 3 membered heteroalkylene, wherein the 2 to 3 membered heteroalkylene is optionally replaced by one or more R 11b In some embodiments, L 1 is one or more R 11b (such as one, two or three R 11b ) substituted C 1-3 Alkylene.
[0439] In some embodiments, for a compound of Formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), Not present or selected from C 4-8 Carbocyclic and 4- to 8-membered heterocyclic rings, each of which is optionally substituted by one or more R 11a In some embodiments, is absent or is selected from phenyl and 4 to 8 membered heterocyclic rings, each of which is optionally replaced by one or more R 11a In some embodiments, is selected from phenyl and 4 to 8 membered heterocyclic rings, each of which is optionally replaced by one or more R 11a In some embodiments, is absent or selected from phenyl, azetidine, pyrrolidine and piperidine, each of which is optionally replaced by one or more R11a In some embodiments, is selected from phenyl, azetidine, pyrrolidine and piperidine, each of which is optionally replaced by one or more R 11a In some embodiments, is selected from azetidine, pyrrolidine and piperidine, each of which is optionally substituted with one or more -CH3. In some embodiments, is phenyl, which is optionally replaced by one or more R 11a In some embodiments, yes which are optionally replaced by one or more R 11a In some embodiments, yes In some embodiments, is an azetidine, which is optionally replaced by one or more R 11a In some embodiments, yes which are optionally replaced by one or more R 11a In some embodiments, yes In some embodiments, is pyrrolidine, which is optionally replaced by one or more R 11a In some embodiments, is piperidine, optionally substituted with one or more R 11a In some embodiments, yes which are optionally replaced by one or more R 11a In some embodiments, yes In some embodiments, is unsubstituted. In some embodiments, By one or more R 11a (such as one, two or three R 11a ) is substituted. In some embodiments, R 11a is independently selected at each occurrence from halogen, -CN, C 1-6 Alkyl, C 3-6 Carbocycle, 3- to 6-membered heterocycle, -OR 12 、-N(R 12 )(R 13 )、-N(R 14 )S(O)2R 15 、-C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R15 、-S(O)2R 15 and -S(O)2N(R 12 )(R 13 ), where C 1-6 Alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted by one, two or three R 20 In some embodiments, R 11a is independently selected at each occurrence from halogen, C 1-6 Alkyl and C 1-6 In some embodiments, R 11a In each occurrence, independently selected from C 1-6 In some embodiments, R 11a It is -CH3.
[0440] In some embodiments, for compounds of Formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), L 2 Selected from C 5-25 Alkylene, C 5-25 Alkenylene, C 5-25 Alkyne, 5- to 25-membered heteroalkylene, and 5- to 25-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b In some embodiments, L 2 Selected from C 5-25 Alkylene, C 5-25 alkenylene, 5- to 25-membered heteroalkylene, and 5- to 25-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b In some embodiments, L 2 Together with the atoms to which it is attached, it forms a 16- to 36-membered macrocyclic ring, such as a 16- to 24-membered macrocyclic ring. 2 Selected from C 6-15 Alkylene, C 6-15 Alkenylene, C 6-15 Alkyne, 6 to 15 membered heteroalkylene and 6 to 15 membered heteroalkenylene, each of which is optionally substituted by one or more R 11b In some embodiments, L 2 Selected from C 5-10 Alkylene, C 5-10 alkenylene, 5- to 10-membered heteroalkylene, and 5- to 10-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b In some embodiments, L 2The alkenylene or heteroalkenylene group contains one carbon-carbon double bond. In some embodiments, L 2 The heteroalkylene or heteroalkenylene group comprises at least one oxygen or nitrogen atom. 2 The heteroalkylene or heteroalkenylene group comprises at least one basic nitrogen. In some embodiments, L 2 Selected from C 5-9 Alkylene, C 5-9 Alkenylene and 5 to 9 membered heteroalkylene, each of which is optionally substituted by one or more R 11b In some embodiments, L 2 Selected from C 6-9 Alkylene, C 6-9 Alkenylene and 6 to 9 membered heteroalkylene, each of which is optionally substituted by one or more R 11b In some embodiments, L 2 Selected from C 5-8 Alkylene, C 5-8 Alkenylene and 5 to 8 membered heteroalkylene, each of which is optionally substituted by one or more R 11b In some embodiments, L 2 Selected from C 6-8 Alkylene, C 6-8 Alkenylene and 6 to 8 membered heteroalkylene, each of which is optionally substituted by one or more R 11b In some embodiments, L 2 Selected from C 6-8 Alkylene and C 6-8 alkenylene, each of which is optionally substituted by one or more R 11b In some embodiments, L 2 Selected from C6 alkylene and C6 alkenylene, each of which is optionally substituted by one or more R 11b In some embodiments, L 2 Selected from C7 alkylene and C7 alkenylene, each of which is optionally substituted by one or more R 11b In some embodiments, L 2 Selected from C8 alkylene and C8 alkenylene, each of which is optionally substituted by one or more R 11b In some embodiments, L 2 is -CH2CHCH(CH2)4-. In some embodiments, L 2 is a 6- to 8-membered heteroalkylene group, which is optionally substituted by one or more R 11b In some embodiments, L 2 is a 6-membered heteroalkylene group, which is optionally replaced by one or more R 11b In some embodiments, L2 is a 7-membered heteroalkylene group, which is optionally substituted by one or more R 11b In some embodiments, L 2 is an 8-membered heteroalkylene group, which is optionally replaced by one or more R 11b In some embodiments, L 2 is an 8-membered heteroalkylene group, wherein the heteroalkylene group contains one oxygen atom. 2 Yes - (CH2) 2-5 O(CH2) 0-5 -, such as L 2 Yes - (CH2) 2-5 O(CH2) 2-5 -. In some embodiments, L 2 is -(CH2)4O(CH2)3-. In some embodiments, R 11b is independently selected at each occurrence from halogen, oxo, C 1-6 Alkyl, C 1-6 Halogenated alkyl, (C 1-6 In some embodiments, R 11b is independently selected at each occurrence from -F, =O, -CH3, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2OH, and -OH. In some embodiments, R 11b is independently selected at each occurrence from -CH3, -CH2OH, -CH2F, -CHF2 and -CF3, or two R 11b Combine to form =O or C 3-6 In some embodiments, R 11b is independently selected at each occurrence from -CH3, -CH2OH, -CH2F, -CHF2 and -CF3, or two R 11b Combine to form C 3-6 In some embodiments, R 11b is independently selected at each occurrence from -CH3, -F, -CN, and -OH. In some embodiments, L 2 Contains -C(O)N(R 14 )-or-N(R 14 )C(O)-. In some embodiments, L 2 Contains -O-. In some embodiments, L 2 is substituted with at least one -CH3, -CH2OH, -CH2F, -CHF2 or -CF3, or two substituents are combined to form a cyclopropyl group. 2is substituted with at least one -CH3, -F, -CN or -OH. In some embodiments, L 2 is unsubstituted.
[0441] In some embodiments, for compounds of Formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), L 2 Yes-(C 1-5 Alkylene)-C(O)N(R 14 )-(C 1-5 Alkylene)-, such as -(C 1-5 Alkylene)-C(O)N(CH3)-(C 1-5 Alkylene)-or-(C 1-5 Alkylene)-C(O)NH-(C 1-5 Alkylene)-, wherein C 1-5 The alkylene group is optionally replaced by one or more R 11b In some embodiments, L 2 Yes-(C 1-2 Alkylene)-C(O)N(R 14 )-(C 3-4 Alkylene)-, such as -(C 1-2 Alkylene)-C(O)N(CH3)-(C 3-4 Alkylene)-or-(C 1-2 Alkylene)-C(O)NH-(C 3-4 Alkylene)-, wherein C 1-2 Alkylene and C 3-4 The alkylene groups are each independently optionally substituted with one or more R 11b In some embodiments, R 11b is independently selected at each occurrence from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, (C 1-6 In some embodiments, R 11b is independently selected at each occurrence from -F, -CH3, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2OH, and -OH. In some embodiments, R 11b is independently selected at each occurrence from -CH3, -CH2OH, -CH2F, -CHF2 and -CF3, or two R 11b Combine to form C 3-6 In some embodiments, R 11bis independently selected at each occurrence from -CH3, -F, -CN, and -OH. In some embodiments, L 2 Substituted with at least one -CH3, -F, -CN or -OH.
[0442] In some embodiments, L 2 Selected from -C(R 11b )(R 11b )-(C 3-10 Alkylene)-C(R 11b )(R 11b )-、-CH(R 11b )-(C 3-10 Alkylene)-C(R 11b )(R 11b )-、-CH2-(C 3-10 Alkylene)-C(R 11b )(R 11b )-、-CH(R 11b )-(C 3-10 Alkylene)-CH(R 11b )-、-CH2-(C 3-10 Alkylene)-CH(R 11b )-、-C(R 11b )(R 11b )-(C 3-10 alkenylene)-C(R 11b )(R 11b )-、-CH(R 11b )-(C 3-10 alkenylene)-C(R 11b )(R 11b )-、-CH2-(C 3-10 alkenylene)-C(R 11b )(R 11b )-、-CH(R 11b )-(C 3-10 alkenylene)-CH(R 11b )-、-CH2-(C 3-10 alkenylene)-CH(R 11b )-、-C(R 11b )(R 11b )-(3- to 10-membered heteroalkylene)-C(R 11b )(R 11b )-、-CH(R 11b )-(3- to 10-membered heteroalkylene)-C(R 11b )(R 11b )-、-CH2-(3 to 10 membered heteroalkylene)-C(R 11b )(R 11b )-、-CH(R 11b)-(3- to 10-membered heteroalkylene)-CH(R 11b )-、-CH2-(3 to 10 membered heteroalkylene)-CH(R 11b )-、-C(R 11b )(R 11b )-(3- to 10-membered heteroalkenylene)-C(R 11b )(R 11b )-、-CH(R 11b )-(3- to 10-membered heteroalkenylene)-C(R 11b )(R 11b )-、-CH2-(3 to 10 membered heteroalkenylene)-C(R 11b )(R 11b )-、-CH(R 11b )-(3- to 10-membered heteroalkenylene)-CH(R 11b )- and -CH2-(3 to 10 membered heteroalkenylene)-CH(R 11b )-. In some embodiments, L 2 Selected from -C(R 11b )(R 11b )-(C 3-10 Alkylene)-C(R 11b )(R 11b )-、-CH(R 11b )-(C 3-10 Alkylene)-C(R 11b )(R 11b )-、-CH2-(C 3-10 Alkylene)-C(R 11b )(R 11b )-、-CH(R 11b )-(C 3-10 Alkylene)-CH(R 11b )- and -CH2-(C 3-10 Alkylene)-CH(R 11b )-. In some embodiments, L 2 Selected from -C(R 11b )(R 11b )-(C 3-10 alkenylene)-C(R 11b )(R 11b )-、-CH(R 11b )-(C 3-10 alkenylene)-C(R 11b )(R 11b )-、-CH2-(C 3-10 alkenylene)-C(R 11b )(R 11b )-、-CH(R 11b )-(C 3-10alkenylene)-CH(R 11b )- and -CH2-(C 3-10 alkenylene)-CH(R 11b )-. In some embodiments, L 2 Selected from -C(R 11b )(R 11b )-(3- to 10-membered heteroalkylene)-C(R 11b )(R 11b )-、-CH(R 11b )-(3- to 10-membered heteroalkylene)-C(R 11b )(R 11b )-、-CH2-(3 to 10 membered heteroalkylene)-C(R 11b )(R 11b )-、-CH(R 11b )-(3- to 10-membered heteroalkylene)-CH(R 11b )- and -CH2-(3 to 10 membered heteroalkylene)-CH(R 11b )-. In some embodiments, L 2 Selected from -C(R 11b )(R 11b )-(3- to 10-membered heteroalkenylene)-C(R 11b )(R 11b )-、-CH(R 11b )-(3- to 10-membered heteroalkenylene)-C(R 11b )(R 11b )-、-CH2-(3 to 10 membered heteroalkenylene)-C(R 11b )(R 11b )-、-CH(R 11b )-(3- to 10-membered heteroalkenylene)-CH(R 11b )- and -CH2-(3 to 10 membered heteroalkenylene)-CH(R 11b )-. Any C in this paragraph 3-10 Alkylene, C 3-10 The alkenylene, 3- to 10-membered heteroalkylene, or 3- to 10-membered heteroalkenylene may be optionally substituted by one or more R 11b In some embodiments, R 11b is independently selected at each occurrence from halogen, oxo, C 1-6 Alkyl, C 1-6 Halogenated alkyl, (C 1-6 In some embodiments, R 11b is independently selected at each occurrence from -F, -CH3, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2OH, and -OH. In some embodiments, R11b is independently selected at each occurrence from -CH3, -CH2OH, -CH2F, -CHF2 and -CF3, or two R 11b Combine to form =O or C 3-6 Cycloalkyl, such as cyclopropyl.
[0443] In some embodiments, for compounds of Formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), L 2 Yes-L 3 -DL 4 -, where L 3 Selected from C 1-10 Alkylene, C 1-10 Alkenylene, C 1-10 Alkyne, 2- to 10-membered heteroalkylene, and 2- to 10-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b Substitution; D is absent or selected from C 3-12 Carbocyclic and 3 to 12 membered heterocyclic rings, each of which is optionally substituted by one or more R 11d Replace; and L 4 Selected from C 1-10 Alkylene, C 1-10 Alkenylene, C 1-10 Alkyne, 2- to 10-membered heteroalkylene, and 2- to 10-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b As described above, alkenylene and alkynylene groups each contain one or more carbon-carbon double or triple bonds (i.e., contain two or more carbon atoms, such as in C 2-10 Alkenylene, C 2-10 Alkynylidene, C 2-8 Alkenylene, C 2-8 Alkynylidene, C 5-25 Alkenylene, C 5-25 Alkynylidene, C 6-15 Alkenylene, C 6-15 Alkynylidene, C 5-10 Alkenylene and C 5-10 Similarly, heteroalkenylene contains one or more carbon-carbon double bonds (i.e., contains two or more carbon atoms and one or more heteroatoms, e.g., as in 3- to 10-membered heteroalkenylene, 3- to 8-membered heteroalkenylene, 5- to 25-membered heteroalkenylene, 6- to 15-membered heteroalkenylene, and 5- to 10-membered heteroalkenylene). In some embodiments, L 2 Yes-L 3 -DL 4 -, where L 3Selected from C 1-10 Alkylene, C 1-10 Alkenylene, C 1-10 Alkyne, 2- to 10-membered heteroalkylene, and 2- to 10-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b Substituted; D is selected from C 3-12 Carbocyclic and 3 to 12 membered heterocyclic rings, each of which is optionally substituted by one or more R 11d Replace; and L 4 In some embodiments, L 2 Yes-L 3 -DL 4 -, where L 3 Selected from C 1-8 Alkylene, C 1-8 alkenylene, 2 to 8 membered heteroalkylene and 2 to 8 membered heteroalkenylene, each of which is optionally substituted by one or more R 11b Substitution; D is absent or selected from C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted by one or more R 11d Replace; and L 4 Selected from C 1-8 Alkylene, C 1-8 alkenylene, 2 to 8 membered heteroalkylene and 2 to 8 membered heteroalkenylene, each of which is optionally substituted by one or more R 11b In some embodiments, L 2 Yes-L 3 -DL 4 -, where L 3 Selected from C 1-8 Alkylene, C 1-8 alkenylene, 2 to 8 membered heteroalkylene and 2 to 8 membered heteroalkenylene, each of which is optionally substituted by one or more R 11b Substituted; D is selected from C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted by one or more R 11d Replace; and L 4 Selected from C 1-8 Alkylene, C 1-8 alkenylene, 2 to 8 membered heteroalkylene and 2 to 8 membered heteroalkenylene, each of which is optionally substituted by one or more R 11b In some embodiments, R 11b is independently selected at each occurrence from halogen, oxo, C 1-6 Alkyl, C 1-6 Halogenated alkyl, (C 1-6 In some embodiments, R 11bis independently selected at each occurrence from -F, -CH3, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2OH, and -OH. In some embodiments, R 11b is independently selected at each occurrence from -CH3, -CH2OH, -CH2F, -CHF2 and -CF3, or two R 11b Combine to form =O or C 3-6 In some embodiments, D is selected from phenyl and 5 to 8 membered heteroaryl, such as triazole and imidazole. In some embodiments, D is unsubstituted. In some embodiments, D is replaced by one or more R 11d (such as one, two or three R 11d )replace.
[0444] In some embodiments, for compounds of formula (I), L 2 Covalently bound to W 3 、W 4 、W 5 、W 6 or W 7 One of; or L 2 Yes-L 3 -DL 4 -, where L 4 Covalently bound to W 3 、W 4 、W 5 、W 6 or W 7 For example, L 2 Can be covalently bound to W 3 —where R 3b or R 3 Yes and L 2 In some embodiments, L 2 Covalently bound to W 4 —where R 4b or R 4 Yes and L 2 In some embodiments, L 2 Covalently bound to W 5 —where R 5b or R 5 Yes and L 2 In some embodiments, L 2 Covalently bound to W 6 —where R 6b or R 6 Yes and L 2In some embodiments, L 2 Covalently bound to W 7 —where R 7b or R 7 Yes and L 2 The bond of - as described in formula (IE).
[0445] In some embodiments, for compounds of Formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1):
[0446] R 20 is independently selected at each occurrence from halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3- to 10-membered heterocycle, -CH2-(3- to 10-membered heterocycle), -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 )、-OCH2C(O)OR 22 and -OC(O)R 25 , where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3 to 10 membered heterocycle and -CH2-(3 to 10 membered heterocycle) are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 、-SR 21 and -N(R 22 )(R 23 );
[0447] R 21 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0448] R 22 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0449] R 23 independently selected at each occurrence from H and C 1-6 alkyl;
[0450] R 24 independently selected at each occurrence from H and C 1-6 alkyl; and
[0451] R 25 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-10The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 3-10 carbocyclic rings and 3- to 10-membered heterocyclic rings.
[0452] In some embodiments, for compounds of Formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), R 20 is independently selected at each occurrence from halogen, oxo, ═NR 22 、-CN、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3- to 10-membered heterocycle, -CH2-(3- to 10-membered heterocycle), -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)(NR 22 )R 25 、-S(O)2N(R 22 )(R 23 )、-OCH2C(O)OR 22 and -OC(O)R 25 , where C 1-6 Alkyl, C 2-6 Alkenyl, C2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3 to 10 membered heterocycle and -CH2-(3 to 10 membered heterocycle) are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, oxo, =NR 22 、-CN、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 、-SR 21 and -N(R 22 )(R 23 ).
[0453] In some embodiments, for compounds of Formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), R 20 is independently selected at each occurrence from halogen, oxo, =NH, -CN, -NO2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3- to 10-membered heterocycle, -CH2-(3- to 10-membered heterocycle), -OH, -OCH3, -OCH2CH3, -NH2, -NHCH3, and -NHCH2CH3, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 -C(CH3)3, -OH, -OCH3, -OCH2CH3, -NH2, -NHCH3 and -NHCH2CH3.
[0454] In some embodiments, for compounds of Formula (I-B1), R 5b is -CH3; R 7 Selected from C 1-6 Alkyl, C 3-10 Carbocyclic ring, 3- to 10-membered heterocyclic ring, -N(R 12 )(R 13),-C(O)R 15 、-C(O)N(R 12 )(R 13 )、-S(O)2R 15 and -SO2N(R 12 )(R 13 ), where C 1-6 Alkyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 Replace; and R 8 In some embodiments, for compounds of formula (I-B2), R 5 is hydrogen; R 6 is selected from hydrogen and -OCH3; R 7 Selected from C 1-6 Alkyl, C 3-10 Carbocyclic ring, 3- to 10-membered heterocyclic ring, -N(R 12 )(R 13 ),-C(O)R 15 、-C(O)N(R 12 )(R 13 )、-S(O)2R 15 and -SO2N(R 12 )(R 13 ), where C 1-6 Alkyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 Replace; and R 8 It's hydrogen.
[0455] In some embodiments, for compounds of formula (I-C1), R 3 is hydrogen or -CH3; R 7 Selected from C 1-6 Alkyl, C 3-10 Carbocyclic ring, 3- to 10-membered heterocyclic ring, -N(R 12 )(R 13 ),-C(O)R 15 、-C(O)N(R 12 )(R 13 )、-S(O)2R 15 and -SO2N(R 12 )(R 13 ), where C 1-6 Alkyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 Replace; and R 8 In some embodiments, for compounds of formula (I-C2), R 3b is -CH3; R7 Selected from C 1-6 Alkyl, C 3-10 Carbocyclic ring, 3- to 10-membered heterocyclic ring, -N(R 12 )(R 13 ),-C(O)R 15 、-C(O)N(R 12 )(R 13 )、-S(O)2R 15 and -SO2N(R 12 )(R 13 ), where C 1-6 Alkyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 Replace; and R 8 In some embodiments, for compounds of formula (I-C3), R 3 is hydrogen or -CH3; R 6 is selected from hydrogen and -OCH3; R 7 Selected from C 1-6 Alkyl, C 3-10 Carbocyclic ring, 3- to 10-membered heterocyclic ring, -N(R 12 )(R 13 ),-C(O)R 15 、-C(O)N(R 12 )(R 13 )、-S(O)2R 15 and -SO2N(R 12 )(R 13 ), where C 1-6 Alkyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 Replace; and R 8 It's hydrogen.
[0456] In some embodiments, for compounds of Formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1): R 1 is -CH3; is selected from phenyl and 5- to 7-membered heteroaryl, each of which is optionally substituted by one or more R 11 Replace; L 1 Selected from bonds and C 1-3 alkylene halide; is selected from the group consisting of absent, phenyl and 4 to 8 membered heterocyclic rings, wherein the phenyl and 4 to 8 membered heterocyclic rings are optionally replaced by one or more R 11a Replace; and L 2Selected from C 5-10 Alkylene, C 5-10 alkenylene, 5- to 10-membered heteroalkylene, and 5- to 10-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b In some embodiments, R 11 When present, it is fluorine; R 11a When present, it is -CH3; and R 11b When present, is selected from halogen, oxo, C 1-6 Alkyl, C 1-6 Halogenated alkyl, (C 1-6 alkyl)-OH and -OH.
[0457] In some embodiments, for compounds of Formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1): R 1 is -CH3; Selected from and L 1 It is C 1-2 alkylene halide; yes which are optionally replaced by one or more R 11a Replace; and L 2 Selected from C 6-8 Alkylene, C 6-8 Alkenylene and 6 to 8 membered heteroalkylene, each of which is optionally substituted by one or more R 11b In some embodiments, R 1 is -CH3; yes L 1 It is C 1-2 alkylene halide; yes And L 2 is a 6- to 8-membered heteroalkylene group, which is optionally substituted by one or more R 11b In some embodiments, R 1 is -CH3; Selected from L 1 It is C 1-2 alkylene halide; yes which are optionally replaced by one or more R 11a Replace; and L 2 Selected from C 6-8 Alkylene and C 6-8alkenylene, each of which is optionally substituted by one or more R 11b In some embodiments, R 1 is -CH3; yes L 1 It is C 1-2 alkylene halide; yes And L 2 It is C 6-8 Alkenylene, which is optionally substituted by one or more R 11b In some embodiments, R 1 is -CH3; Selected from and L 1 It is C 1-2 alkylene halide; yes which are optionally replaced by one or more R 11a Replace; and L 2 Yes-(C 1-2 Alkylene)-C(O)N(CH3)-(C 3-4 Alkylene)-or-(C 1-2 Alkylene)-C(O)NH-(C 3-4 Alkylene)-, wherein C 1-2 Alkylene and C 3-4 The alkylene groups are each independently optionally substituted with one or more R 11b In some embodiments, R 11a When present, it is -CH3; and R 11b When present, is selected from halogen, -CN, oxo, C 1-3 Alkyl, C 1-3 Halogenated alkyl, (C 1-3 alkyl)-OH and -OH.
[0458] In some embodiments, for compounds of Formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1): R 1 is -CH3; Selected from L 1 It is C 1-2 alkylene halide; yes And L 2 Selected from C 6-8 Alkylene, C 6-8Alkenylene and 6 to 8 membered heteroalkylene, each of which is optionally substituted by one or more R 11b In some embodiments, R 1 is -CH3; Selected from L 1 It is C 1-2 alkylene halide; yes And L 2 Selected from C 6-8 Alkylene and C 6-8 alkenylene, each of which is optionally substituted by one or more R 11b In some embodiments, R 1 is -CH3; Selected from L 1 It is C 1-2 alkylene halide; yes And L 2 Yes-(C 1-2 Alkylene)-C(O)N(CH3)-(C 3-4 Alkylene)-or-(C 1-2 Alkylene)-C(O)NH-(C 3-4 Alkylene)-, wherein C 1-2 Alkylene and C 3-4 The alkylene groups are each independently optionally substituted with one or more R 11b In some embodiments, R 11b When present, is selected from halogen, -CN, oxo, C 1-3 Alkyl, C 1-3 Halogenated alkyl, (C 1-3 alkyl)-OH and -OH.
[0459] In some embodiments, the compound of formula (I) is a compound of the formula:
[0460]
[0461] where R 50 is hydrogen or R 11 and R 51 is hydrogen or a halogen.
[0462] In some embodiments, the compound of formula (I) is a compound of the formula: like where R 50In some embodiments, the compound of formula (IA) is a compound of the formula: like where R 50 In some embodiments, the compound of formula (IB) is a compound of the formula: like where R 50 In some embodiments, the compound of formula (IC) is a compound of the formula: like where R 50 In some embodiments, the compound of formula (IC) is a compound of the formula: like where R 50 In some embodiments, the compound of formula (ID) is a compound of the formula:
[0463] like where R 50 In some embodiments, the compound of formula (IE) is a compound of the formula:
[0464] like where R 50 is hydrogen or fluorine. In some embodiments, L 1 It is C 1-3 Halogenated alkylene, such as C 1-2 Haloalkylene or C 1-2 In some embodiments, L 2 Selected from C 6-8 Alkylene, C 6-8 Alkenylene and 6 to 8 membered heteroalkylene, each of which is optionally substituted by one or more R 11b In some embodiments, L 2 Selected from C 6-8 Alkylene and C 6-8 alkenylene, each of which is optionally substituted by one or more R 11b In some embodiments, L 2 Yes-(C 1-2 Alkylene)-C(O)N(CH3)-(C 3-4 Alkylene)-or-(C 1-2 Alkylene)-C(O)NH-(C3-4 Alkylene)-, wherein C 1-2 Alkylene and C 3-4 The alkylene groups are each independently optionally substituted with one or more R 11b In some embodiments, R 11b When present, is selected from halogen, -CN, C 1-3 Alkyl, C 1-3 Halogenated alkyl, (C 1-3 In some embodiments, R 50 In some embodiments, R 50 It's fluorine.
[0465] In certain aspects, the present disclosure provides a compound of formula (I-C1):
[0466]
[0467] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0468] Selected from
[0469] is selected from azetidine, pyrrolidine and piperidine, each of which is optionally substituted with one or more -CH3;
[0470] L 1 It is C 1-3 alkylene halide;
[0471] L 2 Selected from C 5-10 Alkylene, C 5-10 alkenylene, 5- to 10-membered heteroalkylene, and 5- to 10-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b replace;
[0472] R 1 is -CH3;
[0473] R 3 is hydrogen or -CH3;
[0474] R 7 Selected from
[0475] R 8 It is hydrogen;
[0476] R 11 is selected from fluorine and -CH3; and
[0477] R 11bSelected from halogen, oxo, C 1-6 Alkyl, C 1-6 Halogenated alkyl, (C 1-6 alkyl)-OH and -OH.
[0478] In certain aspects, the present disclosure provides a compound of formula (I-C1):
[0479]
[0480] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0481] Selected from
[0482] selected from azetidine, pyrrolidine and piperidine;
[0483] L 1 Selected from -CF2-, -CF2CH2- and -CF2CH2CH2-;
[0484] L 2 Selected from C 5-10 Alkylene, C 5-10 alkenylene, 5- to 10-membered heteroalkylene, and 5- to 10-membered heteroalkenylene;
[0485] R 1 is -CH3;
[0486] R 3 is hydrogen or -CH3;
[0487] R 7 Selected from
[0488] and
[0489] R 8 It's hydrogen.
[0490] In certain aspects, the present disclosure provides a compound of formula (I-C1):
[0491]
[0492] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0493] Selected from
[0494] is selected from azetidine, pyrrolidine and piperidine, each of which is optionally substituted with one or more -CH3;
[0495] L 1 It is C 1-3 alkylene halide;
[0496] L 2 is optionally replaced by one or more R 11b Substituted C 5-10 alkenylene;
[0497] R 1 is -CH3;
[0498] R 3 is -CH3;
[0499] R 7 Selected from
[0500] R 8 It is hydrogen;
[0501] R 11 is selected from fluorine and -CH3; and
[0502] R 11b Selected from halogen, oxo, C 1-6 Alkyl, C 1-6 Halogenated alkyl, (C 1-6 alkyl)-OH and -OH.
[0503] In certain aspects, the present disclosure provides a compound of formula (I-C1):
[0504]
[0505] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0506] Selected from
[0507] is selected from azetidine, pyrrolidine and piperidine, each of which is optionally substituted with one or more -CH3;
[0508] L 1 It is C 1-3 alkylene halide;
[0509] L 2 Selected from optionally one or more R 11b substituted 5- to 10-membered heteroalkylene;
[0510] R 1 is -CH3;
[0511] R 3 is hydrogen or -CH3;
[0512] R 7 Selected from
[0513] R 8 It is hydrogen;
[0514] R 11 is selected from fluorine and -CH3; and
[0515] R 11b Selected from halogen, oxo, C 1-6 Alkyl, C 1-6 Halogenated alkyl, (C 1-6 alkyl)-OH and -OH.
[0516] In certain aspects, the present disclosure provides a compound of formula (I):
[0517]
[0518] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0519] is selected from phenyl and 5- to 7-membered heteroaryl, each of which is optionally substituted by one or more R 11 replace;
[0520] is absent or is selected from phenyl and 4 to 8 membered heterocyclic rings, each of which is optionally replaced by one or more R 11a replace;
[0521] L 1 Selected from bonds and C 1-3 alkylene halide;
[0522] L 2 Selected from C 5-10 Alkylene, C 5-10 alkenylene, 5- to 10-membered heteroalkylene, and 5- to 10-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b Substituted, where L 2 Covalently bound to W 3 、W 4 、W 5 、W 6 or W 7 One of; or L 2 Yes-L 3 -DL 4 -, where L 4 Covalently bound to W 3 、W 4 、W5 、W 6 or W 7 one of;
[0523] L 3 Selected from C 1-8 Alkylene, C 1-8 alkenylene, 2 to 8 membered heteroalkylene and 2 to 8 membered heteroalkenylene, each of which is optionally substituted by one or more R 11b replace;
[0524] D is selected from C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted by one or more R 11d replace;
[0525] L 4 Selected from C 1-8 Alkylene, C 1-8 alkenylene, 2 to 8 membered heteroalkylene and 2 to 8 membered heteroalkenylene, each of which is optionally substituted by one or more R 11b replace
[0526] W 2 It is N;
[0527] W 3 Selected from N(R 3b )、N、C(R 3 ) and C(O);
[0528] W 4 Selected from N(R 4b )、N、C(R 4 ) and C(O);
[0529] W 5 Selected from N(R 5b ), N and C (R 5 );
[0530] W 6 Selected from C(R 6 ) and C(O);
[0531] W 7 It is C(R 7 );
[0532] W 8 It is C(R 8 );
[0533] W 9 and W 10 Each is C;
[0534] R 1 is -CH3;
[0535] R2 、R 2a 、R 3a 、R 4a 、R 5a 、R 6a 、R 7a 、R 8 and R 8a are each independently selected from hydrogen and -CH3;
[0536] R 3 、R 4 、R 5 and R 6 Each independently selected from L 2 bonds, hydrogen, halogen, -CN, C 1-3 Alkyl, C 1-3 Haloalkyl, -OH, -OCH3, -NH2, -NHCH3, -N(CH3)2;
[0537] R 7 Selected from L 2 Key, C 1-6 Alkyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-N(R 12 )(R 13 ),-C(O)R 15 、-C(O)N(R 12 )(R 13 )、-S(O)2R 15 and -SO2N(R 12 )(R 13 ), where C 1-6 Alkyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0538] R 3b 、R 4b and R 5b Each independently selected from L 2 bonds, hydrogen and C 1-3 alkyl;
[0539] R 11 、R 11a and R 11d Each occurrence is independently selected from halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 、-CH2S(O)2N(R 12 )(R 13 )、-CH2N(R 12 )S(O)2(R 13 ) and -P(O)(R 17 )(R 17a ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 Replacement; R 11b is independently selected at each occurrence from halogen, oxo, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 、-CH2S(O)2N(R 12 )(R 13 )、-CH2N(R 12 )S(O)2(R 13 ) and -P(O)(R 17 )(R 17a ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 Replacement; R 12 independently selected at each occurrence from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 2-6Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 Replacement; R 13 independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 haloalkyl; or R 12 and R 13 Together with the nitrogen atom to which they are attached, they form a 20 substituted 3- to 10-membered heterocycle;
[0540] R 14 independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 alkyl halide;
[0541] R 15 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0542] R 17 and R 17a Each occurrence is independently selected from C 1-6 Alkyl and C 3-6 Cycloalkyl, wherein C 1-6 Alkyl and C 3-6 The cycloalkyl group is optionally substituted by one, two or three R 20 Replacement; or R 17 and R 17a Together with the phosphorus atom to which they are attached, they form a 3- to 10-membered heterocyclic ring;
[0543] R 20 is independently selected at each occurrence from halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3- to 10-membered heterocycle, -CH2-(3- to 10-membered heterocycle), -OR 21 、-SR 21 、-N(R 22 )(R23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 )、-OCH2C(O)OR 22 and -OC(O)R 25 , where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3 to 10 membered heterocycle and -CH2-(3 to 10 membered heterocycle) are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 ) and -OC(O)R 25 ;
[0544] R 21 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0545] R 22 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0546] R 23 independently selected at each occurrence from H and C 1-6 alkyl;
[0547] R 24 independently selected at each occurrence from H and C 1-6 alkyl;
[0548] R 25 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6Alkoxy, C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings; and represents a single or double bond such that all valences are satisfied.
[0549] In certain aspects, the present disclosure provides a compound of formula (III):
[0550]
[0551] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0552] Selected from optionally one or more R 11a substituted 3- to 8-membered heterocycles;
[0553] L 1 Selected from bond, C 1-6 Alkylene and C 1-6 alkylene halide;
[0554] L 2 Selected from C 5-25 Alkylene, C 5-25 Alkenylene, C 5-25 Alkyne, 5- to 25-membered heteroalkylene, and 5- to 25-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b Substituted, where L 2 Covalently bound to W 3 、W 4 、W 5 、W 6 or W 7 One of; or L 2 Yes-L 3 -DL 4 -, where L 4 Covalently bound to W 3 、W 4 、W 5 、W 6 or W 7 one of;
[0555] L 3 Selected from C 1-10 Alkylene, C 1-10 Alkenylene, C 1-10 Alkyne, 2- to 10-membered heteroalkylene, and 2- to 10-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b replace;
[0556] D does not exist or is selected from C 3-12 Carbocyclic and 3 to 12 membered heterocyclic rings, each of which is optionally substituted by one or more R 11d replace;
[0557] L 4 Selected from C 1-10 Alkylene, C 1-10 Alkenylene, C 1-10 Alkyne, 2- to 10-membered heteroalkylene, and 2- to 10-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b replace;
[0558] W 3 Selected from N(R 3b ) and N, and W 4 Selected from C(R 4 ) and C(O); or W 3 Selected from C(R 3 ) and C(O), and W 4 Selected from N(R 4b ) and N;
[0559] W 5 Selected from N(R 5b ), N and C (R 5 );
[0560] W 6 Selected from N, C(R 6 ) and C(O);
[0561] W 7 Selected from N, C(R 7 ) and C(O);
[0562] R 50 is hydrogen or a halogen;
[0563] R 3 、R 4 、R 5 、R 6 and R 7 Each independently selected from L 2 bonds, hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14)C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0564] R 3b 、R 4b and R 5b Each independently selected from L 2 bonds, hydrogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 ),-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12)(R 13 )、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0565] R 11a and R 11d Each occurrence is independently selected from halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 、-CH2S(O)2N(R 12 )(R 13 )、-CH2N(R 12 )S(O)2(R 13 ) and -P(O)(R 17 )(R 17a ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 Replacement; R 11b is independently selected at each occurrence from halogen, oxo, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 、-CH2S(O)2N(R 12 )(R 13 )、-CH2N(R 12 )S(O)2(R 13 ) and -P(O)(R 17 )(R 17a ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 Replacement; R 12 independently selected at each occurrence from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 Replacement; R 13 independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 haloalkyl; or R 12 and R 13 Together with the nitrogen atom to which they are attached, they form a 20 substituted 3- to 10-membered heterocycle;
[0566] R 14 independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 alkyl halide;
[0567] R 15 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0568] R 17 and R 17a Each occurrence is independently selected from C 1-6 Alkyl and C 3-6 Cycloalkyl, wherein C 1-6 Alkyl and C 3-6 The cycloalkyl group is optionally substituted by one, two or three R 20 Replacement; or R 17 and R 17a Together with the phosphorus atom to which they are attached, they form a 3- to 10-membered heterocyclic ring;
[0569] R 20 is independently selected at each occurrence from halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3- to 10-membered heterocycle, -CH2-(3- to 10-membered heterocycle), -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 )、-OCH2C(O)OR22 and -OC(O)R 25 , where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3 to 10 membered heterocycle and -CH2-(3 to 10 membered heterocycle) are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 ) and -OC(O)R 25 ;
[0570] R 21 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0571] R22 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0572] R 23 independently selected at each occurrence from H and C 1-6 alkyl;
[0573] R 24 independently selected at each occurrence from H and C 1-6 alkyl;
[0574] R 25 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings; and represents a single or double bond such that all valences are satisfied.
[0575] In certain aspects, the present disclosure provides a compound of formula (III):
[0576]
[0577] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0578] Selected from optionally one or more R 11a substituted 3- to 8-membered heterocycles;
[0579] L 1 Selected from bond, C 1-6 Alkylene and C 1-6 alkylene halide;
[0580] L 2 Selected from C 5-25 Alkylene, C5-25 Alkenylene, C 5-25 Alkyne, 5- to 25-membered heteroalkylene, and 5- to 25-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b Substituted, where L 2 Covalently bound to W 3 、W 4 、W 5 、W 6 or W 7 one of;
[0581] W 3 Selected from N(R 3b ) and N, and W 4 Selected from C(R 4 ) and C(O); or W 3 Selected from C(R 3 ) and C(O), and W 4 Selected from N(R 4b ) and N;
[0582] W 5 Selected from N(R 5b ), N and C (R 5 );
[0583] W 6 Selected from N, C(R 6 ) and C(O);
[0584] W 7 Selected from N, C(R 7 ) and C(O);
[0585] R 50 is hydrogen or a halogen;
[0586] R 3 、R 4 、R 5 、R 6 and R 7 Each independently selected from L 2 bonds, hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0587] R 3b 、R 4b and R 5b Each independently selected from L 2 bonds, hydrogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 ),-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0588] R 11a is independently selected at each occurrence from halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 、-CH2S(O)2N(R 12 )(R 13 )、-CH2N(R 12 )S(O)2(R 13 ) and -P(O)(R 17 )(R 17a ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0589] R 11b is independently selected at each occurrence from halogen, oxo, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 、-CH2S(O)2N(R 12 )(R 13 )、-CH2N(R 12 )S(O)2(R 13 ) and -P(O)(R 17 )(R 17a ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 Replacement; R 12 independently selected at each occurrence from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 Replacement; R 13 independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 haloalkyl; or R 12 and R 13 Together with the nitrogen atom to which they are attached, they form a 20 substituted 3- to 10-membered heterocycle;
[0590] R 14 independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 alkyl halide;
[0591] R 15 In each occurrence, independently selected from C 1-6Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0592] R 17 and R 17a Each occurrence is independently selected from C 1-6 Alkyl and C 3-6 Cycloalkyl, wherein C 1-6 Alkyl and C 3-6 The cycloalkyl group is optionally substituted by one, two or three R 20 Replacement; or R 17 and R 17a Together with the phosphorus atom to which they are attached, they form a 3- to 10-membered heterocyclic ring;
[0593] R 20 is independently selected at each occurrence from halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3- to 10-membered heterocycle, -CH2-(3- to 10-membered heterocycle), -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R22 )(R 23 )、-OCH2C(O)OR 22 and -OC(O)R 25 , where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3 to 10 membered heterocycle and -CH2-(3 to 10 membered heterocycle) are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 ) and -OC(O)R 25 ;
[0594] R 21 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6alkyl;
[0595] R 22 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0596] R 23 independently selected at each occurrence from H and C 1-6 alkyl;
[0597] R 24 independently selected at each occurrence from H and C 1-6 alkyl;
[0598] R 25 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings; and represents a single or double bond such that all valences are satisfied.
[0599] In some embodiments, the compound of formula (III) is a compound of the formula:
[0600]
[0601] In some embodiments, the compound of formula (III) is a compound of the formula:
[0602]
[0603] In some embodiments, for the compound of formula (III), is selected from azetidine, pyrrolidine and piperidine, each of which is optionally replaced by one or more R 11a In some embodiments, yes Each of them is optionally replaced by one or more R 11a In some embodiments, yes which are optionally replaced by one or more R 11a In some embodiments, L 1 It is C 1-3 In some embodiments, L 2 Selected from C 5-10 Alkylene, C 5-10 alkenylene, 5- to 10-membered heteroalkylene, and 5- to 10-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b Substituted, where L 2 Covalently bound to W 3 、W 4 、W 5 、W 6 or W 7 One of; or L 2 Yes-L 3 -DL 4 -, where L 4 Covalently bound to W 3 、W 4 、W 5 、W 6 or W 7 One of them; L 3 Selected from C 1-8 Alkylene, C 1-8 alkenylene, 2 to 8 membered heteroalkylene and 2 to 8 membered heteroalkenylene, each of which is optionally substituted by one or more R 11b Substituted; D is selected from C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted by one or more R 11d Replace; and L 4 Selected from C 1-8 Alkylene, C 1-8 alkenylene, 2 to 8 membered heteroalkylene and 2 to 8 membered heteroalkenylene, each of which is optionally substituted by one or more R 11b replace.
[0604] In certain aspects, the present disclosure provides compounds of the formula:
[0605]
[0606] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0607] L 2 Selected from C 5-10 Alkylene, C 5-10alkenylene, 5- to 10-membered heteroalkylene, and 5- to 10-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b Substituted, where L 2 Covalently bound to W 3 、W 4 、W 5 、W 6 or W 7 One of; or L 2 Yes-L 3 -DL 4 -, where L 4 Covalently bound to W 3 、W 4 、W 5 、W 6 or W 7 one of;
[0608] L 3 Selected from C 1-8 Alkylene, C 1-8 alkenylene, 2 to 8 membered heteroalkylene and 2 to 8 membered heteroalkenylene, each of which is optionally substituted by one or more R 11b replace;
[0609] D is selected from C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted by one or more R 11d replace;
[0610] L 4 Selected from C 1-8 Alkylene, C 1-8 alkenylene, 2 to 8 membered heteroalkylene and 2 to 8 membered heteroalkenylene, each of which is optionally substituted by one or more R 11b replace;
[0611] W 2 Selected from N(R 2b )、N、C(R 2 )、C(R 2 )(R 2a ) and C(O);
[0612] W 3 Selected from N(R 3b )、N、C(R 3 )、C(R 3 )(R 3a ) and C(O);
[0613] W 4 Selected from N(R 4b )、N、C(R 4 )、C(R 4 )(R4a ) and C(O);
[0614] W 5 Selected from N(R 5b )、N、C(R 5 )、C(R 5 )(R 5a ) and C(O);
[0615] W 6 Selected from N(R 6b )、N、C(R 6 )、C(R 6 )(R 6a ) and C(O);
[0616] W 7 Selected from N(R 7b )、N、C(R 7 )、C(R 7 )(R 7a ) and C(O);
[0617] W 8 Selected from N(R 8b )、N、C(R 8 )、C(R 8 )(R 8a ) and C(O);
[0618] W 9 Selected from N, C(R 9 ) and C;
[0619] W 10 Selected from N, C(R 10 ) and C;
[0620] R 2 、R 2a 、R 3a 、R 4a 、R 5a 、R 6a 、R 7a 、R 8 and R 8a are independently selected from hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13)、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0621] R 3 、R 4 、R 5 、R 6 and R 7 Each independently selected from L 2 bonds, hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12)(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0622] R 2b and R 8b Each independently selected from hydrogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 ),-C(O)R 15 、-S(O)R 15 、-OC(O)R 15、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0623] R 3b 、R 4b 、R 5b 、R 6b and R 7b Each independently selected from L 2 bonds, hydrogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 ),-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13)、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0624] R 9 and R 10 are each independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocyclic ring), 3- to 10-membered heterocyclic ring, and -CH2-(3- to 10-membered heterocyclic ring), wherein each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocyclic ring), 3 to 10 membered heterocyclic ring and -CH2-(3 to 10 membered heterocyclic ring) are independently optionally replaced by one, two or three R 20 Replacement; R 11d is independently selected at each occurrence from halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 、-CH2S(O)2N(R 12 )(R 13 )、-CH2N(R 12 )S(O)2(R 13 ) and -P(O)(R 17 )(R 17a ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0625] R 11b is independently selected at each occurrence from halogen, oxo, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 、-CH2S(O)2N(R 12 )(R 13 )、-CH2N(R 12 )S(O)2(R 13 ) and -P(O)(R 17 )(R 17a ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0626] R 12 independently selected at each occurrence from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0627] R 13 independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 haloalkyl; or R 12 and R 13Together with the nitrogen atom to which they are attached, they form a 20 substituted 3- to 10-membered heterocycle;
[0628] R 14 independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 alkyl halide;
[0629] R 15 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0630] R 17 and R 17a Each occurrence is independently selected from C 1-6 Alkyl and C 3-6 Cycloalkyl, wherein C 1-6 Alkyl and C 3-6 The cycloalkyl group is optionally substituted by one, two or three R 20 Replacement; or R 17 and R 17a Together with the phosphorus atom to which they are attached, they form a 3- to 10-membered heterocyclic ring;
[0631] R 20 is independently selected at each occurrence from halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3- to 10-membered heterocycle, -CH2-(3- to 10-membered heterocycle), -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24)C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 )、-OCH2C(O)OR 22 and -OC(O)R 25 , where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3 to 10 membered heterocycle and -CH2-(3 to 10 membered heterocycle) are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 ) and -OC(O)R 25 ;
[0632] R 21 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0633] R 22 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0634] R 23 independently selected at each occurrence from H and C 1-6 alkyl;
[0635] R 24 independently selected at each occurrence from H and C 1-6 alkyl;
[0636] R 25 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings; and represents a single or double bond such that all valences are satisfied.
[0637] In certain aspects, the present disclosure provides a compound of formula (II-B) or (II-C):
[0638] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0639] Absent or optionally replaced by one or more R 11a substituted 4- to 8-membered heterocycles;
[0640] L 1 It is C 1-3 alkylene halide;
[0641] L 2 Selected from C 5-10 Alkylene, C 5-10 alkenylene, 5- to 10-membered heteroalkylene, and 5- to 10-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b Replace; or L 2 Yes-L 3 -DL 4 -;
[0642] L 3 Selected from C 1-8 Alkylene, C 1-8 alkenylene, 2 to 8 membered heteroalkylene and 2 to 8 membered heteroalkenylene, each of which is optionally substituted by one or more R 11b replace;
[0643] D is selected from C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted by one or more R 11d replace;
[0644] L 4 Selected from C 1-8 Alkylene, C 1-8 alkenylene, 2 to 8 membered heteroalkylene and 2 to 8 membered heteroalkenylene, each of which is optionally substituted by one or more R 11b replace;
[0645] R 3 and R 8 are each independently selected from hydrogen and -CH3;
[0646] R 7 Selected from C 3-8 Carbocyclic and 3- to 8-membered heterocyclic rings, each of which is optionally substituted by one, two or three R 20 replace;
[0647] R 5b Selected from hydrogen and C 1-3 alkyl;
[0648] R 50 selected from hydrogen and halogen;
[0649] R11a and R 11d Each occurrence is independently selected from halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 、-CH2S(O)2N(R 12 )(R 13 )、-CH2N(R 12 )S(O)2(R 13 ) and -P(O)(R 17 )(R 17a ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20Replacement; R 11b is independently selected at each occurrence from halogen, oxo, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 、-CH2S(O)2N(R 12 )(R 13 )、-CH2N(R 12 )S(O)2(R 13 ) and -P(O)(R 17 )(R 17a ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 Replacement; R12 independently selected at each occurrence from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 Replacement; R 13 independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 haloalkyl; or R 12 and R 13 Together with the nitrogen atom to which they are attached, they form a 20 substituted 3- to 10-membered heterocycle;
[0650] R 14 independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 alkyl halide;
[0651] R 15 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0652] R 17 and R 17a Each occurrence is independently selected from C 1-6 Alkyl and C 3-6 Cycloalkyl, wherein C 1-6 Alkyl and C 3-6 The cycloalkyl group is optionally substituted by one, two or three R 20 Replacement; or R 17 and R 17a Together with the phosphorus atom to which they are attached, they form a 3- to 10-membered heterocyclic ring;
[0653] R 20 is independently selected at each occurrence from halogen, oxo, =NH, -CN, C 1-6 Alkyl, C2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3- to 10-membered heterocycle, -CH2-(3- to 10-membered heterocycle), -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 )、-OCH2C(O)OR 22 and -OC(O)R 25 , where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3 to 10 membered heterocycle and -CH2-(3 to 10 membered heterocycle) are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23)、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 ) and -OC(O)R 25 ;
[0654] R 21 independently selected at each occurrence from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0655] R 22 independently selected at each occurrence from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0656] R 23 independently selected at each occurrence from hydrogen and C 1-6 alkyl;
[0657] R 24 independently selected at each occurrence from hydrogen and C 1-6 alkyl; and
[0658] R 25 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 3-10 carbocyclic rings and 3- to 10-membered heterocyclic rings.
[0659] In some embodiments, the present disclosure provides a compound of formula (II-B) or (II-C):
[0660] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0661] Absent or optionally replaced by one or more R 11a substituted 4- to 8-membered heterocycles;
[0662] L 1 It is C 1-3 alkylene halide;
[0663] L 2 Selected from C 5-10 Alkylene, C 5-10 alkenylene, 5- to 10-membered heteroalkylene, and 5- to 10-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b replace;
[0664] R 3 、R 5b and R 8 are each independently selected from hydrogen and -CH3;
[0665] R 7 Selected from C 3-8 Carbocyclic and 3- to 8-membered heterocyclic rings, each of which is optionally substituted by one, two or three R 20 replace;
[0666] R 50 selected from hydrogen and halogen;
[0667] R 11a is independently selected at each occurrence from halogen, C 1-3 Alkyl and C 1-3 alkyl halide;
[0668] R 11b is independently selected at each occurrence from halogen, oxo, -CN, C 1-3 Alkyl and -OH; and R 20is independently selected at each occurrence from halogen, oxo, -CN and C 1-6 alkyl.
[0669] In some embodiments, the present disclosure provides a compound of formula (II-C):
[0670]
[0671] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0672] Absent or optionally replaced by one or more R 11a substituted 4- to 8-membered heterocycles;
[0673] L 1 It is C 1-3 alkylene halide;
[0674] L 2 Selected from C 5-10 Alkylene, C 5-10 alkenylene, 5- to 10-membered heteroalkylene, and 5- to 10-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b replace;
[0675] R 3 It is hydrogen;
[0676] R 8 selected from hydrogen and -CH3;
[0677] R 7 Selected from
[0678] R 50 selected from hydrogen and halogen;
[0679] R 11a is independently selected at each occurrence from halogen, C 1-3 Alkyl and C 1-3 alkyl halide;
[0680] R 11b is independently selected at each occurrence from halogen, oxo, -CN, C 1-3 alkyl and -OH; and
[0681] R 20 is independently selected at each occurrence from halogen, oxo, -CN and C 1-6 alkyl.
[0682] In some embodiments, the present disclosure provides a compound of formula (II-C):
[0683]
[0684] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0685] is optionally replaced by one or more R 11a substituted 4- to 8-membered heterocycles;
[0686] L 1 It is C 1-3 alkylene halide;
[0687] L 2 Selected from C 5-10 Alkylene, C 5-10 alkenylene, 5- to 10-membered heteroalkylene, and 5- to 10-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b replace;
[0688] R 3 selected from hydrogen and -CH3;
[0689] R 8 selected from hydrogen and -CH3;
[0690] R 7 Selected from
[0691] R 50 selected from hydrogen and halogen;
[0692] R 11a is independently selected at each occurrence from halogen, C 1-3 Alkyl and C 1-3 haloalkyl; and R 11b is independently selected at each occurrence from halogen, oxo, -CN, C 1-3 Alkyl and -OH.
[0693] In some embodiments, the present disclosure provides a compound of formula (II-C):
[0694]
[0695] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0696] is a 4- to 6-membered heterocyclic ring;
[0697] L 1 It is C 1-3 alkylene halide;
[0698] L 2 Selected from C 5-10 Alkylene, C 5-10 alkenylene and 5- to 10-membered heteroalkylene;
[0699] R 3 selected from hydrogen and -CH3;
[0700] R 8 It is hydrogen;
[0701] R 7 Selected from And R 50 is selected from hydrogen and halogen.
[0702] In some embodiments, the present disclosure provides a compound of formula (II-C):
[0703]
[0704] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0705] yes
[0706] L 1 is -CF2CH2-;
[0707] L 2 is a 5- to 10-membered heteroalkylene group, wherein the heteroalkylene group contains one oxygen atom;
[0708] R 3 selected from hydrogen and -CH3;
[0709] R 8 It is hydrogen;
[0710] R 7 Selected from and
[0711] R 50 is selected from hydrogen and halogen.
[0712] In some embodiments, the present disclosure provides a compound of formula (II-C):
[0713]
[0714] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0715] yes
[0716] L 1 is -CF2-;
[0717] L 2 Selected from C 5-10 alkenylene;
[0718] R 3selected from hydrogen and -CH3;
[0719] R 8 It is hydrogen;
[0720] R 7 Selected from and
[0721] R 50 is selected from hydrogen and halogen.
[0722] In some embodiments, the compound of formula (II-B) is a compound of the formula:
[0723] In some embodiments, R 5b is -CH3; R 8 is hydrogen; and R 50 In some embodiments, R 5b is -CH3; R 8 is hydrogen; and R 50 In some embodiments, R 5b is -CH3; R 8 is hydrogen; and R 50 In some embodiments, R 7 Selected from In some embodiments, R 5b is -CH3; R 8 is hydrogen; R 50 is hydrogen; and R 7 Selected from In some embodiments, R 5b is -CH3; R 8 is hydrogen; R 50 is fluorine; and R 7 Selected from In some embodiments, R 5b is -CH3; R 8 is hydrogen; R 50 is selected from hydrogen and fluorine; and R 7 yes In some embodiments, R 5b is -CH3; R 8 is hydrogen; R 50 is selected from hydrogen and fluorine; and R 7 yes In some embodiments, R 5b is -CH3; R 8 is hydrogen; R 50 is selected from hydrogen and fluorine; and R 7 yes
[0724] In some embodiments, the compound of formula (II-C) is a compound of the formula:
[0725]
[0726] In some embodiments, the compound of formula (II-C) is a compound of the formula:
[0727]
[0728] In some embodiments, R 3 is selected from hydrogen and -CH3; R 8 is hydrogen; and R 50 In some embodiments, R 3 is selected from hydrogen and -CH3; R 8 is hydrogen; and R 50 In some embodiments, R 3 is selected from hydrogen and -CH3; R 8 is hydrogen; and R 50 In some embodiments, R 3 is hydrogen; R 8 is hydrogen; and R 50 In some embodiments, R 3 is hydrogen; R 8 is hydrogen; and R 50 In some embodiments, R 3 is -CH3; R 8 is hydrogen; and R 50 In some embodiments, R 3 is -CH3; R 8 is hydrogen; and R 50 In some embodiments, R 7 Selected from In some embodiments, R 3 is selected from hydrogen and -CH3; R 8 is hydrogen; R 50 is hydrogen; and R 7 Selected from In some embodiments, R 3 is selected from hydrogen and -CH3; R 8 is hydrogen; R 50 is fluorine; and R 7 Selected from In some embodiments, R 3 is hydrogen; R 8 is hydrogen; R 50is selected from hydrogen and fluorine; and R 7 Selected from In some embodiments, R 3 is hydrogen; R 8 is hydrogen; R 50 is hydrogen; and R 7 Selected from In some embodiments, R 3 is hydrogen; R 8 is hydrogen; R 50 is fluorine; and R 7 Selected from In some embodiments, R 3 is -CH3; R 8 is hydrogen; R 50 is hydrogen; and R 7 Selected from In some embodiments, R 3 is -CH3; R 8 is hydrogen; R 50 is fluorine; and R 7 Selected from In some embodiments, R 3 is selected from hydrogen and -CH3; R 8 is hydrogen; R 50 is selected from hydrogen and fluorine; and R 7 yes In some embodiments, R 3 is selected from hydrogen and -CH3; R 8 is hydrogen; R 50 is selected from hydrogen and fluorine; and R 7 yes In some embodiments, R 3 is selected from hydrogen and -CH3; R 8 is hydrogen; R 50 is selected from hydrogen and fluorine; and R 7 yes
[0729] Embodiments disclosed herein relating to compounds of Formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), and / or (I-E1) are also intended to apply to compounds of Formula (II-B), (II-C), and (III), unless the context of the embodiment clearly dictates otherwise (e.g., the embodiment refers only to variables that are not present in the compounds of Formula (II-B), (II-C), or (III), such as R 1 ).
[0730] Also provided is a compound selected from the group consisting of:
[0731]
[0732]
[0733]
[0734]
[0735]
[0736]
[0737]
[0738]
[0739]
[0740] or a pharmaceutically acceptable salt or solvate thereof.
[0741] Also provided is a compound selected from the group consisting of:
[0742]
[0743]
[0744] or a pharmaceutically acceptable salt or solvate thereof.
[0745] In some embodiments, the present disclosure provides a compound selected from the group consisting of:
[0746]
[0747]
[0748]
[0749]
[0750]
[0751] or a pharmaceutically acceptable salt or solvate thereof.
[0752] In some embodiments, the present disclosure provides a compound selected from the group consisting of:
[0753]
[0754]
[0755] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the present disclosure provides a compound selected from the following:
[0756]
[0757]
[0758]
[0759] or a pharmaceutically acceptable salt or solvate thereof.
[0760] In some embodiments, the present disclosure provides a compound selected from the group consisting of:
[0761] or a pharmaceutically acceptable salt or solvate thereof.
[0762] In some embodiments, the present disclosure provides a compound selected from the group consisting of:
[0763]
[0764]
[0765]
[0766]
[0767] or a pharmaceutically acceptable salt or solvate thereof.
[0768] In some embodiments, the compound of formula (I) is a compound of the formula:
[0769]
[0770]
[0771] or a salt or solvate thereof.
[0772] In some embodiments, the compound of Formula (I), such as a compound of Formula (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), (I-E1), (II-B), (II-C), or (III), is provided as a substantially pure stereoisomer. In some embodiments, the stereoisomer is provided in an enantiomeric excess of at least 80%, such as at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.9%.
[0773] In some embodiments, the compounds described herein exist in the form of pharmaceutically acceptable salts thereof. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts as pharmaceutical compositions.
[0774] In some embodiments, the compounds described herein possess acidic or basic groups and therefore react with any of a number of inorganic or organic bases or acids to form pharmaceutically acceptable salts. In some embodiments, such salts are prepared in situ during the final isolation and purification of the compounds described herein, or by separately reacting the purified compound in its free form with a suitable acid or base and isolating the salt thus formed.
[0775] In some embodiments, the compounds described herein exist in the form of solvates. In some embodiments, methods of treating a disease are performed by administering such solvates. Methods of treating a disease by administering such solvates as pharmaceutical compositions are also described herein.
[0776] Solvates contain stoichiometric or non-stoichiometric amounts of solvent and, in some embodiments, are formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol, and the like. When the solvent is water, hydrates are formed, or when the solvent is alcohol, alcoholates are formed. Solvates of the compounds described herein are conveniently prepared or formed during the processes described herein. By way of example only, hydrates of the compounds described herein are conveniently prepared by recrystallization from an aqueous solvent / organic solvent mixture using an organic solvent, including but not limited to dioxane, tetrahydrofuran, or MeOH. In addition, provided herein are compounds that exist in unsolvated and solvated forms. In general, for the purposes of the compounds and methods provided herein, the solvated form is considered equivalent to the unsolvated form.
[0777] In certain aspects, the present disclosure provides a formula AL AB -B, wherein: A is a monovalent form of a compound described herein;
[0778] L AB is a covalent linker bonded to A and B; and
[0779] B is the monovalent form of the degradation enhancer.
[0780] "Degradation enhancer" is a compound that can bind to a ubiquitin ligase protein (e.g., an E3 ubiquitin ligase protein), or a compound that can bind to such a protein, which can bind to the ubiquitin ligase protein to form a protein complex that can conjugate the ubiquitin protein to the target protein. In some embodiments, the degradation enhancer can bind to an E3 ubiquitin ligase protein or a protein complex comprising an E3 ubiquitin ligase protein. In some embodiments, the degradation enhancer can bind to an E2 ubiquitin conjugating enzyme. In some embodiments, the degradation enhancer can bind to a protein complex comprising an E2 ubiquitin conjugating enzyme and an E3 ubiquitin ligase protein.
[0781] In some embodiments, the degradation enhancer is capable of binding to a protein selected from the group consisting of: E3A, mdm2, APC, EDD1, SOCS / BC-box / eloBC / CUL5 / RING, LNXp80, CBX4, CBLL1, HACE1, HECTD1, HECTD2, HECTD3, HECTD4, HECW1, HECW2, HERC1, HERC2, HERC3, HERC4, HER5, HERC6, HUWE1, ITCH, NEDD4, NEDD4L, PPIL2, PRPF19, PIAS1, PIAS2, PIAS3, PIAS4, RANBP2, RNF4, RBX1, SMURF1, SMURF2, S TUB1, TOPORS, TRIP12, UBE3A, UBE3B, UBE3C, UBE3D, UBE4A, UBE4B, UBOX5, UBR5, VHL (von-Hippel-Lindau ubiquitin ligase), WWP1, WWP2, Parkin, MKRN1, CMA (chaperone-mediated autophagy), SCFb-TRCP (slip-retaining protein-F box (β-TRCP) ubiquitin complex), b-TRCP (b-transducing repeat-containing protein), cIAP1 (inhibitor of apoptosis protein 1), APC / C (anaphase-promoting complex / cyclin), CRBN (cereblon), CUL4-RBX1-DDB1-CRBN (CRL4 CRBN) ubiquitin ligases, XIAP, IAP, KEAP1, DCAF15, RNF114, DCAF16, AhR, SOCS2, KLHL12, UBR2, SPOP, KLHL3, KLHL20, KLHDC2, SPSB1, SPSB2, SPSB4, SOCS6, FBXO4, FBXO31, BTRC, FBW7, CDC20, PML, TRIM21, TRIM24, TRIM33, GID4, avadomide, ibidomide, and CC-885. In some embodiments, the degradation enhancer is capable of binding to a protein selected from the group consisting of: UBE2A, UBE2B, UBE2C, UBE2D1, UBE2D2, UBE2D3, UBE2DR, UBE2E1, UBE2E2, UBE2E3, UBE2F, UBE2G1, UBE2G2, UBE2H, UBE2I, UBE2J1, UBE2J2, UBE2K, UBE2L3, UBE2L6, UBE2L1, UBE2L2, UBE2L4, UBE2M, UBE2N, UBE2O, UBE2Q1, UBE2Q2, UBE2R1, UBE2R2, UBE2S, UBE2T, UBE2U, UBE2V1, UBE2V2, UBE2W, UBE2Z, ATG3, BIRC6, and UFC1. In some embodiments, the degradation enhancer is a compound described in Ishida and Ciulli, SLAS Discovery 2021, Vol. 25(4)484-502, which is incorporated by reference in its entirety for any purpose, such as VH032, VH101, VH298, thalidomide, bestatidine, bestatidine methyl, nutlin, idasanutlin, bardoxolone, bardoxolone methyl, indisulam (E7070), E7820, chloroquinoxaline sulfonamide (CQS), nimbolide, KB02, ASTX660, lenalidomide, or pomalidomide.
[0782] In some embodiments, the degradation enhancer is a compound described in US20180050021, WO2016146985, WO2018189554, WO2018119441, WO2018140809, WO2018119448, WO2018119357, WO2018118598, WO2018102067, WO201898280 ...819441, WO2018140809, WO20181819448, WO20181819357, 1889736, WO201881530, WO201871606, WO201864589, WO201852949, WO2017223452, WO201720444 5. WO2017197055, WO2017197046, WO2017180417, WO2017176958, WO201711371, WO2018226542, WO 2018223909, WO2018189554, WO2016169989, WO2016146985, CN105085620B, CN106543185B, US10 040804, US9938302, US10144745, US10145848, US9938264, US9632089, US9821068, US9758522, U S9500653, US9765019, US8507488, US8299057, US20180298027, US20180215731, US20170065719, US20170037004, US20160272639, US20150291562, or US20140356322, each of which is incorporated by reference in its entirety for any purpose.
[0783] In some embodiments, L AB Yes-L AB1 -L AB2 -L AB3 -L AB4 -L AB5 -;
[0784] L AB1 , L AB2 , L AB3 , L AB4 and L AB5 Each independently selected from a bond, -O-, -N(R 100 )-、-C(O)-、-N(R 100 )C(O)-、-C(O)N(R 100 )-, -S-, -S(O)2-, -S(O)-, -S(O)2N(R 100)-、-S(O)N(R 100 )-、-N(R 100 )S(O)-、-N(R 100 )S(O)2-、C 1-6 Alkylene, -(OC 1-6 alkyl) z -、-(C 1-6 Alkyl-O) z -、C 2-6 Alkenylene, C 2-6 Alkynylidene, C 1-6 Halogenated alkylene, C 3-12 Carbocyclylene and 3 to 10 membered heterocyclylene, wherein C 1-6 Alkylene, C 2-6 Alkenylene, C 2-6 Alkynylidene, C 1-6 Halogenated alkylene, C 3-12 Carbocyclylene and 3 to 10 membered heterocyclylene are optionally substituted by one, two or three R 20 Replace; and wherein – (OC 1-6 alkyl) z -and–(C 1-6 Alkyl-O) z - Each C 1-6 The alkyl group is optionally substituted by one, two or three R 20 replace;
[0785] Each z is independently an integer from 0 to 10;
[0786] R 100 independently selected at each occurrence from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocyclic ring), 3 to 10 membered heterocyclic ring and -CH2-(3 to 10 membered heterocyclic ring), wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3 to 10 membered heterocycle and -CH2-(3 to 10 membered heterocycle) are optionally substituted by one, two or three R 20 replace;
[0787] R 20 is independently selected at each occurrence from halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C3-10 carbocycle), 3- to 10-membered heterocycle, -CH2-(3- to 10-membered heterocycle), -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 )、-OCH2C(O)OR 22 and -OC(O)R 25 , where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3 to 10 membered heterocycle and -CH2-(3 to 10 membered heterocycle) are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 ) and -OC(O)R 25 ;
[0788] R 21 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0789] R 22 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0790] R 23 independently selected at each occurrence from H and C 1-6 alkyl;
[0791] R 24 independently selected at each occurrence from H and C 1-6 alkyl; and
[0792] R 25 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 3-10 carbocyclic rings and 3- to 10-membered heterocyclic rings.
[0793] In some embodiments, L AB is -(O-C2 alkyl) z -, and z is an integer from 1 to 10. In some embodiments, L AB is -(C2 alkyl-O-) z -, and z is an integer from 1 to 10. In some embodiments, L AB Yes - (CH2) zz1 L AB2 (CH2O) zz2 -, where L AB2 is a bond, a 5- or 6-membered heterocyclylene group, a phenylene group, -C 2-4 alkylene, -SO2- or -NH-; and zz1 and zz2 are independently an integer from 0 to 10. In some embodiments, L AB Yes - (CH2) zz1 (CH2O) zz2 -, wherein zz1 and zz2 are each independently an integer from 0 to 10. In some embodiments, L AB is a PEG linker (e.g., a divalent linker of 1 to 10 ethylene glycol subunits). In some embodiments, B is a monovalent form of a compound selected from:
[0794] In some embodiments, B is a monovalent form of a compound selected from:
[0795] Also provided is a compound selected from the group consisting of:
[0796]
[0797] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the present invention provides a compound selected from the following:
[0798]
[0799]
[0800]
[0801]
[0802] or a pharmaceutically acceptable salt or solvate thereof.
[0803] Chemical entities as described herein can be synthesized according to one or more illustrative schemes and / or techniques known in the art herein. Materials used herein are commercially available or prepared by synthetic methods generally known in the art. These schemes are not limited to the compounds listed in the examples or any specific substituents, and these schemes are for illustrative purposes. Although various steps are described and depicted in schemes 1-8 and Examples 1-36, in some cases, these steps can be carried out in an order different from that shown in schemes 1-8 and Examples 1-36. Various modifications can be made to these synthesis reaction schemes, and with reference to those skilled in the art of the present disclosure various modifications will be expected. Unless otherwise noted, the numbers or R groups in each scheme are generally the same as those defined elsewhere herein.
[0804] Unless otherwise indicated, the reactions described herein are carried out at atmospheric pressure, generally in the temperature range of -10°C to 200°C. Furthermore, unless otherwise indicated, reaction times and conditions are intended to be approximate, e.g., at a temperature range of about -10°C to about 110°C, over a period of about 1 to about 24 hours, at about atmospheric pressure; reactions left to run overnight last an average of about 16 hours.
[0805] Generally speaking, the compounds of the present disclosure can be prepared by the following reaction scheme:
[0806] Solution 1
[0807]
[0808] In some embodiments, compounds of Formula 1e can be prepared according to Scheme 1. For example, heteroarylamine 1b can be formed from chloride 1a via a nucleophilic aromatic substitution reaction. Lactam substitution can be carried out under basic conditions to provide diene 1c, which can undergo a cross-metathesis reaction (such as a Grubbs cross-metathesis reaction) to form a macrocycle 1d. Optionally, 1d can undergo one or more subsequent reactions (such as a hydrogenation reaction) to provide a compound of Formula 1e.
[0809] Option 2
[0810]
[0811] Similarly, in some embodiments, compounds of Formula 2e can be prepared according to Scheme 2. For example, heteroarylamine 2b can be formed from chloride 2a via a nucleophilic aromatic substitution reaction. Lactam substitution can be carried out under alkaline conditions to provide diene 2c, which can undergo a cross-metathesis reaction (such as a Grubbs cross-metathesis reaction) to form macrocycle 2d. Optionally, 2d can undergo one or more subsequent reactions (such as a hydrogenation reaction) to provide a compound of Formula 2e.
[0812] Option 3
[0813]
[0814] In some embodiments, compounds of Formula 3e can be prepared according to Scheme 3. For example, heteroarylamine 3b can be formed from chloride 3a via a substitution reaction. Substitution of the lactam can yield protected amine 3c. Hydrolysis of the ester can yield carboxylic acid 3d, which can undergo deprotection and peptide coupling to yield the macrocyclic compound of Formula 3e.
[0815] Option 4
[0816]
[0817] Similarly, in some embodiments, compounds of Formula 4e can be prepared according to Scheme 4. For example, heteroarylamine 4b can be formed from chloride 4a via a substitution reaction. Substitution of the lactam can yield protected amine 4c. Hydrolysis of the ester can yield carboxylic acid 4d, which can undergo deprotection and peptide coupling to yield the macrocyclic compound of Formula 4e.
[0818] Option 5
[0819]
[0820] In some embodiments, compounds of Formula 5g can be prepared according to Scheme 5. For example, heteroarylamine 3c can be formed by coupling chloride 5a with amine 5b. Oxidation of the alcohol can provide aldehyde 5d, which is then substituted with a phenol to provide 5e. Removal of the amine protecting group can provide 5f, which can undergo reductive amination to form the macrocycle of Formula 5g.
[0821] Option 6
[0822]
[0823] In some embodiments, compounds of Formula 6f can be prepared according to Scheme 6. For example, heteroarylamine 6c can be formed by coupling chloride 1a with amine 6b. Following substitution of the phenol to olefin 6d, a second olefin can be installed to provide diene 6e. A cross-metathesis reaction (such as a Grubbs cross-metathesis reaction) can be followed by hydrogenation of the resulting double bond to provide a macrocycle of Formula 6f.
[0824] Option 7
[0825]
[0826] In some embodiments, compounds of Formula 7e can be prepared according to Scheme 7. For example, heteroarylamine 7b can be formed by coupling chloride 7a with amine 5b. Substitution of the phenol can provide 7c. Ester hydrolysis and amine deprotection can provide 7d, which can be cyclized via a peptide coupling reaction to form a macrocycle of Formula 7e.
[0827] Option 8
[0828]
[0829] In some embodiments, compounds of Formula 8g can be prepared according to Scheme 8. For example, substitution of lactam 8a with an appropriate bromodioxolane (8b) can provide acetal 8c. Nucleophilic aromatic substitution with amine 8d can provide heteroarylamine 8e, which can be treated with an appropriate acid such as HCl to remove the Boc protecting group and reveal the aldehyde. Finally, cyclization of 8f can be carried out via reductive amination conditions to provide the macrocycle of Formula 8g.
[0830] In some embodiments, the compounds of the present disclosure, such as compounds of the formula given in Table 1, are synthesized according to one of the general routes outlined in Schemes 1-8, Examples 1-36, or by methods generally known in the art. In some embodiments, exemplary compounds can include, but are not limited to, compounds selected from Table 1, or salts or solvates thereof.
[0831] Table 1
[0832]
[0833]
[0834]
[0835]
[0836]
[0837]
[0838]
[0839]
[0840]
[0841]
[0842]
[0843]
[0844]
[0845]
[0846]
[0847]
[0848]
[0849]
[0850]
[0851]
[0852]
[0853]
[0854]
[0855]
[0856]
[0857]
[0858]
[0859]
[0860]
[0861]
[0862]
[0863]
[0864] In some embodiments, the compounds of the present disclosure exhibit one or more functional properties described herein. For example, the subject compounds are capable of reducing Ras signaling output. In some cases, the subject compounds are capable of disrupting Ras-SOS interactions, including disrupting the interaction or binding between mutant Kras (e.g., Kras G12C) and SOS1, or between wild-type Kras and SOS1, thereby reducing Ras signaling output. In some embodiments, the subject compounds specifically bind to SOS proteins, including SOS1. In some embodiments, the IC50 of the subject compounds (including those shown in Table 1) for SOS proteins is less than about 5 μM, less than about 1 μM, less than about 50 nM, less than about 10 nM, less than about 1 nM, less than about 0.5 nM, less than about 100 pM, or less than about 50 pM, as measured in in vitro assays known in the art or exemplified herein.
[0865] A reduction in Ras signaling output can be demonstrated by one or more of the following: (i) an increase in the steady-state level of GDP-bound Ras protein; (ii) a decrease in the steady-state level of GTP-bound Ras protein; (iii) a decrease in phosphorylated AKTs473, (iv) a decrease in phosphorylated ERKT202 / y204, (v) a decrease in phosphorylated S6S235 / 236, (vi) a decrease (e.g., inhibition) in cell growth of Ras-driven tumor cells (e.g., tumor cells from a tumor cell line disclosed herein), and (vii) interference with or disruption of the interaction or binding between an SOS protein (e.g., SOS1) and a Ras protein, such as wild-type or mutant Ras. In some cases, a reduction in Ras signaling output can be demonstrated by two, three, four, five, six, or all of (i)-(vii) above.
[0866] It should be understood that the different aspects of the present invention can be understood individually, collectively, or in combination with each other. The various aspects of the present invention described herein can be applied to any specific application disclosed herein. The material composition comprising the compound of any chemical formula disclosed in the composition section of this disclosure can be used in the method section, including the use and production methods disclosed herein, or vice versa.
[0867] method
[0868] In certain aspects, the present disclosure provides a method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound as described herein or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the cancer is a solid tumor or a hematological cancer. In some embodiments, an additional agent or therapy is administered to the subject.
[0869] In certain aspects, the present disclosure provides a method for reducing Ras signaling output, comprising contacting an SOS1 protein with an effective amount of a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, thereby reducing Ras signaling output. In some embodiments, the compound disrupts the interaction between the Ras protein and SOS1. In some embodiments, the Ras protein is wild-type K-Ras or a mutant K-Ras.
[0870] In certain aspects, the present disclosure provides a method of inhibiting cell growth, comprising administering an effective amount of a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, to a cell expressing SOS1, thereby inhibiting the growth of the cell.
[0871] In certain aspects, the present disclosure provides a method of reducing the Ras signaling output of a cell, comprising contacting the cell with an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof and an additional agent, wherein the additional agent is a chemotherapeutic agent, a radiopharmaceutical agent, an immunomodulatory agent, or an inhibitor of one or more targets selected from MEK, epidermal growth factor receptor (EGFR), FGFR1, FGFR2, FGFR3, FGFR4, mitotic kinase, topoisomerase, ALK, c-MET, ErbB2, AXL, NTRK1, RET, A-Raf, B-Raf, C-Raf, ERK, MDM2, mTOR, BET, IGF1 / 2, IGF1-R, CDK9, SHC, GAB, GRB, PI3-kinase, MAPK, SHIP1, SHIP2, SHP1, SHP2, SRC, JAK, PARP, BTK, FLT3, HDAC, VEGFR, PDGFR, LCK, Bcr-Abl, AKT, wild-type KRas, KRas mutants (e.g., KrasG12C, KRasG12D, KRasG12S, KRasG12V, KRasG13D, KRasG13C or KRasG13V), ROS1, CDK4 / 6, and mutants of one or more targets thereof, wherein the compound of Formula (I) has the following structure:
[0872]
[0873] in:
[0874] Selected from C 5-7 Carbocyclic and 5- to 7-membered heterocyclic rings, each of which is optionally substituted by one or more R 11 replace;
[0875] Not present or selected from C3-8 Carbocyclic and 3 to 8 membered heterocyclic rings, each of which is optionally substituted by one or more R 11a replace;
[0876] L 1 Selected from bond, C 1-6 Alkylene and C 1-6 alkylene halide;
[0877] L 2 Selected from C 5-25 Alkylene, C 5-25 Alkenylene, C 5-25 Alkyne, 5- to 25-membered heteroalkylene, and 5- to 25-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b Substituted, where L 2 Covalently bound to W 3 、W 4 、W 5 、W 6 or W 7 One of; or L 2 Yes-L 3 -DL 4 -, where L 4 Covalently bound to W 3 、W 4 、W 5 、W 6 or W 7 one of;
[0878] L 3 Selected from C 1-10 Alkylene, C 1-10 Alkenylene, C 1-10 Alkyne, 2- to 10-membered heteroalkylene, and 2- to 10-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b replace;
[0879] D does not exist or is selected from C 3-12 Carbocyclic and 3 to 12 membered heterocyclic rings, each of which is optionally substituted by one or more R 11d replace;
[0880] L 4 Selected from C 1-10 Alkylene, C 1-10 Alkenylene, C 1-10 Alkyne, 2- to 10-membered heteroalkylene, and 2- to 10-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b replace;
[0881] W 2 Selected from N(R 2b )、N、C(R2 )、C(R 2 )(R 2a ) and C(O);
[0882] W 3 Selected from N(R 3b )、N、C(R 3 )、C(R 3 )(R 3a ) and C(O);
[0883] W 4 Selected from N(R 4b )、N、C(R 4 )、C(R 4 )(R 4a ) and C(O);
[0884] W 5 Selected from N(R 5b )、N、C(R 5 )、C(R 5 )(R 5a ) and C(O);
[0885] W 6 Selected from N(R 6b )、N、C(R 6 )、C(R 6 )(R 6a ) and C(O);
[0886] W 7 Selected from N(R 7b )、N、C(R 7 )、C(R 7 )(R 7a ) and C(O);
[0887] W 8 Selected from N(R 8b )、N、C(R 8 )、C(R 8 )(R 8a ) and C(O);
[0888] W 9 Selected from N, C(R 9 ) and C;
[0889] W 10 Selected from N, C(R 10 ) and C;
[0890] R 1 is optionally replaced by one or more R 11c Substituted C 1-3 alkyl;
[0891] R 2 、R 2a 、R 3a 、R 4a 、R 5a 、R 6a 、R 7a 、R 8 and R 8a are independently selected from hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0892] R 3 、R 4 、R 5 、R 6 and R 7 Each independently selected from L 2 bonds, hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0893] R 2b and R 8b Each independently selected from hydrogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 ),-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0894] R 3b 、R 4b 、R 5b 、R 6b and R 7b Each independently selected from L 2 bonds, hydrogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 ),-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are independently optionally substituted by one, two or three R 20 replace;
[0895] R 9 and R 10 are each independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocyclic ring), 3- to 10-membered heterocyclic ring, and -CH2-(3- to 10-membered heterocyclic ring), wherein each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocyclic ring), 3 to 10 membered heterocyclic ring and -CH2-(3 to 10 membered heterocyclic ring) are independently optionally replaced by one, two or three R 20 replace;
[0896] R 11 、R 11a and R11d Each occurrence is independently selected from halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 、-CH2S(O)2N(R 12 )(R 13 )、-CH2N(R 12 )S(O)2(R 13 ) and -P(O)(R 17 )(R 17a ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0897] R 11b is independently selected at each occurrence from halogen, oxo, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocycle, 3- to 10-membered heterocycle, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 、-CH2S(O)2N(R 12 )(R 13 )、-CH2N(R 12 )S(O)2(R 13 ) and -P(O)(R 17 )(R 17a ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0898] R 11c is independently selected at each occurrence from halogen, -OR 12 and -N(R 12 )(R 13 );
[0899] R 12 independently selected at each occurrence from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0900] R 13 independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 haloalkyl; or R 12 and R 13 Together with the nitrogen atom to which they are attached, they form a 20 substituted 3- to 10-membered heterocycle;
[0901] R 14 independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 alkyl halide;
[0902] R 15 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace;
[0903] R 17 and R 17a Each occurrence is independently selected from C 1-6 Alkyl and C 3-6 Cycloalkyl, wherein C1-6 Alkyl and C 3-6 The cycloalkyl group is optionally substituted by one, two or three R 20 Replacement; or R 17 and R 17a Together with the phosphorus atom to which they are attached, they form a 3- to 10-membered heterocyclic ring;
[0904] R 20 is independently selected at each occurrence from halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3- to 10-membered heterocycle, -CH2-(3- to 10-membered heterocycle), -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 )、-OCH2C(O)OR 22 and -OC(O)R 25 , where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocycle), 3 to 10 membered heterocycle and -CH2-(3 to 10 membered heterocycle) are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 ) and -OC(O)R 25 ;
[0905] R 21 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0906] R 22 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl;
[0907] R 23independently selected at each occurrence from H and C 1-6 alkyl;
[0908] R 24 independently selected at each occurrence from H and C 1-6 alkyl;
[0909] R 25 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings; and represents a single or double bond such that all valences are satisfied.
[0910] In some embodiments, the additional agent is an inhibitor of one or more targets selected from MEK, epidermal growth factor receptor (EGFR), A-Raf, B-Raf, C-Raf, ErbB2 (Her2), SHP2, wild-type KRas, KRas mutants, and CDK4 / 6. In some embodiments, the additional agent is a chemotherapeutic agent, a radiopharmaceutical agent, or an immunomodulatory agent.
[0911] In certain aspects, the present disclosure provides an SOS1 protein bound by a compound described herein or a pharmaceutically acceptable salt or solvate thereof, wherein the interaction of the SOS1 protein with the Ras protein is reduced compared to the SOS1 protein not bound to the compound.
[0912] In certain aspects, the present disclosure provides a method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), (I-E1), (II-B), (II-C), or (III), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the cancer is a solid tumor or a hematological cancer, such as a solid tumor. In some embodiments, the cancer is selected from the group consisting of prostate cancer, brain cancer, colon cancer, rectal cancer, renal cell carcinoma, liver cancer, lung cancer, non-small cell lung cancer, small intestine cancer, esophageal cancer, melanoma, bone cancer, pancreatic cancer, skin cancer, head or neck cancer, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, anal cancer, stomach cancer, testicular cancer, uterine cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, non-Hodgkin's lymphoma, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethra cancer, penile cancer, solid tumors in children, bladder cancer, kidney or ureter cancer, renal pelvis cancer, central nervous system (CNS) tumors, primary CNS lymphoma, tumor angiogenesis, spinal axis (spinal axis) axis tumors, brain stem gliomas, pituitary adenomas, Kaposi's sarcoma, epidermoid carcinomas, squamous cell carcinomas, T-cell lymphomas, environmentally induced cancers, combinations of these cancers, and metastatic lesions of these cancers. In some embodiments, the cancer is a hematological cancer, e.g., chronic lymphocytic leukemia (CLL), acute leukemia, acute lymphocytic leukemia (ALL), B-cell acute lymphocytic leukemia (B-ALL), T-cell acute lymphocytic leukemia (T-ALL), chronic myeloid leukemia (CML), B-cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell or large cell follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin lymphoma, Hodgkin lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom's macroglobulinemia, or a proleukemia. In some embodiments, the cancer is one or more cancers selected from chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia (T-ALL), B-cell acute lymphoblastic leukemia (B-ALL), and acute lymphoblastic leukemia (ALL).
[0913] Any of the methods of treatment disclosed herein can be used alone or in combination or co-administered with another therapy or another agent. "Combination" means comprising (a) preparing a subject composition containing the subject compound and another agent, and (b) using the subject composition separately from another agent as an overall treatment regimen. "Combined" means that another therapy or agent is administered simultaneously, concurrently, or sequentially (without specific time limits) with the subject composition comprising a compound disclosed herein, wherein such co-administration provides a therapeutic effect.
[0914] In some embodiments, subject treatment method is combined with surgery, cell therapy, chemotherapy, radiation and / or immunosuppressive agents. In addition, the compositions of the present disclosure can be combined with other therapeutic agents, such as other anticancer agents, antiallergic agents, antinausea agents (or antiemetics), analgesics, cytoprotectants, immunostimulants and combinations thereof. In some embodiments, subject treatment method is combined with chemotherapeutic agents.
[0915] Exemplary chemotherapeutic agents include anthracyclines (e.g., doxorubicin (e.g., liposomal doxorubicin)), vinca alkaloids (e.g., vinblastine, vincristine, vindesine, vinorelbine), alkylating agents (e.g., cyclophosphamide, decarbazine, melphalan, ifosfamide, temozolomide), immune cell antibodies (e.g., alemtuzumab, gemtuzumab), Monoclonal antibody (gemtuzumab, rituximab, ofatumumab, tositumomab, brentuximab), antimetabolites (including, for example, folic acid antagonists, pyrimidine analogs, purine analogs and adenosine deaminase inhibitors (e.g., fludarabine)), TNFR glucocorticoid-induced TNFR-related protein (GITR) agonists, proteasome inhibitors (e.g., aclacinomycin A, gliotoxin or bortezomib), immunomodulators such as thalidomide or thalidomide derivatives (e.g., lenalidomide). Additional chemotherapeutic agents contemplated for use in combination include busulfan Busulfan injection cladribine Cyclophosphamide (( or ), cytarabine, cytosine arabinoside Cytarabine liposome injection daunorubicin hydrochloride Daunorubicin citrate liposome injection Dexamethasone, doxorubicin hydrochloride Etoposide Fludarabine phosphate Hydroxyurea Idarubicin Mitoxantrone Gemtuzumab Ozogamicin Anastrozole Bicalutamide bleomycin sulfate Busulfan injection Capecitabine N4-pentyloxycarbonyl-5-deoxy-5-fluorocytidine, carboplatin carmustine Chlorambucil Cisplatin Dacarbazine Dactinomycin (Actinomycin D, Cosmegan, dexamethasone, docetaxel) 5-Fluorouracil Flutamide Tezacitibine, gemcitabine (difluorodeoxycytidine), ifosfamide Irinotecan L-asparaginase leucovorin calcium, melphalan 6-Mercaptopurine methotrexate Mitoxantrone Mylotarg, paclitaxel Phoenix (yttrium-90 / MX-DTPA), pentostatin, polyphenylpropanone 20, and carmustine implants Tamoxifen citrate teniposide 6-thioguanine, thiotepa, tirapazamine Topotecan Hydrochloride for Injection Vinblastine vincristine and vinorelbine
[0916] Anticancer agents of particular interest for combination with the compounds of the present disclosure include: anthracyclines; alkylating agents; antimetabolites; drugs that inhibit the calcium-dependent phosphatase calcineurin or p70S6 kinase FK506 or inhibit p70S6 kinase; mTOR inhibitors; immunomodulators; vinca alkaloids; proteasome inhibitors; GITR agonists; protein tyrosine phosphatase inhibitors; CDK4 kinase inhibitors; BTK inhibitors; MKN kinase inhibitors; DGK kinase inhibitors; or oncolytic viruses.
[0917] Exemplary antimetabolites include, but are not limited to, pyrimidine analogs, purine analogs, and adenosine deaminase inhibitors): methotrexate 5-Fluorouracil Floxuridine Cytarabine ( Tarabine PFS), 6-mercaptopurine ), 6-thioguanine (thioguanine ), fludarabine phosphate Pentostatin pemetrexed raltitrexed Cladribine clofarabine Azacitidine Decitabine and gemcitabine Preferred antimetabolites include cytarabine, clofarabine, and fludarabine.
[0918] Exemplary alkylating agents include, but are not limited to, nitrogen mustards, ethyleneimine derivatives, alkyl sulfonates, nitrosoureas, and triazenes: Aminouracil mustard Uracil nitrogen ), chlormethine Cyclophosphamide ( Revimmune TM ), ifosfamide Melphalan Chlorambucil Pipobroman Triethylenemelamine Triethylenethiophosphate, Temozolomide Thiotepa Busulfan Carmustine lomustine Streptozocin and dacarbazine Additional exemplary alkylating agents include, but are not limited to, oxaliplatin Temozolomide ( and ); Dactinomycin (also known as actinomycin-D, ); melphalan (also known as L-PAM, L-sarcolysin, and phenylalanine mustard, ); Altretamine (also known as hexamethylmelamine (HMM), ); Carmustine Bendamustine Busulfan ( and ); carboplatin Lomustine (also known as CCNU, ); Cisplatin (also known as CDDP, and ) ; Chlorambucil Cyclophosphamide ( and ); Dacarbazine (also known as DTIC, DIC, and imidazole carboxamide, ); Hexamethylmelamine (also known as hexamethylmelamine (HMM), ); ifosfamide Prednumustine; Procarbazine Dichloromethyldiethylamine (also known as nitrogen mustard, mustine, and dichloromethyldiethylamine hydrochloride, ); Streptozotocin Thiotepa (also known as thiophosphoamide, TESPA, and TSPA, ); cyclophosphamide and Bendamustine HCl
[0919] In some embodiments, the compositions provided herein can be administered in combination with radiotherapy such as radiation. Whole body radiation can be administered at 12 Gy. The radiation dose can include a cumulative dose of 12 Gy to the whole body including healthy tissue. The radiation dose can include 5 Gy to 20 Gy. The radiation dose can be 5 Gy, 6 Gy, 7 Gy, 8 Gy, 9 Gy, 10 Gy, 11 Gy, 12 Gy, 13 Gy, 14 Gy, 15 Gy, 16 Gy, 17 Gy, 18 Gy, 19 Gy or 20 Gy at the most. Radiation can be whole body radiation or partial body radiation. When radiation is whole body radiation, it may be uniform or uneven. For example, when radiation may not be uniform, a narrower area of the body such as the neck may receive a higher dose than a wider area such as the buttocks.
[0920] When desirable, immunosuppressant can be used in conjunction with theme treatment method.Exemplary immunosuppressant includes but is not limited to cyclosporin (cyclosporin), azathioprine (azathioprine), methotrexate, mycophenolate mofetil and FK506, antibody or other immune ablative agent (immunoablative agent) such as CAMPATH, anti-CD3 antibody (for example, muromonab (muromonab), otelixizumab (otelixizumab)) or other antibody therapy, cytotoxin, fludarabine, cyclosporin, FK506, rapamycin (rapamycin), mycophenolic acid, steroid, FR901228, cytokine and irradiation, peptide vaccine and its any combination.According to the subject of the present disclosure, the various methods described above can include the administration of at least one immunomodulator. In certain embodiments, at least one immunomodulator is selected from immunostimulators, checkpoint immune blockers (e.g., immune checkpoint genes such as PD-1, PD-L1, CTLA-4, IDO, TIM3, LAG3, TIGIT, BTLA, VISTA, ICOS, KIR and CD39 blockers or inhibitors), radiotherapy agents, chemotherapy agents and combinations thereof. In some embodiments, the immunostimulator is selected from IL-12, agonist co-stimulatory monoclonal antibodies and combinations thereof. In one embodiment, the immunostimulator is IL-12. In some embodiments, the agonist co-stimulatory monoclonal antibody is selected from an anti-4-1BB antibody (e.g., urelumab, PF-05082566), an anti-OX40 antibody (pogalizumab, tavolixizumab, PF-04518600), an anti-ICOS antibody (BMS986226, MEDI-570, GSK3359609, JTX-2011), and a combination thereof. In one embodiment, the agonist co-stimulatory monoclonal antibody is an anti-4-1BB antibody. In some embodiments, the checkpoint immune blocker is selected from anti-PD-L1 antibodies (atezolizumab, avelumab, durvalumab, BMS-936559), anti-CTLA-4 antibodies (e.g., tremelimumab, ipilimumab), anti-PD-1 antibodies (e.g., pembrolizumab, nivolumab), anti-LAG3 antibodies (e.g., C9B7W, 410C9), anti-B7-H3 antibodies (e.g., DS-5573a), anti-TIM3 antibodies (e.g., F38-2E2), and combinations thereof.In one embodiment, the checkpoint immune blocker is an anti-PD-L1 antibody. In some cases, the compounds of the present disclosure can be combined with bone marrow transplantation, the use of chemotherapy agents such as fludarabine, external beam radiotherapy (XRT), cyclophosphamide or antibodies such as OKT3 or CAMPATH T cell purification therapy (for example, before, simultaneously with or after) administered to the subject. In some cases, amplified cells can be administered before or after surgery. Alternatively, the composition comprising the compound as described herein can be administered together with an immunostimulant. An immunostimulant can be a vaccine, colony stimulating agent, interferon, interleukin, virus, antigen, co-stimulator, immunogenic agent, immunomodulator or immunotherapy agent. An immunostimulant can be a cytokine such as an interleukin. One or more cytokines can be introduced together with the modified cells provided herein. Cytokines can be used to strengthen the function of modified T lymphocytes (including adoptively transferred tumor-specific cytotoxic T lymphocytes) to expand within the tumor microenvironment. In some cases, IL-2 can be used to promote the expansion of modified cells as described herein. It is also possible to use cytokines such as IL-15. It is also possible to utilize other related cytokines in the field of immunotherapy, such as IL-2, IL-7, IL-12, IL-15, IL-21 or any combination thereof. The interleukin can be IL-2 or aldesleukin (aldeskeukin). Aldesleukin can be administered in low doses or high doses. The high-dose aldesleukin regimen can be directed to administering aldesleukin intravenously every 8 hours with about 0.037mg / kg (600,000IU / kg) when tolerated, for up to about 14 doses. Immunostimulants (e.g., aldesleukin) can be administered within 24 hours after cell administration. Immunostimulants (e.g., aldesleukin) can be administered in an infusion form in about 15min about every 8 hours after cell infusion, for up to about 4 days. The immunostimulant (e.g., aldesleukin) can be administered at a dose of about 100,000 IU / kg, 200,000 IU / kg, 300,000 IU / kg, 400,000 IU / kg, 500,000 IU / kg, 600,000 IU / kg, 700,000 IU / kg, 800,000 IU / kg, 900,000 IU / kg, or up to about 1,000,000 IU / kg. In some instances, aldesleukin can be administered at a dose of about 100,000 IU / kg to 300,000 IU / kg, 300,000 IU / kg to 500,000 IU / kg, 500,000 IU / kg to 700,000 IU / kg, 700,000 IU / kg to about 1,000,000 IU / kg.
[0921] In some embodiments, the compounds disclosed herein that are capable of modulating SOS proteins (e.g., SOS1) to reduce Ras signaling output can be combined or co-administered with one or more pharmacologically active agents, including but not limited to: (1) inhibitors of MEK (e.g., MEK1, MEK2) or mutants thereof (e.g., trametinib, cobimetinib, binimetinib, selumetinib, refametinib, AZD6244); (2) inhibitors of epidermal growth factor receptor (EGFR) and / or mutants thereof (e.g., afatinib, erlotinib); (i) gefitinib, lapatinib, cetuximab, panitumumab, osimertinib, olmutinib, EGF-816); (ii) immunotherapeutic agents (e.g., checkpoint immune blockers, as disclosed herein); (iii) taxanes (e.g., paclitaxel, docetaxel); (iv) antimetabolites (e.g., antifolates such as methotrexate, raltitrexed, pyrimidine analogs such as 5-fluorouracil (5-FU), ribonucleoside and deoxyribonucleoside analogs, capecitabine and gemcitabine, purine and adenosine analogs such as mercaptopurine, thioguanine, cladribine and pentostatin, cytarabine (arabinoside)); (C), fludarabine); (6) inhibitors of FGFR1 and / or FGFR2 and / or FGFR3 and / or their mutants (e.g., nintedanib); (7) mitotic kinase inhibitors (e.g., CDK4 / 6 inhibitors, such as, for example, palbociclib, ribociclib, abemaciclib); (8) anti-angiogenic drugs (e.g., anti-VEGF antibodies, such as, for example, bevacizumab); (9) topoisomerase inhibitors agents (e.g., epipodophyllotoxins such as etoposide and etopophos, teniposide, amsacrin, topotecan, irinotecan, mitoxantrone); (10) platinum-containing compounds (e.g., cisplatin, oxaliplatin, carboplatin); (11) inhibitors of ALK and / or its mutants (e.g., crizotinib, alectinib, entrectinib, brigatinib);(12) inhibitors of c-MET and / or its mutants (e.g., K252a, SU11274, PHA665752, PF2341066); (13) inhibitors of BCR-ABL and / or its mutants (e.g., imatinib, dasatinib, nilotinib); (14) inhibitors of ErbB2 (Her2) and / or its mutants (e.g., afatinib, lapatinib, trastuzumab, pertuzumab); (15) inhibitors of AXL and / or its mutants (e.g., R428, amuvatinib, XL-880); (16) inhibitors of NTRK1 and / or its mutants (17) inhibitors of RET and / or its mutants (e.g., BLU-667, Lenvatinib); (18) inhibitors of A-Raf, B-Raf (e.g., Sorafenib, Vemurafenib, Debrafenib, Encorafenib) and / or C-Raf and / or its mutants (RAF-709, LY-3009120); (19) inhibitors of ERK and / or its mutants (e.g., ulixertinib); (20) MDM2 inhibitors (e.g., HDM-201, NVP-CGM097, RG-71 12, MK-8242, RG-7388, SAR405838, AMG-232, DS-3032, RG-7775, APG-115); (21) mTOR inhibitors (e.g., rapamycin, temsirolimus, everolimus, ridaforolimus); (22) BET inhibitors (e.g., I-BET 151, I-BET762, OTX-015, TEN-010, CPI-203, CPI-0610, olionon, RVX-208, ABBC-744, LY294002, AZD5153, MT-1, MS645); (23) inhibitors of IGF1 / 2 and / or IGF1-R (e.g., xentuzumab, MEDI-573); (24)...
Claims
1. A compound of formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein: Selected from C 5-7 Carbocyclic and 5- to 7-membered heterocyclic rings, each of which is optionally substituted by one or more R 11 replace; Not present or selected from C 3-8 Carbocyclic and 3 to 8 membered heterocyclic rings, each of which is optionally substituted by one or more R 11a replace; L 1 Select from key, C 1-6 Alkylene and C 1-6 Haloalkylene; L 2 Selected from C 5-25 Alkylene, C 5-25 Alkenylene, C 5-25 alkynylene, 5 to 25 membered heteroalkylene and 5 to 25 membered heteroalkenylene, each of which is optionally substituted by one or more R 11b Substitution, where L 2 Covalently bound to W 3 , W 4 , W 5 , W 6 or W 7 One of; or L 2 Yes-L 3 -DL 4 -, where L 4 Covalently bound to W 3 , W 4 , W 5 , W 6 or W 7 one of; L 3 Selected from C 1-10 Alkylene, C 1-10 Alkenylene, C 1-10 alkynylene, 2 to 10 membered heteroalkylene, and 2 to 10 membered heteroalkenylene, each of which is optionally substituted by one or more R 11b replace; D does not exist or is selected from C 3-12 Carbocyclic and 3 to 12 membered heterocyclic rings, each of which is optionally substituted by one or more R 11d replace; L 4 Selected from C 1-10 Alkylene, C 1-10 Alkenylene, C 1-10 alkynylene, 2 to 10 membered heteroalkylene and 2 to 10 membered heteroalkenylene, each of which is optionally substituted by one or more R 11b replace; W 2 Selected from N(R 2b )、N、C(R 2 )、C(R 2 )(R 2a ) and C(O); W 3 Selected from N(R 3b )、N、C(R 3 )、C(R 3 )(R 3a ) and C(O); W 4 Selected from N(R 4b )、N、C(R 4 )、C(R 4 )(R 4a ) and C(O); W 5 Selected from N(R 5b )、N、C(R 5 )、C(R 5 )(R 5a ) and C(O); W 6 Selected from N(R 6b )、N、C(R 6 )、C(R 6 )(R 6a ) and C(O); W 7 Selected from N(R 7b )、N、C(R 7 )、C(R 7 )(R 7a ) and C(O); W 8 Selected from N(R 8b )、N、C(R 8 )、C(R 8 )(R 8a ) and C(O); W 9 Selected from N, C (R 9 ) and C; W 10 Selected from N, C (R 10 ) and C; R 1 is optionally replaced by one or more R 11c Substituted C 1-3 alkyl; R 2 , R 2a , R 3a , R 4a , R 5a , R 6a , R 7a , R 8 and R 8a are each independently selected from hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, 3- to 10-membered heterocyclic ring, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are independently optionally substituted by one, two or three R 20 replace; R 3 , R 4 , R 5 , R 6 and R 7 Each independently selected from 2 bonds, hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, 3- to 10-membered heterocyclic ring, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are independently optionally substituted by one, two or three R 20 replace; R 2b and R 8b are independently selected from hydrogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, 3- to 10-membered heterocyclic ring, -OR 12 、-SR 12 、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are independently optionally substituted by one, two or three R 20 replace; R 3b , R 4b , R 5b , R 6b and R 7b Each independently selected from 2 bonds, hydrogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, 3- to 10-membered heterocyclic ring, -OR 12 、-SR 12 、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are independently optionally substituted by one, two or three R 20 replace; R 9 and R 10 are each independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocyclic ring), 3- to 10-membered heterocyclic ring, and -CH2-(3- to 10-membered heterocyclic ring), wherein each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocyclic ring), 3 to 10 membered heterocyclic ring and -CH2-(3 to 10 membered heterocyclic ring) are independently optionally substituted by one, two or three R 20 replace; R 11 , R 11a and R 11d is independently selected at each occurrence from halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, 3- to 10-membered heterocyclic ring, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 、-CH2S(O)2N(R 12 )(R 13 )、-CH2N(R 12 )S(O)2(R 13 ) and -P(O)(R 17 )(R 17a ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace; R 11b is independently selected at each occurrence from halogen, oxo, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, 3- to 10-membered heterocyclic ring, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 、-CH2S(O)2N(R 12 )(R 13 )、-CH2N(R 12 )S(O)2(R 13 ) and -P(O)(R 17 )(R 17a ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace; R 11c is independently selected at each occurrence from halogen, -OR 12 and -N(R 12 )(R 13 ); R 12 is independently selected at each occurrence from hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace; R 13 is independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 haloalkyl; or R 12 and R 13 Together with the nitrogen atom to which they are attached, they form a 20 substituted 3- to 10-membered heterocyclic ring; R 14 is independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 Haloalkyl; R 15 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace; R 17 and R 17a Each occurrence is independently selected from C 1-6 Alkyl and C 3-6 Cycloalkyl, wherein C 1-6 Alkyl and C 3-6 The cycloalkyl group is optionally substituted by one, two or three R 20 Replace; or R 17 and R 17a Together with the phosphorus atom to which they are attached, they form a 3- to 10-membered heterocyclic ring; R 20 is independently selected at each occurrence from halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocyclic ring), 3- to 10-membered heterocyclic ring, -CH2-(3- to 10-membered heterocyclic ring), -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 )、-OCH2C(O)OR 22 and -OC(O)R 25 , where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocyclic ring), 3 to 10 membered heterocyclic ring and -CH2-(3 to 10 membered heterocyclic ring) are optionally substituted by one, two or three groups independently selected from the following: halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、 -C(O)C(O)N(R 22 )(R 23 )、 -OC(O)N(R 22 )(R 23 )、 -N(R 24 )C(O)N(R 22 )(R 23 )、 -N(R 24 )C(O)OR 25 、 -N(R 24 )C(O)R 25 、 -N(R 24 )S(O)2R 25 、 -C(O)R 25 、 -S(O)2R 25 、 -S(O)2N(R 22 )(R 23 ) and -OC(O)R 25 ; R 21 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl; R 22 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl; R 23 is independently selected at each occurrence from H and C 1-6 alkyl; R 24 is independently selected at each occurrence from H and C 1-6 alkyl; R 25 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-10 carbocyclic rings and 3- to 10-membered heterocyclic rings; and represents a single or double bond such that all valences are satisfied.
2. The compound according to claim 1, which has the structure of formula (IA): or a pharmaceutically acceptable salt or solvate thereof.
3. The compound according to claim 1, which has the structure of formula (IB): or a pharmaceutically acceptable salt or solvate thereof.
4. The compound according to claim 1, which has the structure of formula (IC): or a pharmaceutically acceptable salt or solvate thereof.
5. The compound according to claim 1, which has the structure of formula (ID): or a pharmaceutically acceptable salt or solvate thereof.
6. The compound according to claim 1, which has the structure of formula (IE): or a pharmaceutically acceptable salt or solvate thereof.
7. The compound, salt or solvate according to any one of claims 1 to 6, wherein: L 2 Selected from C 5-25 Alkylene, C 5-25 Alkenylene, C 5-25 alkynylene, 5 to 25 membered heteroalkylene and 5 to 25 membered heteroalkenylene, each of which is optionally substituted by one or more R 11b Substitution, where L 2 Covalently bound to W 3 , W 4 , W 5 , W 6 or W 7 one of them.
8. The compound, salt or solvate according to any one of claims 1 to 7, wherein: Selected from C 5-7 Cycloalkyl, 5- to 7-membered heterocycloalkyl, 5- to 7-membered heteroaryl and phenyl, each of which is optionally substituted by one or more R 11 replace; L 1 Select from key, C 1-2 Alkylene and C 1-2 a haloalkylene group; and R 1 is optionally replaced by one or more R 11c Substituted C 1-2 alkyl.
9. The compound, salt or solvate according to any one of claims 1 to 8, wherein: R 7 Selected from L 2 bonds, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, 3- to 10-membered heterocyclic ring, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are independently optionally substituted by one, two or three R 20 replace; R 7b Selected from L 2 The bond of -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, 3- to 10-membered heterocyclic ring, -OR 12 、-SR 12 、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are independently optionally substituted by one, two or three R 20 replace.
10. The compound, salt or solvate according to any one of claims 1 to 9, wherein W 2 It is N.
11. The compound, salt or solvate according to any one of claims 1 to 10, wherein W 3 Selected from N(R 3b )、N、C(R 3 ) and C(O).
12. The compound, salt or solvate according to claim 11, wherein W 3 Selected from C(R 3 ) and C(O).
13. The compound, salt or solvate according to any one of claims 1 to 12, wherein W 4 Selected from N(R 4b )、N、C(R 4 ) and C(O).
14. The compound, salt or solvate according to claim 13, wherein W 4 Selected from N(R 4b ) and N.
15. The compound, salt or solvate according to any one of claims 1 to 14, wherein W 5 Selected from N(R 5b )、N、C(R 5 ) and C(O).
16. The compound, salt or solvate according to claim 15, wherein W 5 Selected from N(R 5b ), N and C (R 5 ).
17. The compound, salt or solvate according to claim 16, wherein W 5 Selected from N(R 5b ) and C(R 5 ).
18. A compound, salt or solvate according to any one of claims 1 to 17, wherein W 6 Selected from C(R 6 ) and C(O).
19. A compound, salt or solvate according to any one of claims 1 to 18, wherein W 7 is C(R 7 ).
20. The compound, salt or solvate according to any one of claims 1 to 19, wherein W 8 is C(R 8 ).
21. The compound, salt or solvate according to claim 20, wherein W 8 It is CH.
22. A compound, salt or solvate according to any one of claims 1 to 21, wherein W 9 It is C.
23. A compound, salt or solvate according to any one of claims 1 to 22, wherein W 10 It is C.
24. A compound, salt or solvate according to any one of claims 1 to 23, wherein: W 2 is N; W 3 is N(R 3b ); W 4 is C(O); and W 9 and W 10 Each is C.
25. The compound, salt or solvate according to any one of claims 1 to 23, wherein: W 2 is N; W 3 is C(O); W 4 is N(R 4b );and W 9 and W 10 Each is C.
26. A compound, salt or solvate according to any one of claims 1 to 23, wherein: W 2 is N; W 3 is C(R 3 ); W 4 is N; and W 9 and W 10 Each is C.
27. A compound, salt or solvate according to any one of claims 1 to 26, wherein: W 5 is C(R 5 ); W 6 is C(R 6 ); W 7 is C(R 7 ); W 8 is C(R 8 );and W 9 and W 10 Each is C.
28. A compound, salt or solvate according to any one of claims 1 to 26, wherein: W 5 is N(R 5b ); W 6 is C(O); W 7 is C(R 7 ); W 8 is C(R 8 );and W 9 and W 10 Each is C.
29. The compound, salt or solvate according to any one of claims 1 to 26, wherein: W 5 is N; W 6 is C(R 6 ); W 7 is C(R 7 ); W 8 is C(R 8 );and W 9 and W 10 Each is C.
30. A compound, salt or solvate according to any one of claims 1 to 23, wherein: W 2 is N; W 3 Selected from N(R 3b )、N、C(R 3 ) and C(O); W 4 Selected from N(R 4b )、N、C(R 4 ) and C(O); W 5 Selected from N(R 5b ), N and C (R 5 ); W 6 Selected from C(R 6 ) and C(O); W 7 is C(R 7 ); W 8 is C(R 8 );and W 9 and W 10 Each is C.
31. A compound, salt or solvate according to any one of claims 1 to 23, wherein: W 2 is N; W 3 Selected from C(R 3 ) and C(O); W 4 Selected from N(R 4b ) and N; W 5 Selected from N(R 5b ) and C(R 5 ); W 6 Selected from C(R 6 ) and C(O); W 7 is C(R 7 ); W 8 is CH; and W 9 and W 10 Each is C.
32. The compound according to claim 3, which has the structure of formula (I-B1) or (I-B2): or a pharmaceutically acceptable salt or solvate thereof.
33. The compound according to claim 4, having the structure of formula (I-C1), (I-C2) or (I-C3): or a pharmaceutically acceptable salt or solvate thereof.
34. The compound according to claim 5, which has the structure of formula (I-D1) or (I-D2): or a pharmaceutically acceptable salt or solvate thereof.
35. The compound according to claim 6, which has the structure of formula (I-E1): or a pharmaceutically acceptable salt or solvate thereof.
36. A compound, salt or solvate according to any one of claims 1 to 35, wherein R 1 is unsubstituted C 1-2 alkyl.
37. The compound, salt or solvate of claim 36, wherein R 1 It is -CH3.
38. A compound, salt or solvate according to any one of claims 1 to 37, wherein R 3 Selected from hydrogen, halogen, -CN, -OR 12 and optionally one, two or three R 20 Substituted C 1-6 alkyl.
39. The compound, salt or solvate of claim 38, wherein R 3 is optionally replaced by one, two or three R 20 Substituted C 1-6 alkyl.
40. The compound, salt or solvate of claim 38, wherein R 3 It is hydrogen or -CH3.
41. A compound, salt or solvate according to any one of claims 1 to 37, wherein R 3b It is -CH3.
42. A compound, salt or solvate according to any one of claims 1 to 41, wherein R 5 Selected from hydrogen, -OR 12 and optionally one, two or three R 20 Substituted C 1-6 alkyl.
43. The compound, salt or solvate of claim 42, wherein R 5 It's hydrogen.
44. A compound, salt or solvate according to any one of claims 1 to 41, wherein R 5b is selected from hydrogen and optionally substituted by one, two or three R 20 Substituted C 1-6 alkyl.
45. The compound, salt or solvate of claim 44, wherein R 5b It is -CH3.
46. A compound, salt or solvate according to any one of claims 1 to 45, wherein R 6 Selected from hydrogen, -OR 12 and optionally one, two or three R 20 Substituted C 1-6 alkyl, and wherein R 12 Selected from C 1-6 alkyl.
47. The compound, salt or solvate of claim 46, wherein R 6 Selected from hydrogen and -OCH3.
48. A compound, salt or solvate according to any one of claims 1 to 47, wherein R 7 Selected from C 1-6 Alkyl, C 3-10 Carbocyclic ring, 3- to 10-membered heterocyclic ring, -N(R 12 )(R 13 )、-C(O)R 15 、-C(O)N(R 12 )(R 13 )、-S(O)2R 15 and -SO2N(R 12 )(R 13 ), where C 1-6 Alkyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace.
49. The compound, salt or solvate of claim 48, wherein R 7 Selected from C 1-6 Alkyl, C 3-10 Cycloalkyl, 3- to 10-membered heterocycloalkyl, and -N(R 12 )(R 13 ), where C 1-6 Alkyl, C 3-10 Cycloalkyl and 3 to 10 membered heterocycloalkyl are optionally substituted by one, two or three R 20 replace.
50. The compound, salt or solvate of claim 48, wherein R 7 is optionally replaced by one, two or three R 20 Substituted 3- to 10-membered heterocycloalkyl.
51. The compound, salt or solvate of claim 48, wherein R 7 is optionally replaced by one, two or three R 20 Substituted C 3-10 Cycloalkyl.
52. The compound, salt or solvate of claim 48, wherein R 7 is optionally replaced by an R 20 Substituted C 3-4 Cycloalkyl.
53. A compound, salt or solvate according to any one of claims 48 to 52, wherein R 20 Yes-CN.
54. The compound, salt or solvate of claim 52, wherein R 7 yes 55. The compound, salt or solvate of claim 48, wherein R 7 is optionally replaced by one, two or three R 20 Substituted C 1-6 alkyl.
56. The compound, salt or solvate of claim 48, wherein R 7 Yes-N(R 12 )(R 13 ).
57. A compound, salt or solvate according to any one of claims 1 to 47, wherein R 7 Selected from:
58. The compound, salt or solvate of claim 57, wherein R 7 Selected from 59. The compound, salt or solvate of claim 58, wherein R 7 Selected from 60. A compound, salt or solvate according to any one of claims 1 to 59, wherein R 8 is selected from hydrogen, halogen and optionally substituted by one, two or three R 20 Substituted C 1-6 alkyl.
61. The compound, salt or solvate of claim 60, wherein R 8 It's hydrogen.
62. A compound, salt or solvate according to any one of claims 1 to 61, wherein is selected from phenyl and 5- to 7-membered heteroaryl, each of which is optionally substituted by one or more R 11 replace.
63. A compound, salt or solvate according to any one of claims 1 to 61, wherein is selected from phenyl, pyridyl and thienyl, each of which is optionally substituted by one or more R 11 replace.
64. A compound, salt or solvate according to any one of claims 1 to 61, wherein Selected from 65. according to any one of claims 62 to 64, the compound, salt or solvate, wherein R 11 When present at each occurrence is independently selected from fluoro and -CH3.
66. According to any one of claims 1 to 65, the compound, salt or solvate, wherein L 1 Select from the key and C 1-3 Halogenated alkylene.
67. The compound, salt or solvate of claim 66, wherein L 1 It is C 1-3 Halogenated alkylene.
68. The compound, salt or solvate of claim 67, wherein L 1 Selected from -CF2-, -CF2CH2- and -CF2CH2CH2-.
69. A compound, salt or solvate according to any one of claims 1 to 68, wherein is selected from the group consisting of absence, phenyl and a 4- to 8-membered heterocyclic ring, wherein the phenyl and 4- to 8-membered heterocyclic ring are optionally replaced by one or more R 11a replace.
70. The compound, salt or solvate of claim 69, wherein is selected from the group consisting of absence, phenyl, azetidine, pyrrolidine and piperidine, wherein the phenyl, azetidine, pyrrolidine and piperidine are optionally replaced by one or more R 11a replace.
71. The compound, salt or solvate of claim 69, wherein is selected from azetidine, pyrrolidine and piperidine, each of which is optionally substituted with one or more -CH3.
72. A compound, salt or solvate according to any one of claims 1 to 71, wherein L 2 Together with the atoms to which it is attached, it forms a 16- to 36-membered macrocyclic ring.
73. The compound, salt or solvate of claim 72, wherein L 2 Together with the atoms to which it is attached, it forms a 16- to 24-membered macrocyclic ring.
74. A compound, salt or solvate according to any one of claims 1 to 73, wherein L 2 Selected from C 6-15 Alkylene, C 6-15 Alkenylene, C 6-15 alkynylene, 6 to 15 membered heteroalkylene and 6 to 15 membered heteroalkenylene, each of which is optionally substituted by one or more R 11b replace.
75. A compound, salt or solvate according to any one of claims 1 to 73, wherein L 2 Selected from C 5-10 Alkylene, C 5-10 alkenylene, 5- to 10-membered heteroalkylene, and 5- to 10-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b replace.
76. The compound, salt or solvate of claim 74 or 75, wherein the alkenylene and heteroalkenylene groups contain one carbon-carbon double bond.
77. The compound, salt or solvate of claim 74 or 75, wherein the heteroalkylene and heteroalkenylene groups contain at least one oxygen or nitrogen atom.
78. A compound, salt or solvate according to any one of claims 1 to 77, wherein R 11b is independently selected at each occurrence from halogen, oxo, C 1-6 Alkyl, C 1-6 Haloalkyl, (C 1-6 alkyl)-OH and -OH.
79. The compound, salt or solvate of claim 78, wherein R 11b is independently selected at each occurrence from -F, =O, -CH3, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2OH and -OH.
80. The compound, salt or solvate of claim 32, wherein: R 5 It is hydrogen; R 5b is -CH3; R 6 is selected from hydrogen and -OCH3; R 7 Selected from C 1-6 Alkyl, C 3-10 Carbocyclic ring, 3- to 10-membered heterocyclic ring, -N(R 12 )(R 13 )、-C(O)R 15 、-C(O)N(R 12 )(R 13 )、-S(O)2R 15 and -SO2N(R 12 )(R 13 ), where C 1-6 Alkyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace; and R 8 It's hydrogen.
81. The compound, salt or solvate of claim 33, wherein: R 3 is hydrogen or -CH3; R 3b is -CH3; R 6 is selected from hydrogen and -OCH3; R 7 Selected from C 1-6 Alkyl, C 3-10 Carbocyclic ring, 3- to 10-membered heterocyclic ring, -N(R 12 )(R 13 )、-C(O)R 15 、-C(O)N(R 12 )(R 13 )、-S(O)2R 15 and -SO2N(R 12 )(R 13 ), where C 1-6 Alkyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace; and R 8 It's hydrogen.
82. The compound, salt or solvate according to claim 80 or 81, wherein R 7 Selected from 83. A compound, salt or solvate according to any one of claims 1 to 35 or 80 to 82, wherein: R 1 is -CH3; is selected from phenyl and 5- to 7-membered heteroaryl, each of which is optionally substituted by one or more R 11 replace; L 1 Select from the key and C 1-3 Haloalkylene; is selected from the group consisting of absence, phenyl and a 4- to 8-membered heterocyclic ring, wherein the phenyl and 4- to 8-membered heterocyclic ring are optionally replaced by one or more R 11a replace; and L 2 Selected from C 5-10 Alkylene, C 5-10 alkenylene, 5- to 10-membered heteroalkylene, and 5- to 10-membered heteroalkenylene, each of which is optionally substituted by one or more R 11b replace.
84. The compound, salt or solvate of claim 83, wherein: R 11 When present it is fluorine; R 11a When present, it is -CH3; and R 11b When present, each occurrence is independently selected from halogen, oxo, C 1-6 Alkyl, C 1-6 Haloalkyl, (C 1-6 alkyl)-OH and -OH.
85. A compound according to any one of claims 1 to 7, 9 to 35, 38 to 61 or 72 to 82 having the following structure: or a pharmaceutically acceptable salt or solvate thereof.
86. The compound according to claim 33, having the structure of formula (I-C1): or a pharmaceutically acceptable salt or solvate thereof, wherein: Selected from is selected from azetidine, pyrrolidine and piperidine, each of which is optionally substituted with one or more -CH3; L 1 It is C 1-3 Haloalkylene; L 2 is optionally replaced by one or more R 11b Substituted C 5-10 alkenylene; R 1 is -CH3; R 3 is -CH3; R 7 Selected from R 8 It is hydrogen; R 11 is selected from fluorine and -CH3; and R 11b Selected from halogen, oxo, C 1-6 Alkyl, C 1-6 Haloalkyl, (C 1-6 alkyl)-OH and -OH.
87. The compound according to claim 33, having the structure of formula (I-C1): or a pharmaceutically acceptable salt or solvate thereof, wherein: Selected from is selected from azetidine, pyrrolidine and piperidine, each of which is optionally substituted with one or more -CH3; L 1 It is C 1-3 Haloalkylene; L 2 Selected from optionally one or more R 11b substituted 5- to 10-membered heteroalkylene; R 1 is -CH3; R 3 is hydrogen or -CH3; R 7 Selected from R 8 It is hydrogen; R 11 is selected from fluorine and -CH3; and R 11b Selected from halogen, oxo, C 1-6 Alkyl, C 1-6 Haloalkyl, (C 1-6 alkyl)-OH and -OH.
88. A compound of formula (III): or a pharmaceutically acceptable salt or solvate thereof, wherein: Selected from optionally one or more R 11a substituted 3 to 8 membered heterocyclic ring; L 1 Select from key, C 1-6 Alkylene and C 1-6 Haloalkylene; L 2 Selected from C 5-25 Alkylene, C 5-25 Alkenylene, C 5-25 alkynylene, 5 to 25 membered heteroalkylene and 5 to 25 membered heteroalkenylene, each of which is optionally substituted by one or more R 11b Substitution, where L 2 Covalently bound to W 3 , W 4 , W 5 , W 6 or W 7 One of; or L 2 Yes-L 3 -DL 4 -, where L 4 Covalently bound to W 3 , W 4 , W 5 , W 6 or W 7 one of; L 3 Selected from C 1-10 Alkylene, C 1-10 Alkenylene, C 1-10 alkynylene, 2 to 10 membered heteroalkylene and 2 to 10 membered heteroalkenylene, each of which is optionally substituted by one or more R 11b replace; D does not exist or is selected from C 3-12 Carbocyclic and 3 to 12 membered heterocyclic rings, each of which is optionally substituted by one or more R 11d replace; L 4 Selected from C 1-10 Alkylene, C 1-10 Alkenylene, C 1-10 alkynylene, 2 to 10 membered heteroalkylene and 2 to 10 membered heteroalkenylene, each of which is optionally substituted by one or more R 11b replace; W 3 Selected from N(R 3b ) and N, and W 4 Selected from C(R 4 ) and C(O); or W 3 Selected from C(R 3 ) and C(O), and W 4 Selected from N(R 4b ) and N; W 5 Selected from N(R 5b ), N and C (R 5 ); W 6 Selected from N, C (R 6 ) and C(O); W 7 Selected from N, C (R 7 ) and C(O); R 50 is hydrogen or a halogen; R 3 , R 4 , R 5 , R 6 and R 7 Each independently selected from 2 bonds, hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, 3- to 10-membered heterocyclic ring, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are independently optionally substituted by one, two or three R 20 replace; R 3b , R 4b and R 5b Each independently selected from 2 bonds, hydrogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, 3- to 10-membered heterocyclic ring, -OR 12 、-SR 12 、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 and -CH2S(O)2N(R 12 )(R 13 ), where each C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are independently optionally substituted by one, two or three R 20 replace; R 11a and R 11d is independently selected at each occurrence from halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, 3- to 10-membered heterocyclic ring, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 、-CH2S(O)2N(R 12 )(R 13 )、-CH2N(R 12 )S(O)2(R 13 ) and -P(O)(R 17 )(R 17a ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace; R 11b is independently selected at each occurrence from halogen, oxo, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, 3- to 10-membered heterocyclic ring, -OR 12 、-SR 12 、-N(R 12 )(R 13 )、-C(O)OR 12 、-OC(O)N(R 12 )(R 13 )、-N(R 14 )C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)OR 15 、-N(R 14 )S(O)2R 15 、-C(O)R 15 、-S(O)R 15 、-OC(O)R 15 、-C(O)N(R 12 )(R 13 )、-C(O)C(O)N(R 12 )(R 13 )、-N(R 14 )C(O)R 15 、-S(O)2R 15 、-S(O)2N(R 12 )(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 、-CH2S(O)2N(R 12 )(R 13 )、-CH2N(R 12 )S(O)2(R 13 ) and -P(O)(R 17 )(R 17a ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace; R 12 is independently selected at each occurrence from hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace; R 13 is independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 haloalkyl; or R 12 and R 13 Together with the nitrogen atom to which they are attached, they form a 20 substituted 3- to 10-membered heterocyclic ring; R 14 is independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 Haloalkyl; R 15 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three R 20 replace; R 17 and R 17a Each occurrence is independently selected from C 1-6 Alkyl and C 3-6 Cycloalkyl, wherein C 1-6 Alkyl and C 3-6 The cycloalkyl group is optionally substituted by one, two or three R 20 Replace; or R 17 and R 17a Together with the phosphorus atom to which they are attached, they form a 3- to 10-membered heterocyclic ring; R 20 is independently selected at each occurrence from halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocyclic ring), 3- to 10-membered heterocyclic ring, -CH2-(3- to 10-membered heterocyclic ring), -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 )、-OCH2C(O)OR 22 and -OC(O)R 25 , where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocyclic ring), 3 to 10 membered heterocyclic ring and -CH2-(3 to 10 membered heterocyclic ring) are optionally substituted by one, two or three groups independently selected from the following: halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、 -C(O)C(O)N(R 22 )(R 23 )、 -OC(O)N(R 22 )(R 23 )、 -N(R 24 )C(O)N(R 22 )(R 23 )、 -N(R 24 )C(O)OR 25 、 -N(R 24 )C(O)R 25 、 -N(R 24 )S(O)2R 25 、 -C(O)R 25 、 -S(O)2R 25 、 -S(O)2N(R 22 )(R 23 ) and -OC(O)R 25 ; R 21 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl; R 22 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl; R 23 is independently selected at each occurrence from H and C 1-6 alkyl; R 24 is independently selected at each occurrence from H and C 1-6 alkyl; R 25 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-10 carbocyclic rings and 3- to 10-membered heterocyclic rings; and represents a single or double bond such that all valences are satisfied.
89. A compound selected from Table 1, or a pharmaceutically acceptable salt or solvate thereof.
90. A compound selected from the group consisting of: or a pharmaceutically acceptable salt or solvate thereof.
91. A pharmaceutical composition comprising a compound according to any one of claims 1 to 90 or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.
92. A method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 90, or a pharmaceutically acceptable salt or solvate thereof.
93. The method of claim 92, wherein the cancer is a solid tumor or a hematological cancer.
94. The method of claim 92, wherein an additional agent or therapy is administered to the subject.
95. A method of reducing a Ras signaling output, comprising contacting a SOS1 protein with an effective amount of a compound according to any one of claims 1 to 90, or a pharmaceutically acceptable salt or solvate thereof, thereby reducing the Ras signaling output.
96. The method of claim 95, wherein the compound disrupts the interaction between Ras protein and SOS1.
97. The method of claim 96, wherein the Ras protein is wild-type K-Ras or mutant K-Ras.
98. A method for inhibiting cell growth, comprising administering an effective amount of a compound according to any one of claims 1 to 90 or a pharmaceutically acceptable salt or solvate thereof to a cell expressing SOS1, thereby inhibiting the growth of the cell.
99. A method of reducing the Ras signaling output of a cell, comprising contacting the cell with an effective amount of a compound according to any one of claims 1 to 90, or a pharmaceutically acceptable salt or solvate thereof, and an additional agent, wherein the additional agent is a chemotherapeutic agent, a radiopharmaceutical, an immunomodulator, or an inhibitor of one or more targets selected from: MEK, epidermal growth factor receptor (EGFR), FGFR1, FGFR2, FGFR3, FGFR4, mitotic kinase, topoisomerase, ALK, c-MET, ErbB2, A XL, NTRK1, RET, A-Raf, B-Raf, C-Raf, ERK, MDM2, mTOR, BET, IGF1 / 2, IGF1-R, CDK9, SHC, GAB, GRB, PI3-kinase, MAPK, SHIP1, SHIP2, SHP1, SHP2, SRC, JAK, PARP, BTK, FLT3, HDAC, VEGFR, PDGFR, LCK, Bcr-Abl, AKT, wild-type KRas, KRas mutants (e.g., KrasG12C, KRas G12D, KRas G12S, KRas G12V, KRas G13D, KRas G13C or KRas G13V), ROS1, CDK4 / 6, and mutants of one or more targets thereof.
100. The method of claim 99, wherein the additional agent is an inhibitor against one or more targets selected from MEK, epidermal growth factor receptor (EGFR), A-Raf, B-Raf, C-Raf, ErbB2, SHP2, wild-type KRas, KRas mutants, and CDK4 / 6.
101. The method of claim 99, wherein the additional agent is a chemotherapeutic agent, a radiopharmaceutical, or an immunomodulatory agent.
102. A SOS1 protein bound by a compound according to any one of claims 1 to 90, or a pharmaceutically acceptable salt or solvate thereof, wherein the interaction of the SOS1 protein with the Ras protein is reduced compared to the SOS1 protein not bound to the compound.
103. A method having the formula AL AB -B, wherein: A is a monovalent form of a compound according to any one of claims 1 to 90; L AB is a covalent linker bonded to A and B; and B is the monovalent form of the degradation enhancer.
104. The compound of claim 103, wherein the degradation enhancer is capable of binding to a protein selected from the group consisting of E3A, mdm2, APC, EDD1, SOCS / BC-box / eloBC / CUL5 / RING, LNXp80, CBX4, CBLL1, HACE1, HECTD1, HECTD2, HECTD3, HECTD4, HECW1, HECW2, HERC1, HERC2, HERC3, HERC4, HER5, HERC6, HUWE1, ITCH, NEDD4, NEDD4L, PPIL2, PRPF19, PIAS1, PIAS2, PIAS3, PIAS4, RANBP2, RNF4, RBX1, SMURF1, SMURF2, STUB1, TOPORS, TRIP12, UBE3A, UBE3B, UBE3C, UBE3D, UBE4A, UBE4B, UBOX5, UBR5, VHL (von-Hippel-Lindau ubiquitin ligase), WWP1, WWP2, Parkin, MKRN1, CMA (chaperone-mediated autophagy), SCFb-TRCP (skipping-retarding protein-F box (β-TRCP) ubiquitin complex), b-TRCP (b-transducing repeat-containing protein), cIAP1 (apoptosis inhibitory protein 1), APC / C (anaphase-promoting complex / cyclin), CRBN (cereblon), CUL4-RBX1-DDB1-CRBN (CRL4 CRBN ) ubiquitin ligases, XIAP, IAP, KEAP1, DCAF15, RNF114, DCAF16, AhR, SOCS2, KLHL12, UBR2, SPOP, KLHL3, KLHL20, KLHDC2, SPSB1, SPSB2, SPSB4, SOCS6, FBXO4, FBXO31, BTRC, FBW7, CDC20, PML, TRIM21, TRIM24, TRIM33, GID4, avadomide, ibidomide, and CC-885.
105. The compound of claim 103, wherein the degradation enhancer is capable of binding to a protein selected from the group consisting of: UBE2A, UBE2B, UBE2C, UBE2D1, UBE2D2, UBE2D3, UBE2DR, UBE2E1, UBE2E2, UBE2E3, UBE2F, UBE2G1, UBE2G2, UBE2H, UBE2I, UBE2J1, UBE2J2, UBE2K, UBE2L3, UBE2L6, UBE2L1, UBE2L2, UBE2L4, UBE2M, UBE2N, UBE2O, UBE2Q1, UBE2Q2, UBE2R1, UBE2R2, UBE2S, UBE2T, UBE2U, UBE2V1, UBE2V2, UBE2W, UBE2Z, ATG3, BIRC6, and UFC1.
106. A compound according to any one of claims 103 to 105, wherein: L AB Yes-L AB1 -L AB2 -L AB3 -L AB4 -L AB5 -; L AB1 , L AB2 , L AB3 , L AB4 and L AB5 are independently selected from a bond, -O-, -N(R 100 )-、-C(O)-、-N(R 100 )C(O)-、-C(O)N(R 100 )-, -S-, -S(O)2-, -S(O)-, -S(O)2N(R 100 )-、-S(O)N(R 100 )-、-N(R 100 )S(O)-、-N(R 100 )S(O)2-、C 1-6 Alkylene, -(OC 1-6 alkyl) z -、-(C 1-6 Alkyl-O) z -、C 2-6 Alkenylene, C 2-6 Alkynylidene, C 1-6 Halogenated alkylene, C 3-12 Carbocyclylene and 3- to 10-membered heterocyclylene, wherein C 1-6 Alkylene, C 2-6 Alkenylene, C 2-6 Alkynylidene, C 1-6 Halogenated alkylene, C 3-12 Carbocyclylene and 3- to 10-membered heterocyclylene are optionally substituted by one, two or three R 20 Replace; and wherein – (OC 1-6 alkyl) z - and – (C 1-6 Alkyl-O) z - Each C 1-6 The alkyl group is optionally substituted by one, two or three R 20 replace; z is independently an integer from 0 to 10; Each R 100 are independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocyclic ring), 3 to 10 membered heterocyclic ring and -CH2-(3 to 10 membered heterocyclic ring), wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocyclic ring), 3 to 10 membered heterocyclic ring and -CH2-(3 to 10 membered heterocyclic ring) are optionally substituted by one, two or three R 20 replace; R 20 is independently selected at each occurrence from halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocyclic ring), 3- to 10-membered heterocyclic ring, -CH2-(3- to 10-membered heterocyclic ring), -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 )、-OCH2C(O)OR 22 and -OC(O)R 25 , where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic ring, -CH2-(C 3-10 carbocyclic ring), 3 to 10 membered heterocyclic ring and -CH2-(3 to 10 membered heterocyclic ring) are optionally substituted by one, two or three groups independently selected from the following: halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 、-SR 21 、-N(R 22 )(R 23 )、-C(O)OR 22 、-C(O)N(R 22 )(R 23 )、-C(O)C(O)N(R 22 )(R 23 )、-OC(O)N(R 22 )(R 23 )、-N(R 24 )C(O)N(R 22 )(R 23 )、-N(R 24 )C(O)OR 25 、-N(R 24 )C(O)R 25 、-N(R 24 )S(O)2R 25 、-C(O)R 25 、-S(O)2R 25 、-S(O)2N(R 22 )(R 23 ) and -OC(O)R 25 ; R 21 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl; R 22 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen and C 1-6 alkyl; R 23 is independently selected at each occurrence from H and C 1-6 alkyl; R 24 is independently selected at each occurrence from H and C 1-6 Alkyl; and R 25 In each occurrence, independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted by one, two or three groups independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings.
107. according to the compound described in any one of claims 103 to 106, wherein L AB is -(O-C2 alkyl) z -, and z is an integer from 1 to 10.
108. according to the compound described in any one of claims 103 to 106, wherein L AB is -(C2 alkyl-O-) z -, and z is an integer from 1 to 10.
109. according to the compound described in any one of claims 103 to 106, wherein L AB Yes - (CH2) zz1 L AB2 (CH2O) zz2 -, where L AB2 is selected from a bond, a 5- to 6-membered heterocyclylene, a phenylene group, a -C 2-4 zz1 and zz2 are independently an integer from 0 to 10.
110. A compound according to any one of claims 103 to 106, wherein L AB Yes - (CH2) zz1 (CH2O) zz2 -, wherein zz1 and zz2 are each independently an integer from 0 to 10.
111. according to the compound described in any one of claims 103 to 106, wherein L AB is a PEG linker.
112. A compound according to any one of claims 103 to 111, wherein B is a monovalent form of a compound selected from:
